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ABSTRACT 
THE USE OF MATHEMATICAL AND COMPUTATIONAL 
MODELS TO DEFINE THE ROLE OF MUTATION AND 
INFECTION IN COLORECTAL CANCER 
CHANDLER D. GATENBEE 
November 19, 2012 
Research over the past twenty five years has led to the development of the 
hypothesis that colorectal cancer is caused by the accumulation of mutations 
in tumor suppressor genes and proto-oncogenes. The last ten years has also re-
vealed that the common JC Virus (JCV) is frequently found in colorectal tumors. 
This has led to the hypothesis that the virus, which is known to cause tumors in 
the lab, may playa role in colorectal cancer. However, the presence of JCV in col-
orectal tumors does not necessarily indicate a cause-effect relationship. Unlike in 
vivo and in vitro studies, mathematical and computational modeling provides an 
opportunity to evaluate the roles that mutation and infection play in colorectal 
tumorigenesis. Three probability models are developed to asses whether colorec-
tal cancer can occur by mutation alone or if infection is required. Two models 
find that JCV is required for tumorigenesis, and that mutation alone is unable to 
generate any tumors. The third probability model finds the opposite; mutation is 
able to generate realistic numbers of colorectal cancer patients, while infection is 
not. All three models do indicate that selection for a stem cell mutation rate that 
is 100 times lower than transit cells provides protection from cancer, confirming 
the findings of other research groups. An agent based model is also developed 
to simulate many of the complexities that cannot be modeled in the probability 
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models. The results from the agent based model indicate that ICV exacerbates 
colorectal cancer and greatly increases the risk of developing cancer. It also finds 
that mutation alone is able to cause colorectal cancer, although not as frequently 
as IC virus associated cases. All together, these models indicate that both muta-
tion and infection have the capacity to drive tumorigenesis, but that the presence 
of IC Virus increases the risk of developing colorectal cancer. This strongly sug-
gests that the role of ICV in colorectal cancer deserves more attention. If future 
studies confirm these findings, it would indicate that the prevalence of colorectal 
cancer can be reduced by taking measures to prevent infection by IC Virus. 
vi 
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CHAPTER 1 THE BARRIERS TO CANCER 
1.1 OVERVIEW 
Multicellular organisms have evolved several mechanisms to prevent an individ-
ual cell from dividing uncontrollably, a process that results in cancer and possibly 
death. These mechanisms include: tight regulation of the cell cycle; using apop-
tosis to kill cells that have accumulated too much damage; limiting the cell's 
maximum number of divisions; and keeping the cell anchored to the matrix of 
underlying tissue. It happens that interfering with these mechanisms can drive 
a cell to divide uncontrollably, leading to the formation of tumors. It is for this 
reason that these mechanisms have been identified as "cancer barriers", as when 
their presence prevents tumors from forming. These barriers can be removed via 
any combination of mutations (somatic or germline), non-infectious environmen-
tal carcinogens, and infection. The following chapter will review each barrier, the 
relevant signaling pathways, and provide examples of how each barrier can be 
removed. 
1.2 WHAT IS CANCER? 
Imagine if the cells in your body began to divide uncontrollably and without 
limit. Within a relatively short amount of time, the progeny of those cells would 
. form large masses of tissue, called tumors, in and on your organs. Those organs 
would soon cease to function normally, and death would be imminent. It is for 
this reason that cells of multicellular organisms have evolved several sophisti-
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cated mechanisms, herein referred to as cancer barriers, that regulate when and 
where cells can survive and divide. These barriers have been subject to posi-
tive selection, as without them the individual would never survive to reproduce. 
However, transforming from a normal cell into a cancer cell is not like flipping a 
switch, which occurs in an instant; instead, tumor progression is a multistep pro-
cess that can take years to complete. Through careful examination of many types 
of cancers, researchers have been able to identify many of the common steps that 
occur during tumor progression, each of which is considered a hallmark of can-
cer [67, 50]. We will now briefly review how each barrier protects the individual, 
and how disruption of the barrier provides that cell with a selective advantage, 
driving it one step closer to evolving into a cancer cell. 
1.2.1 De-regulation of the Cell Cycle: Pro-growth and Anti-growth Barriers 
One of the largest barriers to cancer is the extremely tight regulation over the cell 
cycle, which determines when and where a cell can divide. The cell cycle consists 
of four distinct phases: G1,S,G2,M. When a cell is stimulated to divide it starts 
an intracellular signaling cascade that stimulates the formation of CDK:cyclin, 
which in turn catalyzes the phosphorylation of pRb. Hypophosphorylated pRb 
keeps the cell frozen in Gl by binding to the E2F transcription factors [146]; phos-
phorylation deactivates the inhibitory properties of pRb, freeing the transcription 
factors and driving the cell into S phase. 
DNA replication takes place during S phase. Afterwards, the cell makes sure 
that no significant DNA damage has occurred during replication, and if there 
is not any the cell continues on into the G2 phase. Gz is in tum followed by M 
phase, which consists of mitosis (division of DNA between daughter cells) and 
cytokinesis (division of cytoplasm and organelles between daughter cells). After-
wards, the cell moves back into G 1 . Once in G 1, the cell ensures that it received 
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the correct number of chromosomes, and if it did not it commits apoptosis (cell 
suicide). 
The cell cycle is primarily regulated in two ways: 1) the cell is stimulated to 
divide in the presence of pro-growth signals; 2) the is cell forced to stop divid-
ing in the presence of anti-growth signals. Pro-growth signals typically come in 
the form of growth factors. Growth factors are secreted by other cells, and when 
they bind to another cell's growth factor receptor, they stimulate that cell to di-
vide by inactivating pRb. If a cell is not stimulated by enough growth factors 
it will remain in G 1; if in G 1 for a prolonged period of time, the cell is said be 
in a quiescent state termed Go. Anti-growth signals come in the form of soluble 
signals and embedded signals, which can block cell division in one of two ways: 
either they force the cell into the Go (quiescent) state, or they force the cell to 
relinquish its ability to divide, usually due to terminal differentiation[50]. Nor-
mal cells have thus evolved pro-growth and anti-growth barriers to regulate cell 
division, helping prevent uncontrolled growth. 
Cancer cells de-regulate the cell-cycle by removing the pro-growth and anti-
growth barriers that normally determine when and where the cell can divide. 
The pro-growth barrier is frequently removed in one of three ways: 1) the cell 
starts producing its own growth factors (autocrine stimulation); 2) the cell pro-
duces growth factor receptors that are permanently activated; 3) the signaling 
pathway from the growth factor receptor is altered [67, 50]. No matter the path, 
the result is that the cell divides even when it is not externally stimulated by 
growth factors. Similarly, the anti-growth barrier can be removed in several dif-
ferent ways, although most of them converge on pRb [50]. The reason for this 
convergence is that if pRb is removed, the cell will always move from Gl into 
S phase, preventing the cell from entering a quiescent state. Another common 
strategy for removing the anti-growth barrier is to avoid terminal differentiation, 
thus allowing the cell to continue dividing. A cancer cell might accomplish this by 
constitutively producing the Myc protein, which supplants Mad in the Mad:Max 
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complex, creating Myc:Max, a protein complex that that impairs differentiation 
and promotes growth [41]. 
While some have argued that the pro-growth barriers and anti-growth barriers 
are separate and distinct [50], others feel that the two should be combined into 
one barrier [38,93]. The debate arises because the two barriers often converge on 
the same pathways, and both lead to a cell that constantly divides. For example, 
removal of pRb is said to remove the anti-growth barrier, yet up-regulation of 
CDI<4 (which is in the same pathway as pRb) is said to remove the pro-growth 
barrier (reviewed in [93]). 
Regardless of whether or not the two barriers are distinct, their removal in-
creases their replication rate, resulting in increased fitness. This cell will then 
experience positive selection, as it can replicate more frequently, leading to an 
increase in its frequency throughout the population. 
1.2.2 Apoptosis Barrier 
Removal of the pro-growth and anti-growth barriers bring the cell very close 
to uncontrolled growth. However, there are several cell-cycle checkpoints that 
ensure the integrity of the cell's DNA; if the cell has accumulated too much dam-
age (i.e. too many mutations, incorrect number of chromosomes, etc. .. ), the P53 
protein accumulates. Accumulation of P53 stimulates the transcription of p21, a 
Cyclin Dependent Kinase (CDK) inhibitor. When there is too much DNA damage, 
P53 indirectly halts the cell cycle, giving the cell time to repair the damage. If 
the damage cannot be repaired, P53 activates Puma (P53 up-regulated modulator 
of apoptosis), which binds to, and inhibits, the omnipresent anti-apoptotic Bcl-2 
protein, increasing the permeability of the mitochondrial membrane, allowing for 
the secretion of cytochrome c. Cytochrome c then stimulates a caspase cascade 
that leads to cell suicide, a process termed apoptosis. Cells not only respond to 
internal DNA damage, but also to other stressors, such as infection or hypoxia 
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[67, 74]. Furthermore, cells can also undergo apoptosis in response to external 
signals, such as TNF-a or FASL, both of which might be secreted in response to 
infection. 
Given the stopping power of apoptosis, a cell that successfully removes both 
pro-growth and anti-growth barriers still has a very good chance of being killed 
off by the accumulation of too many deleterious mutations, being infected, or 
experiencing hypoxia. Such a cell that is continuously dividing will almost in-
evitably acquire so many deleterious mutations that it undergoes apoptosis, thus 
successfully removing a pre-cancerous cell. However, as one might suspect, the 
apoptotic barrier is indeed removed in most cancers, as its removal provides the 
cell with a selective advantage by increasing its survival rate. In fact, inhibition of 
P53 by mutation alone is estimated to occur in 50% of cancers [51]. This statistic 
not only testifies to the critical role of P53, but also to the importance of apopto-
sis, which is able to eliminate unhealthy cells. If those cells cannot be eliminated, 
they remain free to divide, and thereby remove the remaining barriers. 
1.2.3 Replication Limit Barrier 
Removing the pro-growth, anti-growth, and apoptosis barriers should, theoreti-
cally, drive the cell to divide uncontrollably. However, it turns out that there is an 
another barrier that limits cellular replication, and this one does not depend upon 
cell-to-cell signaling. At the ends of each chromosome are several thousand 6bp 
repeats called telomeres. After each division, -50 - 100bp of the telomeres are 
lost, due to the inability of DNA polymerase to completely replicate the 3' ends 
of chromosomal DNA during cellular division [67]. Over enough replication cy-
cles, the telomeres are lost, the chromosomes fuse, the cell experiences crisis and 
eventually is subject to apoptosis. In other words, the cell has its own internal 
mechanism to limit the number of divisions it can undergo, and thus potentially 
how long a cancer lineage would survive. However, 85 - 95% of cancer cells 
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remove this barrier by up-regulating the expression of telomerase, an enzyme 
that adds the 6bp repeat back onto the chromosome's ends [123]; the remaining 
5 - 15% remove the barrier using a recombination-based inter-chromosomal ex-
change mechanism termed the Alternative Lengthening of Telomere (ALT) path-
way [15]. Replacement of telomeres, and thus resetting of the cell's clock and 
removal of the replication limit barrier, gives the cell a selective advantage by 
giving it the potential to divide without limit. 
1.2.4 Angiogenesis: An Intermediate Event 
If a cell gains the ability to divide wherever it wants, without limit, it seems that 
cell would be able to create a massive tumor in a short amount of time. However, 
this is not necessarily the case. It has been demonstrated that tumors grown in 
absence of a blood supply, such as in the anterior chamber of the eye, only grow 
to 2 - 3mm [67,42]. Yet when these same cancer cells are placed in tissue with 
a proper blood supply they are able to rapidly generate large tumors. It seems 
that access to oxygen and nutrients, provided by the blood, are critical for large 
tumor growth. It appears the reason that tumor size is capped at 2 - 3mm when 
in a vessel deprived environment is that the tumor cell outgrow the other cells in 
their micro-environment, including the oxygen supplying capillary Endothelial 
cell (EC)s [42, 136, 135]. As the tumor grows, the distance between the inner-
most tumor cells and the nearest capillary increases. Lack of oxygen (hypoxia) 
prevents those innermost tumor cells from replicating, as they are on the verge 
necrosis. The tumor initially manages to supply the hypoxic cells with oxygen 
first by co-opting the surrounding ECs. However, the inner-most tumor cells re-
main isolated from the co-opted blood vessels, and respond to their hypoxic 
condition by over-expressing compounds, such as Vascular Endothelial Growth 
Factor (VEGF) and fibrolast growth factor (FGF), that induce the production of 
new blood vessels from pre-existing blood vessels, a process called angiogenesis 
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[1I8]. In fact, the amount of VEGF produced is enhanced by hypoxia [62], as the 
most hypoxic tumor cells produce the most VEGF, creating a gradient of VEGF 
from the hypoxic tumor cell to the oxygen supplying EC [58,73]. Taken together, 
these observations suggest that VEGF produced by hypoxic tumor cells will lead 
to the rapid extension of vessel tips, which will eventually "crawl" their way to-
wards the hypoxic tumor cells. Once those cells receive the oxygen they crave, 
they are able to divide, and the tumor grows beyond 2-3mm. 
While angiogenesis is primarily activated by pro-angiogenic molecules like 
VEGF and FGF, the process is also controlled by inhibitors, such as thromspondin. 
Therefore, the must be more activators than inhibitors for angiogenesis to be ini-
tiated [67]. As angiogenesis permits an increase in size of an already growing 
tumor, it generally considered an early to mid-stage event [50]. 
1.2.5 Metastasis Barrier 
While cells dividing uncontrollably can lead to tumors, they may often be be-
nign and removed surgically. If not removed early enough these benign tumors 
may begin to produce cells that invade new tissues, a process call metastasis. 
Unlike benign tumors these metastatic tumors are deadly, a fact illustrated by 
the observation that 90% of human cancer deaths are from metastases [131]. The 
acquisition of mobility is a complex process that is facilitated by angiogenesis. 
Part of the reason for this relationship is that during angiogenesis the dividing 
endothelial cells produce matrix metalloproteinases (MMPs), which break down 
both the extracellular matrix and the basal lamina, a process which creates an 
opening for mobile metastatic cancer cells to enter the blood supply [67]. A sec-
ond reason is that VEGF also directly increases the permeability of the vascular 
wall by loosening cell-cell contacts, making it easier for mobile cancer cells to 
enter the blood stream (reviewed in Saharinen et al. [118]). Finally, the simple ex-
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istence of more blood vessels increases the opportunities for mobile cancer cells 
to enter to blood stream and eventually invade new tissue. 
As already noted, for a cell to gain entry into the blood stream it must first 
acquire mobility. All cells have the fundamental molecular tools for locomo-
tion, but most are rendered immobile because they are bound to the extracel-
lular matrix via integrins, and to their surrounding cells via Cell-Cell Adhesion 
Molecules (CAM)s , such as E-cadherin. Cancer cells, on the other hand, fre-
quently have non-functional CAMs, allowing them to separate from their neigh-
bors [67,5°]. Cancer cells also frequently have the ability to vary which integrins 
they express, giving them the ability to attach to whichever surface they may 
move to [50]. Together, loss of cell-cell adhesion and the an ability to bind to 
different surfaces provides cancer cells the opportunity to separate from the pri-
mary tumor mass and move throughout the environment. Thus, while CAMs 
and integins undoubtedly serve other purposes, they also serve as an effective 
barrier that protects the individual from having rogue cells wander throughout 
the body. 
The next question is where should the mobile cancer cells go, and how do they 
get there? Chen et a1. [21] have developed an agent based model to answer this 
very question. This model is built upon evolutionary dispersal theory, which sug-
gests that when there is resource variability (oxygen, nutrients, etc .. ) in the tumor, 
such as when tumor-induced angiogenesis occurs, mobile cells are selected for, 
as they have the ability to move to areas of high resource concentrations, such 
as where new blood vessels have formed during angiogenesis. Mobile cells may 
move towards the underlying blood vessels by producing proteases, which de-
grade the basal lamina, giving the mobile cell the ability to burrow through the 
underlying tissue and enter the bloodstream. 
Once in circulation the chances of cell survival are low. In an experiment cancer 
cells were radioactively labeled and injected into the bloodstream of lab animals, 
and after a few weeks only one in one thousand were still alive, indicating that 
8 
very few cancer cells can survive in the bloodstream (described in [67]). However, 
if that cell is able to survive the trip through the bloodstream and move into new 
tissue (metastasize), it will, at least initially, be privy to additional resources. If 
the other barriers have been removed, this metastatic cell will be able to divide 
indefinitely, leading to the formation of a potentially deadly metastatic tumor 
[so]. 
1.3 REMOVING THE CANCER BARRIERS 
The causes of disease fall into one of three categories: genetic (mutation and 
methylation), non-infectious environmental, or infectious [23]. However, in many 
cases, diseases have primary causes and secondary causes; the disease cannot oc-
cur without the primary causes, and is exacerbated by the secondary cause(s) [38]. 
In much the same way, each cancer barrier can potentially be removed by mu-
tation (somatic or germline), non-infectious environmental factors, or infectious 
agents [67]. As cancer is a multi-step process requiring the removal of several 
protective barriers, it may also be that for many cancers there are also primary 
and secondary causes. For example, cervical cancer may primarily caused by 
HPV infection, but the rate of tumor progression may be accelerated by inherited 
mutations in TNF-£x [153]. The following section will review how each of the 
different causes can remove the barriers to cancer. 
1.3.1 Genetic Changes and Genomic Instability 
Mutations that remove cancer barriers can generally be divided into two cate-
gories: germline mutations and somatic mutations. A classic example of a germline 
mutation that can increase the risk of cancer is the inheritance of one defec-
tive or missing pRb gene, which can increase an individual's risk of developing 
retinoblastoma by 90% [67]. However, before retinoblastoma can actually develop, 
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the second copy of pRb must also be rendered defective. The dramatic increase 
in cancer risk by simply removing pRb illustrates the protein's key role in regu-
lating division, and how its removal can lead to de-regulation of the cell cycle, 
allowing the cell to divide in the absence of growth factors [67]. 
Novel mutations can potentially occur every time a cell divides, as they result 
from replication errors. It has been estimated that the probability of nucleotide 
mis-incorporation is _10-6 per replication event, but proof-reading exonucleases 
and mismatch repair improves replication fidelity -1000 fold[143], leading to 
a mutation rate of 10-9, or one mis-incorporation for every 109 bp every cell 
generation (J]. 
This extremely low mutation rate led Hanahan and Weinberg [50] to state that 
"mutations are rare events, indeed so rare that the multiple mutations known to 
be present in tumor cell genomes are highly unlikely to occur within a human 
lifespan". This observation leads to two (not mutually exclusive) explanations for 
how cells acquire the ability cause cancer: 1) one or more of the other categories 
of barrier-removal is involved (i.e. non-infectious environmental, or infectious); 
2) tumor cells have increased mutability, a phenomenon known as genomic in-
stability. 
There are three types of genomic instability: increased point mutation rates, 
Microsatellite Instability (MSI), and Chromosomal Instability (CIN). MSI may 
be caused by mutations in Mismatch Repair Enzymes (MMR), which can cause 
DNA polymerase to slip during replication of tandem repeats, resulting in the 
insertion/ deletion of microsatellites [143]. CIN leads to alterations in large seg-
ments of chromosomes, including losses, gains, translocations, inversions, dele-
tions, amplifications, and frequently aneuploidy [143]. Both MSI and CIN are 
observed in cancers, as MSI is frequently seen in individuals with hereditary 
non-polyposis colorectal cancer (HNPCC), while CIN is characteristic of most 
cancers and will be discussed more thoroughly [93]. 
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Approximately seven genes have been associated with CIN and somatic mu-
tation, which is believed to cause CIN through one of three pathways: chro-
mosome segregation defects, telomere dysfunction, and dysregulation of DNA 
damage response [102]. Normally, the mitotic checkpoint ensures that chromo-
somes are segregated properly, but mutations in genes that regulate segregation 
can result in an unequal distribution of chromosomes, leading to aneudploidy 
[102]. Some of the frequently mutated genes are: mitotic arrest-deficient (MAD), 
budding uninhibited by benzimidazoles (BUB), anaphase-promoting complex/C 
(APC/C; not to be confused with adenomatous poplyposis coli (APC) discussed 
in Chapter 2)[102]. Additionally, an abnormal number of centrosomes can lead to 
formation of multiple spindle fibers during mitosis, which can also result in ane-
uploidy [102]. Telomere dysfunction can induce CIN when telomeres become ex-
tremely short, as the ends begin to fuse with neighboring chromosomes, resulting 
breakage-fusion-bridge cycles that can lead to dramatic genome reorganization[ 102]. 
However, if telomerase is up-regulated during later stages of cancer such CIN 
may cease to occur, and the reorganized tumor cell may gain immortalitY[102]. 
Finally, impaired DNA damage responses can also induce CIN. Normally, DNA 
damage responses protect the cell from exogenous and endogenous stresses by 
initiating signaling cascades that result in cell cycle arrest or apoptosis. If the 
DNA damage responses are impaired, the cell may accumulate large numbers 
of mutations, some of which may result in CIN. Many of the genes involved in 
these DNA damage responses are frequently mutated in cancers. Some of the 
more commonly mutated genes include: ataxia telangiectasia mutated (ATM), 
ataxia telangiectasia and Rad3-related (ATR) protein kinases, P53, BRCA1, and 
BRCA2.[102]. Of them all, P53 mutations are the most common [93]. 
CIN can dramatically increase the rate at which the above barriers are re-
moved. If one allele of a gene is mutated (either through inheritance, novel mu-
tation, or methylation) the cell is considered heterozygous, and may still func-
tion normally. However, if the second allele is also knocked out, possibly by 
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CIN, the heterozygous state is lost, a process known as Loss of Heterozygosity 
(LOH) [67]. LOH is far more common than mutation, occurring ~ lOut of ev-
ery 1000 cell divisions[67], and on average results in the loss of 25%-30% of 
all alleles in a tumor[102]. In fact, LOH is so common that it is considered the 
"hallmark" of CIN-positive tumors [67, 102]. LOH is believed to be caused by 
three different processes: mitotic non-disjunction, mitotic recombination, and 
gene conversion.[67, 102]' During mitotic non-disjunction, one chromatid fails 
to separate during mitosis, resulting in one cell that has 3 copies of a chromo-
some, and a second cell with only one chromosome. Thus, the cell with one 
chromosome would have lost its heterozygous state [67]. Mitotic recombination 
involves the exchange of DNA between homologous chromosomes, a process 
that generates diversity. However, such recombination can also result in a cell 
that is homozygous for an allele, should the swapped allele segregate with a ho-
mologous chromosome containing the same allele [67]. Gene conversion occurs 
when one of the two homologous chromosomes copies and inserts a segment 
of its DNA into the other homologous chromosome, resulting in a cell that has 
three copies of the same allele[67]. After segregation, one of the cells will become 
homozygous for that allele that was copied. LOH is so dangerous because if the 
allele that becomes homozygous is a defective tumor suppressor gene, a barrier 
to cancer will be removed and that cell will be one step closer to becoming a 
cancer cell. 
In addition to mutation, genes may also be silenced via epigenetic changes 
(heritable changes not encoded in DNA) induced by methylation of a gene's 
promoter region [67]. Methylation occurs when methyl groups attach to the 5' 
position of a cytosine (C) nucleotide [67,4]. In humans, the promoter region of 
DNA often contains unmethylated CpG islands. Transcription may be inhibited 
if these CpG islands become methylated, effectively "silencing" the gene [67,4]. 
Such gene silencing via methylation is believed to be just as common as mutation, 
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and so it is possible that mutation could remove one allele while methylation 
silences the other [67,4]. 
1.3.2 Non-Infectious Environmental Carcinogens 
The second way in which a cell's cancer barriers might be removed is via ex-
posure to various non-infectious environmental compounds. Examples of such 
chemical carcinogens include: polycyclic aromatic hydrocarbons (found in coal 
tars, soots, and oils); aromatic amines (found in dyes, tobacco smoke); N-nitroso 
compounds (some are present in cigarette smoke); alkylating agents (used in pro-
duction of plastics, antifreeze, "mustard gas"); various inorganic substances (i.e. 
asbestos); and other natural products, such as aflatoxin, a carcinogen produced 
by the mold Aspergillus [67]. Many of these carcinogens are metabolized in the 
liver, where they become electrophillic and thus tend to bind to electron-rich 
DNA. The interaction between these carcinogens and DNA causes the DNA dou-
ble helix to distort, resulting in an increased number of mutations during cell 
division[67]. Once the damaged DNA molecule has been replicated, it can be 
almost impossible for the cell to repair the damage, and so the mutation can be 
inherited by daughter cells. Once a mutation has occurred, the growth of those 
cells may initially be dependent upon promoting agent carcinogens. Over time, 
however, these cells may acquire additional mutations or epigenetic changes that 
allow them to divide in the absence of the promoting agent, leading to the evo-
lution of self-sufficient cancer cell. 
1.3.3 Infection 
While it is not in the interest of a pathogen to induce cancer in its host, there are 
several reasons why one would expect that most chronic pathogens would evolve 
mechanisms that remove some of the cell's cancer barriers. De-regulation of the 
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cell cycle allows the intracellular pathogen to divide along with the cell while 
minimizing detection by the immune system; inhibiting apoptosis would allow 
the pathogen to survive infection-induced apoptosis; up-regulating telomerase 
increases the number of divisions the host cell and its pathogen can undergo; 
and removing metastasis barrier gives the pathogen the ability to move to differ-
ent areas within the host, where it may have access to more resources or more 
easily get transmitted to other hosts [38]. The virus can increase its intra-host 
fitness by removing several barriers to cancer. However, a strain that frequently 
removed of all barriers would have a lower inter-host fitness, as its host would 
succumb to cancer soon after infection, limiting the number of possible transmis-
sions. It may be that pathogens have to walk a fine line between these competing 
levels of selection, and that many have struck a balance between intra- and inter-
host fitness. Evidence for this hypothesis comes from the observation that only 
a small proportion of individuals infected by oncogenic viruses actually develop 
cancer, suggesting that these viruses may only remove a few of the cell's cancer 
barriers[38] . 
Perhaps one of the best understood examples of a pathogen being the primary 
cause of cancer is that of human papilloma virus (HPV), the high risk strains (i.e. 
HPV 16, 18, and 31) of which are the agents behind cervical cancer. While HPV 
produces many different proteins during its life-cycle, only two appear to be re-
quired to transform a normal cell into a malignant cell [153]. These two proteins 
are E6 and E7, and each is quite efficient at removing various cancer barriers (re-
viewed in [I53]). E6 activates the catalytic subunit of hTERT (human telomerase 
reverse transcriptase), thus removing the replication limit barrier. At the same 
time, E6 also removes the apoptosis barrier by binding to and degrading P53. Re-
moval of apoptosis also results in the loss of the G 1 checkpoint, allowing the cell 
to divide even when there is DNA damage, a process which may induce chromo-
somal instability [153]. While E6 is able to remove apoptosis and the replication 
limit, E7 seems to playa key role in deregulating the cell cycle. E7 has the ability 
to bind pRb, which frees the E2F transcription factors and drives the cell into S 
phase, thus removing the anti-growth barrier. Furthermore, E7 is able to bind to 
the CDK inhibitors p21 and P27, thereby increasing the levels of cyclins in the 
cell and driving it to divide, thus removing the pro-growth barrier[153]. Com-
bined, these observations suggest that high risk HPV is able to de-regulate the 
cell cycle, up-regulate telomerase, inhibit apoptosis, and induce genomic instabil-
ity. This only leaves the metastatic barrier remaining, which might be removed 
by one of the other categories of barrier removal (i.e. mutation or non-infectious 
environmental cause). 
Hosts have evolved a complex set of mechanisms to protect against the damage 
caused by infection, some of which may result in cancer. However, in this evolu-
tionary arms race pathogens frequently have an advantage, as they are able to 
evolve counter-strategies at a much faster rate due to their high replication rates 
and short generation times. zur Hausen [153] developed the concept of three 
Cellular Interfering Factor (CIF) pathways that the pathogen must overcome in 
order to drive the cell to become malignant. The existence of such pathways were 
"initially postulated to explain the restriction of tumor-virus gene expression in 
proliferating cells, and the long latency period [-20-30 years] between primary 
infection and the eventual emergence of invasive cancer" [153]. 
The first CIF pathway is CIF-I, which includes all pathways involved in pathogen 
recognition by the immune system. For example, T-cells have the ability to recog-
nize HPV antigens presented on the surface of infected cells. It is in the interest 
of HPV to find a way to avoid elimination by the immune system. As it turns 
out, HPV has indeed evolved a counter-strategy, allowing it to evade detection 
by the immune system. The E5 protein of high-risk HPVs can down-regulate 
the expression of both MHC class I and MHC class IT molecules, which present 
antigens to CD8 and CD4 T -cells, respectively. This process is believed to delay 
early recognition by the immune system, although it may not be sufficient to 
permit persistent infection [153]. Some lucky HPVs might acquire the ability to 
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avoid detection during persistent infection by being fortunate enough to be in a 
cell that has also acquired mutations in human leukocyte antigen genes (HLA), 
which encode HLA proteins. Indeed, HLA mutations are found in 90% of cervi-
cal cancers [153]. It seems reasonable to assume that a cell which has increased 
genomic instability, possibly induced by HPV, would also be more likely to have 
a mutation in one of these HLA genes, as more mutation events means there is a 
greater chance the mutation will land in a particular locus. 
The second eIF pathway, elF-II, is the collection of mechanisms that inhibit 
the functioning of viral oncoproteins[153]. In the case of HPY, p16INK4 appears 
to limit the effectiveness of E6, while p14ARF may be involved in moving E7 from 
the nucleoplasm to the nucleolus, thereby preventing E7-induced degradation of 
pRb [153]. However, this is only true in cells in which HPV can either express 
only E6 or E7, but not both. When both proteins are expressed, E6 blocks effects 
of p14ARF, while E7 is able to circumvent the activity of p16INK4 . Together these 
proteins are therefore able to II help II each other, blocking the cell's inhibitory 
proteins, allowing HPV's oncoproteins to function. 
The third elF pathway is elF-III, and includes all signals involved in paracrine 
control, particularly cytokines and chemokines. In particular, TNF-ex (a cytokine 
that promotes inflammation and/or induces apoptosis) appears to limit the growth 
of HPV-immortalized cells, but not malignant HPV cervical cancer cells. This sug-
gests that TNF-ex is able to limit growth of most HPV infected cells, likely through 
the external stimulation of P53-independent apoptosis, and that something must 
happen in order for them to become malignant. This IIsomething" might be mu-
tations in the TNF-ex gene, a hypothesis that is supported by the observation that 
many polymorphisms in the TNF-ex promoter increase the risk of cervical cancer 
[153]· 
There has likely been great selection pressure on pathogens to evolve ways to 
circumvent these eIF barriers. Those strains that have such abilities will have a 
much greater fitness, as they would be able to survive longer and replicate more 
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frequently than strains that cannot overcome these barriers. In the case of HPV, 
it seems that the high-risk strains have evolved such strategies to overcome the 
three elF pathways, a feat which not only increases the fitness of those strains, 
but simultaneously increases the risk of cervical cancer. 
1.4 CANCER AS AN EVOLUTIONARY PROCESS 
If a cell is able to remove the barriers to cancer, through any combination of the 
mechanisms described above, it will gain a selective advantage [84].De-regulation 
of the cell cycle gives the cell the ability to divide when and where others cannot; 
inhibition of apoptosis reduces the probability of cell death; removal of the repli-
cation limit allows the cell to divide more times than other cells; metastasis may 
give the cell the ability to escape a necrotic environment, moving to one that has 
more abundant resources. Given the selective advantage conferred on these cells, 
the removal of these barriers can be considered beneficial to the cell, but harmful 
to the host. 
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CHAPTER 2 MUTATION AND COLORECTAL CANCER 
2.1 OVERVIEW 
Colorectal cancer, the third most common cancer in men and women, is expected 
to kill 51,690 Americans in 2012. Due to its relevancy, researchers have spent 
the past 20 years trying to understand what drives colorectal tumorigenesis. Be-
ginning in 1990, a hypothesis was put forth that specific mutations, commonly 
observed in colorectal tumor tissue, occur in a preferred order and are largely re-
sponsible for tumorigenesis. Subsequent studies have built upon this hypothesis, 
making it the most commonly accepted argument of colorectal cancer causation. 
However, the last ten years have revealed that a common infection, the IC poly-
omavirus, is frequently associated with human colorectal tumors. ICV expresses 
several viral oncoproteins that interfere with key cellular pathways, which is 
known to cause cancer in lab animals. Both observations have led many to fur-
ther investigate the role of ICV in colorectal cancer. 
2.2 STRUCTURE OF COLON AND CRYPTS 
The colon is roughly organized as an outer layer of smooth muscle, a central 
layer of connective tissue, and an inner layer of absorptive epithelial lining. The 
structural subunit of the colon is the colon crypt, a collection of -250 cells that 
penetrate into the underlying submucosa [127, 12]. Each of these colon crypts is 
sub-divided into three sections: the crypt base, the mid-crypt (a.k.a. the prolif-
erative zone), and the upper crypt [12]. As the cells of the epithelial lining are 
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constantly shed into the lumen they must be replaced by cells generated from 
the 4 - 6 pluripotent stem cells that reside at the crypt base [12, 105]. These stem 
cells are defined by several abilities that set them apart from other cells: stem cells 
remain undifferentiated; they are capable of proliferation and self-maintenance; 
they are pluripotent (i.e. they can produce many different kinds of cells); they are 
able to regenerate tissue after injury; they can divide indefinitely [12]. The cell 
cycle time of these stem cells has been measured to be between 12 - 32 hours in 
mice, and is believed to be 4 - 8 times longer in humans [104]. This means that 
the stem cell cycle time in humans could be between 2 - 10 days; or, if the average 
cell cycle time is 22 hours, the average stem cell cycle time should be about five 
12+32 . . 
and a half days ( 2 x 6). ApproXImately 95% of the time colon crypt stem 
cells produce one daughter transit amplifying cell and one daughter stem cell, a 
process referred to as asymmetric division [79]. However, 5% of the time a stem 
cell may undergo symmetric division, producing either two daughter stem cells 
or two daughter transit cells [79]. If two stem cells are created, another stem cell 
is lost by differentiation, displacement, or apoptosis [12]. 
The transit cells produced by stem cells migrate upwards into the mid-crypt, 
where they gradually mature into one of four different cell types: absorptive 
colonocytes, mucus secreting goblet cells, and peptide producing endocrine cells 
[127]. As the transit cells migrate through the mid-crypt, they continue to repli-
cate along the way; it has been estimated that 60% of the cells in the crypt are 
replicating, and most can be found in the bottom two-thirds of the crypt [103]. 
By the time the transit cells have differentiated, they have moved into the upper-
crypt. As transit cells migrate towards the lumen they lose their ability to repli-
cate, possibly because the upper-crypt lacks appropriate growth factors [103]. 
This limited replicative ability has been confirmed in studies demonstrating that 
cells in the upper crypt do not have the ability to regenerate a crypt after radi-
ation injury [52]. Eventually, the differentiated cells reach the most superficial 
19 
part of the epithelial lining, where they undergo apoptosis and are shed into the 
lumen [127, 12]. 
It has been estimated that adding an additional stem cell to a crypt could create 
an additional 60 - 120 cells in the crypt, possibly leading to dysplasia [103]. It is 
for this reason that the number of crypt stem cells is tightly regulated. It also ap-
pears stem cells cannot efficiently repairing DNA damage and often undergo P53 
mediated apoptosis [12]. These lost stem cells can then be replaced by symmetric 
division. Not only does this process help regulate the number of stem cells in the 
crypt, it also prevents the accumulation of carcinogenic mutations [12]. 
If a mutation provides a stem cell with an advantage or is neutral (possibly 
because it is a recessive mutation), that mutation may spread through the crypt 
via a niche succession, a process which appears to 'be somewhat stochastic and 
dependent upon symmetric division [56, 12]. The process of niche succession 
begins when a mutated stem cell produces two daughter stem cells during sym-
metric division. Afterwards, the mutation is present in each of the two stem cells, 
as well as each stem cell's progeny. As this process is repeated, a mutation may 
come to be present in all cells in the crypt, a phenomenon that has been estimated 
to occur every 8.2 years in humans [63]. Niche succession might be accelerated if 
the mutation occurs in a tumor suppressor gene or oncogene, which can increase 
the replication and survival rate of the cell [56]. 
It appears that a mutation might not only be able to spread within a crypt, but 
it might also be able to spread between crypts. If a mutation occurs in a gene 
that regulates apoptosis, such as P53 or Bcl-2, the apoptotic regulation of stem 
cell numbers is lost, leading to an excess of stem cells [12]. Should too many 
stem cells accumulate, the crypt will respond by bifurcating, thus distributing 
the number of stem cells between the two crypts, a process termed crypt fission 
[12]. Thus, any mutations in that first crypt will now be in two crypts. One can 
imagine how this can allow a mutation to spread throughout the colon. However, 
it appears that crypt fission is a relatively rare event in humans, and has been 
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estimated that there can be 30 years between crypt fission events suggesting that 
a single mutation may spread across some, but not all, crypts [56]. 
2.3 MUTATION MODEL: THE CANONICAL VIEW OF COLORECTAL CANCER 
Although the incidence of colorectal cancer has been decreasing over the past two 
decades, it remains the third most common cancer in the men and women [1]. 
In 2012, it is estimated that there will be 143,000 new cases of, and 51,690 deaths 
from, colorectal cancer [1]. It is also estimated that 50% of the entire Western 
population will develop a colorectal tumor by the time they are 70 years old, and 
that 10% of those will develop into malignant tumors [64]. 
Beginning in the 1990S, researches began to put together a theory of colorec-
tal cancer that remains strong to this day [56]. At its heart, this theory argues 
that colorectal cancer is initiated by a mutation in a single gene, and that tumori-
genesis progresses by the sequential accumulation of other specific mutations. 
The process of accumulation is believed to be accelerated by genomic instability 
[64, 39]· 
Many of the important genes involved in colorectal cancer have been identified 
by studying two heritable forms of the disease, Family Adenomatous Polyposis 
(FAP) and Hereditary Nonpolyposis Colorectal Cancer (HNPCC) [}9]. FAP is a 
dominantly inherited disease that affects ~ lout of 7,000 individuals (or < 1% of 
all colorectal cancer cases), while HNPCC accounts for 2 - 4% of all colorec-
tal cancers [64]. In both diseases the median age of developing cancer is 42, 
while the median age of sporadic colon cancer is 67 [64]. In the case of FAP, 
researchers have identified five genes that are commonly mutated in colorectal 
cancer: Adenomatous Polyposis Coli (APC), Kristen Rat Sarcoma Virus (KRAS), 
OCC, SMAD, and P53 [39, 28, 64]. It was also discovered that mutations in 
Mismatch Repair Enzymes (MMR), such as MHS2, MLH1, MSH6, and PMS2, are 
common in HNPCC patients [64,4]. It has been estimated that these MMR muta-
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tions lead to a 2 - 3 fold increase in the mutation rate, making it more likely that 
a tumor-suppressor is knocked out or an oncogene activated, leading to tumor 
formation [64]. Together, these observations have led researches to conclude that 
colorectal cancer develops via the sequential accumulation of specific mutations, 
a process which is often accelerated by genomic instability l39, 64]. Furthermore, 
it has been argued that these mutations may spread throughout the crypt via 
niche succession, leading to monoclonal conversion of the crypt l39, 56]. The fol-
lowing sections will review the role of each gene, the proposed timing of each 
mutation, and how it drives tumor progression. 
2.3.1 APC Mutation Required for Formation of Aberrant Crypt Foci and Early Adeno-
mas 
APC regulates the amounts of j3-catenin, the central protein in the Wnt pathway, 
which is involved in activating cellular proliferation during development[67l Un-
der normal conditions j3-catenin is degraded by a multi-protein destruction com-
plex that contains APC, Glycogen Synthase Kinase 3 (GSK3), and axin. When 
this destruction complex is assembled, GSK3 catalyzes the phosphorylation of 
j3-catenin, marking j3-catenin for destruction by proteasomes, leading to a low 
concentration of j3-catenin within the cell [67]. However, if an extracellular Wnt 
protein binds to a transmembrane Wnt receptor, the destruction complex is pre-
vented from forming, leading to an accumulation of cytoplasmic j3-catenin [67]. 
j3-catenin accumulates, moves to the nucleus, binds to and activates several tran-
scription factors, such as T-cell Factor (TCF) [83]. The TCF:j3-catenin complex 
then activates transcription of mye, preventing cellular differentiation and allow-
ing the cell to divide [142]. Interestingly, j3-catenin also plays a major role in colon 
crypt organization, as its expression is down-regulated in the mid-crypt (due to 
a decrease in Wnt signals), resulting in cell cycle arrest and differentiation in the 
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mid-crypt [142]. Finally, given that other catenins bind to cadherins, it has been 
suggested that j3-catenin might also be involved in cellular adhesion [64,40]. 
It has been discovered that FAP patients have a deletion in one of the two copies 
of chromosome 5q [39]. Further research has revealed this deletion is in the APC 
gene, and that this deletion results in a truncated and non-functional APC pro-
tein [64, 134]. Truncated APC losses its ability to form the destruction complex, 
leading to the accumulation of j3-catenin, preventing differentiation and driving 
the cell to divide [67], essentially giving the mutated cells a stem cell phenotype 
[4]. It is believed FAP patients, being APC+I-, have an increased rate of crypt 
fission, allowing the mutation to spread within the colon [56]. However, the true 
effects of losing the tumor suppressor abilities of APC are not felt until both 
alleles are lost via a mutation or methylation of the normal APC allele [56, 37]. 
When APC is completely lost, it is believed that transit cells acquire the ability 
to divide in the mid-crypt [56]. These APC-I- these cells will then out-replicate 
their heterozygous neighbors, leading to monoclonal conversion of the crypt [56]. 
The combination of monoclonal conversion and crypt fission is believed to lead 
to the formation of dysplastic Aberrant Crypt Foci (ACF) (a.k.a. microadenomas), 
which are microscopic collections of abnormal crypts [56]. Formation of ACF is 
also considered the earliest stage of colorectal cancer, and may lead to the forma-
tion of early adenomas (benign epithelial tumors) [39,64]. 
The removal of APC is often considered the initiating event of colorectal can-
cers because it is frequently found in ACFs as well as 78% of adenomas [56,60]. 
Furthermore, APC is lost in 80% of sporadic colorectal cancers, again suggest-
ing that loss of APC is a common mode of initiating colorectal tumorigenesis 
[56]. However, it has also been discovered that 15% of colorectal cancers do not 
have APC mutations, an observation that suggests other mutations are capable of 
initiating tumorigenesis [129]. Gain of function mutations in j3-catenin are also 
commonly found in colorectal tumors, occurring in -50% of colorectal tumors 
with wild-type APC [130], and thus may account for some of the 15% of cases 
23 
without APC mutations. However, it has also been demonstrated that adenomas 
with altered ~-catenin are less likely to progress to malignancy than adenomas 
with APC mutations (~-catenin mutations were found in 12.5% of small adeno-
mas, but only in 1.4% of malignant tumors), indicating that APC and ~-catenin 
mutations do not have the same effect [119]. Even so, the frequency of APC and 
~-catenin mutations indicates that the Wnt pathway plays a central role in col-
orectal tumorigenesis. 
2.3.2 KRAS Mutations Drive Early Adenoma to Intermediate Adenoma 
The Ras-MAPK pathway is involved in stimulating cell division in the presence 
of growth factors [67]. The signaling cascade is initiated when a growth factor, 
such as PDGF or EGF, binds to a growth factor receptor. This binding activates 
Ras via phosphorylation, initiating a cascade of intracellular protein kinases (Raf, 
MEK, and MAPK) [67]. These kinases in turn: activate the production of nuclear 
transcription factors (Ets, Jun, Fos, Myc, and E2F), resulting in the synthesis of 
cyclins and CDK molecules that phosphorylate pRb, driving the cell into S phase, 
resulting in division [67]. 
Mutations in KRAS (the gene that encodes the Ras protein), which are found in 
40% of sporadic colorectal cancers, can produce a hyperactive form of Ras which 
drives the cell to divide even in the absence of growth factors [67, 4]. KRAS 
is thus considered an oncogene because mutating it results in a protein that 
forces cell division. There are several reasons why it believed KRAS mutations 
are responsible for driving an early adenoma to late adenoma [64]. First, KRAS 
mutations are found in 50% of adenomas greater than 1 cm, but only in 10% of 
adenomas less than 1 cm. This observation suggests that knocking out Ras might 
be required for the tumor to grow more than lcm, after the formation of ACF [39]. 
Second, it has been discovered that while cells with only KRAS mutations are 
hyperproliferating, they do not result in the formation of ACF [60], suggesting 
that KRAS mutations are able to accelerate tumorigenesis, but not sufficient to 
initiate it. 
2.3.3 18q Deletions May Drive Intermediate Adenoma Into a Late Adenoma 
I8q deletions are the second most common region lost, and are found in 70% of 
colorectal carcinomas and 50% of late adenomas, suggesting that this deletion 
drives the formation of late adenomas [39]. There is debate over which genes 
are responsible for this shift, although recent candidates include SMAD proteins, 
OCC , and cables [102]. 
SMAD is a protein involved in the TGF-~ (transforming growth factor) path-
way. The binding of TGF-~ to a TGF-~ receptor (TGFR) triggers the phosphoryla-
tion of SMAD [67]. Once activated, SMAD moves the nucleus, where it initiates 
transcription of the cell-cycle inhibiting proteins p2I and PI5 (recall that these 
proteins inhibit Cyclin Dependent Kinase (CDK)s, preventing the formation of 
CDK:cyclin complexes, which are required for division)[67]. Thus, TGF-~ and 
SMAD normally inhibit cellular division. However, SMAD mutations can pre-
vent the transcription of p2I and PI5, leaving the cell free to divide even in the 
presence of anti-growth signals, such as TGF-~. It has been estimated that 30% 
of colorectal cancers have SMAD mutations, and it is believed that these muta-
tions drive intermediate adenomas into late adenomas by increasing the rate of 
cellular proliferation [28]. 
The second most commonly lost region in FAP patients occurs on chromosome 
I8q, a region that contains OCC [39, 4]. It was initially believed that OCC is in-
volved in cellular adhesion, as it has significant homology to adhesion molecules 
[39]. However, more recent research indicates that DCC is involved in cell growth, 
particularly that ofaxons [4, 83]. It is believed that DCC inhibits cell growth 
when it is not bound to its ligand, netrin-I [4]. Mutations in DCC are believed 
to prevent the binding of OCC to netrin-I, a process that results in abnormal cell 
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survival [4]. Even so, recent studies have found that DCC is lost in only about 
6% of colorectal tumors, suggesting that it does not play a major role in most 
colorectal cancers [102]. 
Cables is a linker protein that increases the tyrosine phosphorylation of CDKs 
by non-receptor tyrosine kinases such as Src, Abl, and Weel [102]. These tyro-
sine kinases inactivate CDKs by dual phosphorylation at the N-terminal Thr-Tyr 
sequence in CDKs, inhibiting cell cycle progression [83] . Thus, loss of cables, 
through the 18q deletion, can decrease the concentrations of active tyrosine ki-
nases, increasing the amount of active CDKs, driving the cell to divide. It has be 
estimated that loss of cables occurs in 6 - 70 of sporadic colorectal cancers, and 
that the other allele might be inactivated by hypermethylation [100]. 
2.3.4 Loss of P53 Drives Late Adenoma Into a Carcinoma 
Researchers have discovered that FAP patients often have deletion in the small 
arm of chromosome 17 (Le. 17P), which contains P53 l39]. Complete loss of P53, 
through loss of 17P in one chromosome and mutation in the other P53 allele, 
can prevent the cell from committing apoptosis, even in the presence of signifi-
cant DNA damage. Even so, it appears that loss of P53, which occurs in 80% of 
colorectal cancers, is a fairly late event in colorectal tumorigenesis [64, 5]. Loss 
of P53 is found in 75% of colorectal carcinomas, but is rare in adenomas, sug-
gesting that inhibition of apoptosis is required for an adenoma to develop into 
a carcinoma (a malignant epithelial tumor) [64, 39]. Furthermore, patients with 
inherited P53 mutations are not at a higher risk of developing colorectal cancer 
[46], again suggesting that loss of P53 is not is sufficient for tumor initiation, but 
is required for transformation from benign tumor to a malignant tumor. 
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2.3.5 Other Mutations Required for Metastasis: Possible Role for the Pl3K Pathway 
The above research suggests that APC or j3-catenin mutations initiate carcinogen-
esis, and that subsequent mutations in KRAS, SMAD, DCC, and P53 increase 
cellular proliferation and survival, driving ACF to develop into adenomas and 
eventually carcinomas, the aptly named adenoma-carcinoma sequence. The final 
step towards metastasis is believed to occur via the accumulation of a variety of 
other mutations [56, 64]. One pathway implicated in the metastasis of colorec-
tal cancer cells is the PI3K-Akt pathway. This pathway is turned on when PI3K 
becomes activated by Ras (which is activated in the presence of growth factors) 
[83]. Activated PI3K catalyzes the addition of a phosphate group to PIPz, con-
verting it to PIP3 [67]. PIP3 in turn recruits kinases which phosphorylate and 
activate Akt and Rho/Rac/Cdq2 [67, 71, 83]. Akt is able to phosphorylate and 
inactivate several cell cycle inhibitor proteins (p21,P27,MYT1,GSK3, and FOXO) 
and pro-apoptotic proteins (Bad, FasL,caspase 8, and FOXO), thus encouraging 
division and discouraging apoptosis [83]. Activation of Rho/Rac/Cdq2 changes 
actin and myosin, altering the shape of a cell and inducing mobility, resulting in 
creeping "ameboid" movement, which could play an important role in invasion 
and metastasis [83]. 
Even though Ras plays a key role in activating the PI3K-Akt pathway, KRAS 
mutations may not necessarily result in the activation of Akt or Rho/Rac/Cdq2. 
This is because there is a regulatory protein, PTEN, in the PI3K-Akt pathway [67]. 
PTEN removes a phosphate from PIP3, converting it back to PIPz, thus preventing 
the activation of Akt and Rho/Rac/Cdq2 [67]. In normal cells, concentrations of 
PTEN are high in the absence of growth factors, and so Akt and Rho/Rac/Cdq2 
remain inactive[67]. 
Recent research has revea.led that PTEN is silenced via promoter methylation 
in 82% of Indian patients with sporadic metastatic colorectal cancer [114], and 
that PI3KCA activating mutations are found in 32% of colorectal cancers [120]. 
Furthermore, PI3KCA mutations are only found in 2% of pre-malignant tumors, 
but in 32% of colorectal tumors [120]. Taken together, this evidence suggesting 
that PI3KCA mutations and/or PTEN silencing arises late in tumorigenesis, just 
before invasion and metastasis [120]. 
2.3.6 COX-2 and Angiogenesis 
It has been discovered that COX-2 is over-expressed in 43% of adenomas and 
86% of carcinomas [32]. It is believed that over-expression of COX-2 results in an 
increased production of prostoglandin E2, which regulates proliferation, survival, 
migration, and invasion of colorectal tumors [48]. It is also believed that over-
expression of COX-2 induces the production of VEGF and FGF, both of which are 
involved in angiogenesis [44]. COX-2'S role in angiogenesis is supported by the 
observation that homozygous deletion of COX-2 impairs the growth of tumors 
and reduces tumor vascularity [148]. Thus, the over-expression of COX-2 may 
accelerate the rate of angiogenesis, allowing the tumor to grow beyond 2mm. 
2.3.7 How Many Mutations? 
It has been estimated that the human genome contains more than 100 tumor 
suppressor genes and oncogenes [67]. However, the above data suggests that only 
a handful of mutations are frequently found in colorectal cancer, both inherited 
and sporadic. Given that at least 4 - 5 mutations are required for carcinoma 
formation, and at least one for metastasis, it has been estimated that a metastatic 
tumor may develop after the accumulation of a minimum of 6 - 7 independent 
mutations [39,64]. More recent genome wide sequencing studies have discovered 
that colorectal tumors have an average of 80 mutations, but estimate that less than 
15 of these actually drive tumorigenesis [149,72]. 
2.3.8 Genomic Instability And Tumorigenesis 
As noted in Chapter I, it is argued that, given the low human mutation rate 
(-10-9 per cell generation), it is unlikely that all of the genes required for tumori-
genesis can be knocked out within a human lifetime. As such, genomic instability 
is often invoked to explain how all of the required genes could be "hit" by mu-
tation [78, 77, 50]. Through the study of HNPCC and FAP patients it has been 
discovered that patients with colorectal cancer do indeed exhibit genomic insta-
bility. 
Microsatellite instability (MSI) has been called the "hallmark" of HNPCC [4]. 
Defective MMR enzymes, particularly MLHl, MSH2, MSH6, and PMS2, are com-
mon in these patients. The loss of DNA replication fidelity (i.e. insertion or dele-
tion of microsatellites), due to defects in MMR genes, have been reported to 
increase the mutation rate of HNPCC patients by 2 - 3 orders of magnitude 
[7, 124, 36]. Microsatellite Instability (MSI) does not appear to be limited to HN-
PCC patients either, as it is found in 13 - 20% of sporadic colorectal cancers 
[4,64]. MLHI appears to be the primary MMR gene affected, as it is methylated 
in 80% of sporadic colorectal cancers with MSI [4]. Tumors with MSI also often 
have frameshift mutations in the microsatellite region of the TGFR gene, making 
the cell immune to the growth-suppressing effects of TGF-!3[64]. MSI tumors also 
sometimes have defects in HLA genes, possibly resulting defective MHC proteins 
that allow the tumor cell to evade elimination by the immune system [14]. 
While MSI is characteristic of HNPCC, Chromosomal Instability (CIN) is re-
garded as the hallmark of sporadic cancers, as it is observed in 65 - 70% of such 
cases [102]. It is also observed that these CIN tumors do not usually have MSI or 
higher mutation rates [7, 36], leading some to suggest that tumors only require 
one type of genomic instability [64]. Even though CIN tumors do not have a 
higher mutation rate, they do exhibit losses or gains of entire chromosomes and 
a high frequency of Loss of Heterozygosity (LOH) , which can lead to complete 
deactivation of tumor suppressor genes [102]. 
The three common methods of generating eIN involve chromosome segrega-
tion defects, telomere dysregulation, and defects in DNA damage responses [102]. 
In the case of colorectal cancer, the genes involved in chromosomal segregation 
defects are kinetochore proteins involved in the spindle checkpoint (Le. hZWlO, 
hZwilch/ FLJ 10036, and hRod/KNT), as well as Ding, a protein that is essential 
for proper chromosome disjunction [145]. Plb, which regulates entry into mi-
tosis and centrosome duplication, is mutated in up to 63% of colorectal tumors 
[102]. It has also been reported that 77 - 90% of colon cancer cells have shorter 
telomeres than the normal surrounding cells, suggesting that telomere dysfunc-
tion might also be playing a role in generating eIN in colorectal cancer cells (re-
viewed in [102]). Only P53 has been directly implicated DNA damage response 
defects in colorectal cancer, and may playa permissive role for developing eIN, 
likely by letting eIN cells survive despite having severe genomic abnormalities 
[102]. 
Some research suggests that APe may also be involved in generating eIN. This 
suggestion comes from the observation that APe also plays a role in cytoskeletal 
regulation, and it has the ability to bind spindle micro tubules and centro somes 
[102]. However, further investigation has revealed that the genomic instability in 
mice with these APC mutations is quite different that that observed in actual 
tumors [102]. This finding suggests that APC mutations can cause genomic rear-
rangements, but that these are not consistent with the CIN observed in tumors, 
leading Pino and Chung to conclude that the role of APe in eIN is "provocative 
but incompletely defined". 
Given that eIN is so common in colorectal cancers, the next question is whether 
or not eIN initiates tumorigenesis, or simply exacerbates it. Several studies have 
demonstrated that eIN does indeed occur very early in the adenoma-carcinoma 
sequence, as eIN is frequently observed in adenomas [125]. Once such study 
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found that polyps less than 2mm exhibited CIN on chromosomes Sq, Ip, 8p, lSq, 
and 18q, regions that contain many of the genes frequently mutated/lost in col-
orectal cancer. Mathematical modeling also suggests that CIN initiates colorectal 
cancer, although it is difficult to find experimental evidence to support this model 
[8S, 97, 12S]· Furthermore, currently there id no data that directly connects CIN 
to the acquisition of specific mutations frequently observed in colorectal cancer, 
making it difficult to prove that CIN initiates tumorigenesis[102]. Thus, the de-
bate over whether CIN initiates tumorigenesis or simply accelerates it via LOH 
continues [102, 126]. 
While many consider genomic instability a requirement of tumorigenesis, oth-
ers believe that cancer can develop without such instability [9]. These authors 
support their argument by noting that not all colorectal cancers exhibit CIN, and 
that MMR mutations generally occur after APC mutations. Furthermore, these 
authors argue that selection can drive the mutation to spread within the crypt, 
and that selection would thus override mutation as the primary evolutionary 
force driving tumorigenesis [9]. These authors also note that mutations in critical 
genes, such as APC and PS3, are not truly recessive, and would provide a selec-
tive an advantage after a single mutation. Thus, an alternative hypothesis might 
be that MMR and CIN do not playa critical role in tumorigenesis, but are simply 
the result of mutations that provide the cell with a selective advantage. This hy-
pothesis is also in line with the observation that the aneuploidy, a result of CIN , 
can sometimes inhibit tumor progression [102]. This might be interpreted as CIN 
actually providing the cell with a selective disadvantage, leading to the selection 
of cells that do not exhibit CIN. 
2.3.9 Cancer Stem Cells 
Given that transit cells are rapidly sloughed off, it is frequently argued that colon 
crypt stem cells accumulate the mutations necessary to convert them into cancer 
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stem cells [4, 102]. Cancer stem cells, which make up 0.25% - 2.5% of the cells in 
a tumor, are defined as cells that have the ability to self-renew, perpetuate them-
selves for long periods, maintain the ability generate a variety of differentiated 
cells, and have the ability to generate tumors when transplanted into other tis-
sue [102]. However, there is now some evidence suggesting that transit cells may 
undergo mutation and selection that enables them to linger in the crypt, giving 
them time to accumulate the extra mutations required for tumorigenesis [56, 70]). 
While there is no direct evidence to support this, such a process could explain 
why colorectal tumors are often composed of differentiated cells [56]. 
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CHAPTER 3 IC VIRUS AND COLORECTAL CANCER 
3.1 OVERVIEW 
The last ten years have revealed that a common infection, the JC polyomavirus, 
is frequently associated with human colorectal tumors. JCV expresses several 
viral oncoproteins that interfere with key cellular pathways, and is known to 
cause cancer in lab animals. Both observations have led many to investigate if 
JCV is involved in colorectal tumorigenesis. The results from these studies have 
generated a body of intriguing evidence implicating a role for JCV in colorectal 
tumorigenesis. 
3.2 POLYOMAVIRUSES AND TUMORS 
The past 10 - 15 years have revealed that a common infection, JC Virus (JCV), has 
tumorigenic potential and is frequently associated with a variety of tumors, in-
cluding colorectal tumors[291. Such oncogenic potential likely results from JCV's 
ability to interfere with many of the same pathways that are disrupted in the mu-
tation hypothesis (see Chapter 2). JCV, belongs to the family of polyomaviruses, 
which, prior to 2000, were grouped with the papillomaviruses (such as HPV) 
under the family of papoviruses [471. Polyomaviruses are named for their well 
known oncogenic abilities; poly is Greek for many, while oma is Greek for tumors, 
together meaning "many tumors" [82]. There are five human polyomaviruses: 
JC Virus (JCV) , BK Virus (BKV) (both discovered in 1971), Karolinska Institute 
virus (KN), Washington University virus (WUV) (both discovered in 2007), and 
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Merkel Cell polyomavirus (MCV; discovered in 2008) [47]. JCV, BKV, KIV and 
WUV are all closely related to the non-human primate polyomavirus simian virus 
40 (SV 40), whose gene products are frequently used in the lab to induce tumors, 
illuminating which pathways are often dysregulated during tumorigenesis [47]. 
MCV, a close relative of JCV, is linked to the rare but aggressive Merkel Cell 
skin cancer (MCC) (reviewed in [47] ). Some of the evidence involved in this 
revelation includes the discovery that MCC patients have MCV titers that are 59 
times higher than controls [101, 139]; MCV is found in Merkel cell tumors, with 
an average copy number of 5.2 MCVs per tumor cell [47]; and MCV's interacts 
with several key proteins, such as pRb, HSC70, and PP2A [47]. Interestingly, even 
though MCV is the cause of the rare MCC, it is a common virus, as 88% of adults 
without MCC are seropositive for the virus [101].It is also widespread through-
out the human body [47]. The explanation for this .pattern is that MCV is only 
reactivated in the elderly or immunocompromised individuals, and that Merkel 
cells may be especially susceptible to transformation by MCV [47]. As discussed 
below, this is interesting because JCV, and MCV share many characteristics and 
epidemiological patterns. 
While JCV is associated with many tumors, it is most commonly known as be-
ing the etiologic agent behind the fatal Progressive Multifocal Leukoencephalopathy 
(PML). JCV is able to infect the oligodendrocytes of the brain. If reactivation oc-
curs, the virus becomes lytic, leading to demyelination and cytolytic destruction 
of the oligodenroglia, resulting in PML [69, 82]. It is believed that immunosup-
pression is primarily responsible for the reactivation of JCV. This is supported 
by evidence that 5% - 8% of AIDS patients develop PML, as they are severely 
immunocompromised [6]. Finally, with regards to JCV's association to tumors, it 
is interesting to note that the unusual astrocytes associated with PML are indis-
tinguishable from tumor cells in high-grade glial neoplasia [47]. 
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3.3 JCv EPIDEMIOLOGY 
JCV is a very common DNA virus, occurring in 45%-80.5% of adults [144, 18]. 
JCV is such a common virus that it can be found in all human populations [133], 
suggesting that it has been with humans throughout our evolution, lending itself 
to studies of human migration patterns [66]. However, as might be expected, 
there are several different types and subtypes of JCV found in different regions of 
the world, each identified by polymorphisms in their IG region: A (EU) is almost 
exclusively found in Europe, B (Af2, Af3, B2, MY, SC, Bl, CY) is most common 
in Africa and Asia, while C (Ah) is only found in a few regions in African (sub-
types found in parenthesis) [49, 133]. The prevalence of JCV also varies around 
the world: JCV DNA shed in urine samples was, on average, found in 13.8% of 
samples in Europe, 11.85% of samples in Asia, and 8.9% of samples in Africa 
[133]· 
Seroprevalence studies for JCV antibodies show that seroprevalence increases 
with age. In a study of 2,435 individuals in England and Wales, ranging in ages 
from 1-69 years old, Knowles et al. [68] found that 11% of children under 5 years 
of age are seropositive for JCV's VPl capsid protein, but that prevalence rises 
throughout life, reaching 50% in the 60-69 year old age group 1. In a similar study, 
Viscidi et a1. [144] examined the serum of 947 individuals attending out-patient 
clinics in Rome, ranging in age from 1-93 years old. Like Knowles et a1. [68], the 
authors found that JCV seroprevalence increases with age: the seroprevalence of 
individuals 10 years of age was only 9.5%, but jumped to 50% in individuals 
10-20 years old [144] . Seroprevalence reaches 68.8% by the time individuals are 
40-49, and rna xes out at 80.5% in individuals older than 70 years of age [144] . 
Finally, Egli et a1. [33] examined 400 blood donors in Switzerland for the presence 
1 Seroprevalence values tend to be higher than prevalence values detected from urine samples, as described 
above: In the study conducted by Egli et aI, the seroprevalence for ICV was 58%, while ICV DNA was only 
found in 19% of urine samples l331 
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of JCV antibodies, finding that 58% of individuals had IgG antibodies for JCV but 
no IgM antibodies [33] . 
The above studies reveal several aspects of JCV. First, the increasing seropreva-
lence and spike between the ages of 10-20 suggests that JCV is most frequently 
acquired during childhood and adolescence. Second, the absence of IgM (the first 
antibody produced during novel infection) and presence of IgG (which is charac-
teristic of persistent infections) indicates that JCV is a chronic infection [90]. This 
conclusion is buttressed by the observation that the same strain of JCV can be 
found an individual's urine sample, taken several years apart from one another, 
indicating the individual is persistently shedding the same strain, as opposed to 
being reinfected by a different strain [65]. 
The above prevalence patterns have led researchers to conclude that transmis-
sion of JCV requires close contact, and that JCV is likely transmitted among fam-
ily members [68]. This conclusion is supported by a study finding that, in Tokyo, 
there is no evidence for different JCV genotypes spreading between the local 
American and native Japanese populations [61]. Since JCV is frequently found 
in urban sewage samples, many authors have concluded that the virus is spread 
by consuming contaminated water and/or food, or by coming into contact with 
contaminated surfaces (i.e. clothes, countertops, eating utensils, etc ... ) (reviewed 
in [47]). Once ingested, JCV infects the tonsillar tissue, where it is frequently de-
tected [47,87]. However, JCV is also frequently found in the bone marrow and B 
lymphocytes, which may help the virus spread to other tissues (i.e. colon, brain, 
etc ... ) via the circulatory system [47,86]. It is believed that JCV eventually infects 
the kidneys, where it establishes a persistent infection, leading to the frequent 
shedding of virus via the urine [47]. 
3.4 JCv STRUCTURE AND LIFECYCLE 
The circular dsDNA genome of JCV is S130bp long and is encased within a non-
enveloped 72 pentamer capsid [47]. JCV's genome is evenly divided into early 
and late regions, each with lengths of 2-4 kb and 2.3 kb, respectively [31]. The 
early and late regions are separated by a Non-Coding Regulatory Region (NCRR) 
that contains the origin of replication and transcriptional control elements, and 
usually contains two 98bp tandem repeats that serve as enhancers [47, 31]. The 
early region encodes the Large T Antigen (T-ag) (a.k.a LT), the Small T Antigen (t-
ag) (a.k.a. ST), as well as several T' antigens (T'16S, T'136, and T'13S) which are 
expressed from alternately spliced early transcripts [141]. Its noteworthy that 
these early proteins are named tumor antigens because they were originally de-
tected using antibodies from animals with tumors [47]. The late region encodes 
the viral capsid proteins VPl, VP2, and VP3, as well as agnoprotein [47]. 
It is believed that JCV gains entry into the target cell by using its VPl protein 
to bind the cell's GTlb SHT2AR serotonin receptor [34]. After attachment, JCV 
enters the cell via clathrin-dependent endocytosis, a process in which the virus 
is internalized through the inward budding of the plasma membrane, forming 
clathrin coated pits [47, 82]. JCV is then delivered to endosomes and caveosomes, 
facilitating the movement of the virus to the endoplasmic reticulum, where viral 
un-coating is occurs [82]. Finally, JCV is translocated to the nucleus [82]. 
Once inside the nucleus, the transcription factors API, NF-1, NF-KB, NFAT, and 
YB-1 bind to JCV's promoter region, leading to the transcription of early region 
mRNAs, and eventually translation in the cytoplasm [82]. After translation, T-ag 
accumulates to high concentrations and initiates cellular division by inhibiting 
pRb (see below for more details). T-ag next binds to the origin of replication in 
the NCRR , unwinds the viral DNA, and hijacks the hosts DNA polymerase to 
replicate the viral DNA [31,82]. Eventually, T-ag suppresses early gene transcrip-
tion and initiates transcription of the late viral genes, agnoprotein, VPl, VP2, 
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and VP3 [82]. Agnoprotein is believed to associate with T-ag help regulate viral 
replication [116, 59], while the latter three proteins are assembled together in the 
cytoplam and translocated to the nucleus, where viral encapsidation takes place 
[47]· 
What happens after virion assembly appears to vary. Usually polyomaviruses 
spread from cell to cell by lysing their host cell [47]. However, electron mi-
croscopy studies have demonstrated that virions can be secreted from the plasma 
membrane of intact cells, suggesting that lysis is not always required for cell to 
cell transmission [57, 22]. Furthermore, transformed cells may have some viral 
DNA integrated into its host genome (not all of the genome has to be integrated 
because viral replication is not required to sustain the tumor) [111]. In fact, such 
integration may drive transformation because the absence of viral replication and 
lysis, but expression of T-ag , can promote cell proliferation and tumorigenesis 
[29]. With regard to colon cells, infected cells start to lose viral DNA soon after 
infection, and is only detectable up to 21 days after infection, suggesting that 
infected colon cells are more susceptible to transformation than lysis [111]. 
After successful infection, JCV remains with the host for the remainder of their 
life. This is supported by the observation that individuals that are positive for 
JCV excrete the same strain, have low levels of IgM and high levels of T-ag IgM 
antibodies (see Section 3.3). During this period, healthy immunocompetent indi-
viduals do not exhibit any specific symptoms even though they have low levels of 
viral gene expression and sporadic reactivation, a phenomenon that is observed 
in 0.5-20% of individuals [31]. However, if the individual becomes immunocom-
promised JCV can become completely reactivated, leading to an increase in virus 
titers and disease [31,47]. 
3.5 JCV ONCOPROTEINS AND THE HOST PROTEINS THEY MANIPULATE 
JCV increases its fitness by manipulating many host proteins involved in the 
cell cycle [47], leading to an increased number of replications for both JCV and 
the infected cell. Furthermore, JCV has the ability to increase its survival by 
inhibiting innate immune signaling [47]. As might be expected, these processes 
increase the probability of oncogenic transformation. Finally, it is noteworthy that 
many of the proteins JCV interacts with are the same proteins that are mutated 
in the mutation model. The following section will review the plethora of proteins 
JCV interacts with. 
3.5.1 Large T-Antigen 
The large T antigen of JCV plays a critical role in driving viral replication and 
transforming cells [47]. Lab experiments demonstrate that infected cells express-
ing T-ag often become immortalized, can escape contact inhibition, and exhibit 
anchorage-independent growth (reviewed in [47]). However, T-ag alone is suffi-
cient to induce immortalization; only the combination of T-ag and hTERT (the 
active unit of telomerase) is sufficient to bypass senescence and cell crisis, result-
ing in an immortalized cell (reviewed in [47]). JCV's T-ag induces these pheno-
typic changes by interacting with several proteins, including f3-catenin, pRb, P53, 
P300/CBP, IRS-I, NbSl, and Bub!. 
3.5.1.1 ~-catenin 
Several studies have demonstrated that T-ag is able to bind f3-catenin [111, 35, 45]. 
In particular, it has been determined that T-ag residues from 412-688 of T-ag 
bind the 695-781 residues (C-terminal) of f3-catenin [45]. Experiments show that 
expression of T-ag increases the level of f3-catenin within the cell [45]. T-ag is 
also able to stabilize f3-catenin, possibly by preventing f3-catenin from binding to 
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the APC/CKI/GSK-3j3 destruction complex [45]. Subsequent experiments have 
shown that cells expressing T-ag also have increased levels of T-ag and j3-catenin 
in the nucleus, while cells not expressing T-ag only have j3-catenin in the cyto-
plasm [45]. All together, these experiments demonstrate that T-ag is able trans-
port j3-catenin into the nucleus [45]. Once in the nucleus, j3-catenin increases the 
transcription of Myc, driving cell division [35, 67, 45]. The interaction of T-ag 
and j3-catenin is significant because the interferes with the Wnt pathway much 
like Adenomatous Polyposis Coli (APC) mutations. As it has been argued that 
APC mutations initiate tumorigenesis, the finding that T-ag stabilizes j3-catenin, 
the target of APC and the center of the Wnt pathway, suggests this may be a 
mechanism by which T-ag can initiate tumorigenesis. 
3.5.1.2 pRb 
Like other tumor viruses, JCV's T-ag can interact with pRb [47, 91]. In fact, JCV 
not only interacts with pRb itself, but also with other retinoblastoma proteins, 
PlO3 and PlO7[47]. It has been determined that the N-terminal domain of T-ag 
(which contains the LXCXE motif) is responsible for binding to the pRb family 
of proteins [54]. Such binding of the pRb family proteins disrupts replication 
inhibition, releasing E2F proteins, driving the cell to divide [47]. Furthermore, 
mice with knocked out pRb, PlO7 and P103 are unable to halt the cell cycle in 
Gl, even in the presence of limited resources, contact with other cells (Le. loss of 
contact inhibition), and DNA damage [26, 117]. Thus, via its interaction with pRb 
proteins, T-ag is capable of driving the cell into S phase, even under conditions 
when replication would be normally prevented. 
3·5·1.3 P53 
Most viruses, including JCV, are able to inactivate the pro-apoptotic P53 protein. 
T-ag accomplishes this by binding to P53's core DNA binding domain, thereby 
inhibiting P53'S ability to act as a transcription factor [47, 122]. T-ag and P53 
expression are positively associated, while T-ag and p21 are inversely related, 
suggesting that inhibition of P53 also decreases the amount of p21, thus inde-
pendently allowing for phosphorylation of pRb, driving the cell to divide [96]. 
The power of the relationship between pRb and P53 is increased by the fact that 
T-ag's inhibition of pRb drives the cell to divide in the presence of DNA damage, 
and inactivation of P53 prevents apoptosis or senescence in the presence of such 
damage [47]. Another important role of P53 is its ability to inhibit angiogenesis, 
especially in tumors [83]. Thus, inactivation of P53 may drive the cell to divide, 
avoid apoptosis, and possibly prevent inhibition of angiogenesis. Given that P53 
is mutated or deleted in 50% of human cancers [53], including colon cancer, inac-
tivation of P53 by T-ag is important in that it provides' an alternative mechanism 
by which this crucial tumor suppressor can be removed. 
3.5.1.4 P300/CBP 
While most studies suggest that T-ag inactivates P53, there are handful indicat-
ing that T-ag may also stabilize P53 (reviewed in [47] ). While the exact results 
are unclear, it is hypothesized that such stabilization of P53 may T-ag the ability 
to interact with P300/CBP [13]. CBP /P300 are proteins that act as adapters or 
co-activators by using their acetyltransferase activity [47]. However, it turns out 
that T-ag cannot bind P300/CBP in the absence of P53 [75]. Thus, T-ag may sta-
bilize P53 so as to gain access to P300/CBP [13]. It is argued that T-ag binding to 
P300/CBP, using P53 as an adaptor, can result in the production of Myc, driving 
the cell to divide [128]. It has also been suggested that T-ag uses P300/CBP to 
activate the promotors that are normally inhibited by pRb, such as E2F, again ini-
tiating replication [47]. Although how exactly T-ag acts on P300/CBP is unclear 
[47], one might speculate that T-ag's interaction with P300/CBP inhibits apopto-
sis. Normally, P300/CBP acetylates P53, which is accompanied by the removal of 
phosphates in the regulatory region of P53 [83]. The Ser residue in the transacti-
vating region of P53 is then free to be phosphorylated, a process that can trigger 
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apoptosis [83]. If T-ag inactivates P300/CBP (again, this is unknown), the protein 
would not able to acetylate P53, leaving the phosphates in the regulatory region 
intact, thus preventing apoptosis. 
3.5.1.5 IRS-l 
Insulin receptor substrate-l (IRS-I) is docking protein normally found in asso-
ciation with an insulin growth factor 1 receptor (lGF-IR) and the plasma mem-
brane [83, 47]. However, T-ag has the ability to translocate IRS-l from the cy-
toplasm to the nucleus [106], resulting in cell division, inhibition of apoptosis, 
and induction of genomic instability. IRS-l initiates division and inhibits apopto-
sis via its activation of the PI3K/ Akt pathway, which down-regulates cell cycle 
inhibitors (p21,P27,MyTl,GSK3,and FOXO) and pro-apoptotic molecules (Bad, 
FasL,caspase 8, and FOXO) [83,47]. Furthermore, nuclear IRS-l has been found 
bound to ~-catenin, resulting in increased transcription of Myc and cyclin D, 
thereby increasing cell growth [20] . Nuclear IRS-l has also been found in a 
complex with Rad51, which is the main enzymatic component of homologous 
recombination directed DNA repair (HRR) [137]. It appears that T-ag, through 
its interaction with IRS-I, impairs HRR, which might be compensated for by 
an increase in non-homologous end joining (NHEJ), an alternative DNA repair 
process [110]. However, this compensatory action of NHEJ is associated the accu-
mulation of spontaneous mutations [140], increasing genomic instability. 
3.5.1.6 Nbs 1 
NbSI is a component of the MRN (Mrel1, Radso, NbSl) complex, and plays 
an important in DNA repair and detection of double strand breaks (reviewed 
in [47]). It is believed that T-ag binds to NbSl, and may result in chromosomal 
instability, although the particular result of the interaction is largely unknown 
[47]. This hypothesis comes from the observation that NbSI is mutated in the 
Nijmengen breakage syndrome, which is associated with CIN and an increased 
risk of cancer [47]. Finally, it has also been suggested that LT's binding to NbSl 
may allow for increased replication of JCV DNA [150]. 
3.5.1.7 Bub1 
Bub1 is a mitotic checkpoint kinase and is critical in maintaining genomic in-
tegrity [25]. T-ag is able to bind Bub1, leading to a compromised spindle check-
point [25]. Mice with reduced expression of Bub1 have increased tumorigenesis 
and aneuploidy (reviewed in [47]), suggesting that T-ag's binding to Bub1 may 
induce the Chromosomal Instability (CIN) that is so characteristic of colorectal 
tumor cells. 
3.5.2 Small t-Antigen 
While T-ag is primarily a nuclear protein, t-ag is found in both the nucleus and 
cytoplasm [47]. Like its big brother, t-ag has the ability to induce cellular prolifer-
ation, even in the absence of T-ag [47]. Microarray analyses have shown that t-ag 
can alter many genes involved in proliferation, apoptosis, integrin signaling, and 
immune responses [88]. Most of these alterations can be traced to t-ag's ability to 
bind and inactivate the serine-threonine protein phosphatase PP2A [47]. PP2A 
inactivation leads to stabilization of Myc and has a similar effect as PI3K, lead-
ing to increased rate of division, inhibition of apoptosis, and possibly increased 
mobility [152, 151]. That t-ag has a similar effect as PI3K is significant because 
PI3K is normally activated by Ras, and so may have a similar effect as mutated 
Kristen Rat Sarcoma Virus (KRAS). 
t-ag's inhibition of PP2A also leads to the activation of several kinases, includ-
ing MAPK, Akt, and PKC( (reviewed in 47). Activation of MAPK (which nor-
mally requires growth factors) initiates the production or activation of several 
transcription factors (i.e. Ets, Jun, Fos, Myc, and E2F) that drive the cell to divide 
[67]. As discussed in Section 2.3.5, activation of Akt results in the inhibition of 
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apoptosis. PKC(, is involved in activating NFKB, a protein that increases inflam-
mation, stimulates cell division, and inhibits apoptosis [67, 83]. It is noteworthy 
that several other viruses associated with tumors, either directly or indirectly (i.e. 
hepatitis C virus, herpes simplex virus, HIV, and human T-cell leukemia virus), 
also up-regulate NFKB [83]. 
3.5.3 Agnoprotein 
Agnoprotein is produced late in the viral lifecycle and is primarily found in 
the cytoplasm [27]. In addition to its regulatory role in viral transcription and 
translation, Agnoprotein has the ability to circumvent the cell cycle checkpoint, 
resulting in an accumulation of DNA damage [27]. While some of this many be 
the result of Agnoprotin's ability to bind T-ag and P53, the primary mechanism 
by which Agnoprotein generates genomic instability is through its binding of 
KU70 and Ku80, DNA repair proteins involved in non homologous end joining 
(NHEJ) DNA double strand break repair [27]. This has been demonstrated in an 
experiment in which cells expressing agnoprotein were treated with cisplatin, a 
DNA damaging agent. It was found that cells expressing Agnoprotein had sig-
nificantly lower levels of KU70 and Ku80 than controls (which did not express 
agnoprotein), resulting in aneuploidy [27]. The authors concluded that Angopro-
tein's localization of KU70 to the perinuclear region permitted evasion of the cell 
cycle checkpoint, leading to the accumulation of DNA damage and CIN [27]. 
3.6 IN THE LAB: JCv AND TUMORIGENESIS 
Given ICV's interaction with several key tumor suppressors and DNA repair 
proteins, one might expect that ICV will have the ability to induce tumors. In- . 
deed, lab experiments have demonstrated that ICV is capable of transforming 
cells in culture as well as in laboratory animals. Transgenic experiments involve 
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the insertion of an exogenous gene into the genome of a living organism. It has 
been demonstrated that the expression of T-ag in intestinal enterocytes results in 
hyperplasia, and eventually dysplasia (reviewed in 47). Furthermore, transgenic 
mice that express T-ag and t-ag develop adrenal neuroblastomas, neuroectoder-
mal tumors, pituitary adenomas, and malignant peripheral nerve sheath tumors 
(MPNST) [82, 109]. Finally, it is noteworthy that T-ag positive cells eventually 
lose expression of T-ag but maintain their transformed phenotype, suggesting 
ICV may induce tumorigenesis by some sort of "Hit and Run" mechanism [109]. 
ICV not only has the ability to induce tumors in transgenic models, but injec-
tion of ICV is oncogenic in several animals, including hamsters, rats, and non-
human primates [82]. ICV infection of newborn Syrian hamsters results in the 
development of several different tumors, including medulloblastomas, primitive 
neuroectodermal tumors, astrocytomas, glioblastoma multiforme, and peripheral 
neuroblastomas [log]. It has also been demonstrated that hamsters innoculated 
with the Mad-1 strain of ICV develop medulloblastomas, while those infected 
with the Mad-4 strain develop pineocytomas and medulloblastomas, demonstrat-
ing that different strains can cause tumors in different cell types [98]. In the case 
of rats, injection of the ICV Tokyo-1 strain into the brain results in undifferenti-
ated neuroectodermal tumors in 75% of infected animals, some of which remain 
oncogenic when transplanted into other rats [109]. Finally, owl monkeys and 
squirrel monkeys infected with ICV develop astrocytomas, glioblastomas, and 
neuroblastomas by 16-24 months of age [109]. 
All of the above animals are non-permissive for ICV infection, which may make 
them more susceptible to transformation, presumably because they integrate ICV 
DNA into their genome and are thus unable to lyse the cell, decreasing their intra-
host transmission [111]. However, an equally important finding is that colonic 
cells infected with ICV start to lose JCV DNA 14-21 days after infection, sug-
gesting that colonic cells are also non-permissive to ICV infection and thus more 
susceptible to transformation [111]. 
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3.7 AN ASSOCIATION BETWEEN JCV AND COLORECTAL CANCER 
The above lab experiments demonstrate that ICV has the capacity to be tumori-
genic in lab animals. However, there is considerable debate over whether or not 
ICV is involved in human cancers. Even so, there is intriguing evidence that ICV 
could indeed play such a role. Part of the argument comes from the observation 
that 70% of colorectal cancers are caused by II chance and environment" (mu-
tation and environment), while 5% are from inherited mutations [9]. Similarly, 
it has also been estimated that ~25% of colorectal cancers result from multifac-
torial contributions of different risk factors [9]. While the authors argue that 
these 25% of cases occur as the result of inheriting many rare dominant alleles 
that have low penetrance, but together increase the risk of colorectal cancer [9], 
an alternative hypothesis might be that infection is one of those critical envi-
ronmental factors that accounts for increased risk to cancer. The hypothesis is 
based upon the observation that ICV is frequently associated with many cancers, 
including human brain tumors, lung cancer, esophageal cancer, gastric cancer, 
(reviewed in [76]), and at least five independent laboratories (and several stud-
ies conducted by each lab) have detected both ICV DNA and T-ag in colorectal 
tumors [69, 35, 55, 76, 96]. 
In 1999, the Laghi laboratory used semi-quantitative PCR to detect the presence 
of LT in the mucosa of colorectal tumors as well as adjacent tissue [69]. The 
authors detected T-ag DNA in 89% of 25 healthy colorectal cells, 25 colorectal 
cancer cells, and 4 cancers, indicating that JCV is present in both healthy and 
malignant tissue. However, subsequent semi-quantitative PCR revealed that the 
ICV viral load is ten times higher in cancer tissue that in the adjacent healthy 
tissue, suggesting that ICV is more active in tumor cells. However, the viral load 
in these tumor cells is only 0.1 ICV viral copies per human genome [6g]. Rollison 
[115] argues that there should be at least 1 viral copy per human genome, and so 
the results of Laghi et al. [69] do not indicate that ICV is driving tumorigenesis. 
Two follow-up studies by Ricciardiello et a1. were conducted to shed more 
light on the association between JCV and colorectal tumors. Like Laghi et a1. 
[69], the authors used JCV T-ag specific PCR primers to detect T-ag in 81.2% 
of normal healthy colorectal tissues (the use of JCV specific primers is impor-
tant because it allowed the authors to avoid amplifying other polyomavirus T-ag 
sequences)[l12]' Further investigation revealed that only the Mad-1 strain of JCV 
, which is characterized by two 98bp deletions in the NCRR, is found in healthy 
and malignant colorectal tissue [112]. This is significant because it indicates that 
the circulating archetype strain is unable to infect colorectal tissue, which was 
confirmed by the finding that the archetype strain was absent in all samples [112]. 
The authors offer several hypothesis about why only the Mad-1 strain is found in 
colorectal tissue: 1) genomic rearrangements resulting in the Mad-1 strain might 
occur in non-lymphoid tissue, and then the Mad-1 strain uses lymphocytes to 
infect the colon; 2) genomic rearrangements may occur in the colon, giving the 
Mad-1 strain the ability to proliferate in colorectal tissue; and 3) Mad-1 may be a 
circulating strain that has the ability to infect colorectal tissue [112]. The follow-
ing year, 2001, further revealed that a variant of the Mad-1 strain, which lacks 
one of the 98bp repeats, is found exclusively in colorectal tumors, but is absent 
in the adjacent healthy tissue [113]. Given that higher viral loads are found in col-
orectal tumors, the authors suggest that the ~98 Mad-1 strain is more efficient at 
proliferating in colorectal tissue. The authors also suggest that this strain of JCV 
might be involved in the generation of CIN [113]. Using the information avail-
able, the authors hypothesize that transformation by the ~98 Mad-1 JCV strain 
might occur through two mechanisms: 1) Mad-1 has a selective advantage in col-
orectal tissue, but some impairment of the immune system might select for the 
~98 variant, which has the ability to transform cells; 2) Mad-1 integrates into the 
human genome, and pre-existing genomic instability results in the ~98 variant 
that is capable of transforming cells [113]. 
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In 2002, the Enam lab used PCR, microdissection, and immunohistochemistry 
to detect ICV DNA and proteins in 27 colonic tumors [35]. The authors detected 
early region DNA in 81.5% of samples, Agnoprotein DNA in 59.2% of samples, 
and VP1 DNA in 14.8 % of samples[35]. Immunohistochemisty, which detects 
proteins using specific antibodies, found the expression of T-ag in 62.9% of sam-
ples, Agnoprotein 44.4% in samples, but no VP1 protein in any samples [35]. 
This is significant, because the lack of VP1 protein suggests that JCV! ( JCV!) is 
unable to replicate productively in these tumor cells. Subsequent laser capture 
microdissection, which is capable of isolating specific cells, was conducted on 
normal mucosa, precancerous adenomas, and invasive adenocarcinomas so as to 
verify the presence ICV DNA and proteins in these tissues. Gene amplification 
revealed that early ICV DNA and T-ag protein are found in both precancerous 
adenomas and invasive adenocarcinomas, while only a "weak signal" of ICV 
DNA is found in the adjacent healthy tissue [35]. These results suggest that JCV 
is only found a few healthy tissues, but at higher concentrations in colorectal tu-
mors, where T-ag is able to interact with key host proteins (i.e. P53 and pRb) [35]. 
Furthermore, the presence of T-ag and ICV DNA in pre-cancerous adenomas 
and invasive adenocarcinomas suggests that ICV could potentially be involved 
in initiating tumorigenesis, again by dysregulating key pathways such as the Wnt 
pathway, apoptosis, and cell cycle regulation. 
In a similar study, Hori et al. used nested PCR, Southern Blot, and immuno-
histochemistry to detect the presence of T-ag, Agnoprotein, and VP proteins in 
23 colorectal adenomas and 20 healthy colonic mucosa from Iapan. The authors 
detected T-ag in 26.1% of colorectal cancers, 4.8% of adenomas, and in 0% of 
healthy colonic mucosa [55]. Consistent with the findings of Enam et al. [35], VP1 
was not detected in any samples, but unlike Enam et al. [35], the authors were 
unable to detect Agnoprotein in any samples [55]. The absence of VP1, which 
indicates ICV is not actively replicating, suggests that ICV may integrate early 
DNA in the the host genome, and that subsequent expression of T-ag is involved 
in tumorigenesis [55]. 
That same year, 2005, Theodoropoulos et al. [138] used PCR to detect the pres-
ence of ICV DNA in Greek adenomas and adenocarcinomas, and real-time PCR 
to determine the levels of expression. Similar to previous studies, PCR detected 
ICV DNA in 61% of adenocarcinomas and 60% of adenomas[138]. Also like Laghi 
et al. [69], real-time PCR detected a viral load of 9 x 103 to 20 x 103 copies/llg 
DNA in adenocarcinomas and adenomas, but only 50-450 copies/llg DNA in 
healthy tissue [138]. The finding that ICV viral load is much higher in cancer 
tissue suggests that the higher concentration of ICV increases the risk of cancer. 
The authors conclude that ICV is likely to be involved in initiating tumorigenesis, 
possibly by inducing chromosomal instability [138]. 
In 2008, Lin et al. [76] also used PCR and immunohistochemistry to detect ICV 
DNA, T-ag , and VPl in 22 colrectal tumors from Taiwanese patients. Similar to 
previous studies, T-ag was detected in 63.6% of colorectal cancer tissues but not 
in adjacent healthy tissue [76]. Again, VPl was not detected in any tissue [76], 
suggesting that ICV integrates into the host genome. 
Many of the studies above studies might be criticized because they lack large 
sample sizes. However, in 2009 Nosho et al. [96] conducted a large scale study 
of 766 colorectal cancer samples. The authors used immunohistochemistry to 
detect levels of P53, P21, p-catenin, COX2, Cyclin 01, and ICV T-ag, as well as 
whole-genome amplification to detect Loss of Heterozygosity (LOH) in the re-
gions frequently associated with colorectal cancer (i.e. 2p, 5q, 17q, and 18q) [96]. 
The results show that expression of T-ag is positively associated with expression 
P53 (p < 0.0001), nuclear p-catenin (p < 0.006), COX-2 (p = 0.02), and loss of p21 
(p < 0.0001) [96]. The positive association of T-ag and P53, accompanied with 
loss of p21 (which is activated by P53), strongly suggests that T-ag is able to dys-
regulate the P53 pathway [96]. T-ag's positive association with nuclear p-catenin 
reinforces the argument that JCV is able to translocate p-catenin to the nucleus, 
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thereby disrupting the Wnt pathway. The positive association between T-ag and 
COX-2 suggests that JCV is able to induce angiogenesis. However, expression of 
T-ag is not associated with alterations in Ras, PIK3CA, BRAF or cyclin D1 [96]. 
The authors also found that T-ag is over-expressed in 35% of colorectal cancers, 
again suggesting that T-ag plays a key role in tumorigenesis. Finally, the authors 
discovered that T-ag expression is significantly associated with CIN , which was 
defined as LOH in chromosomes 2P, 5Q, 17Q, and 18Q [96]. This is noteworthy 
because these are the same regions frequently lost in the mutation hypothesis. 
While T-ag expression is not significantly associated with patient survival, the 
authors conclude that T-ag likely contributes to CIN and dysregulation of the 
P53 pathway, the combined effects of which may result in the uncontrolled pro-
liferation of cancer cells [96]. 
In 2010 Del Valle and Khalili [29] examined 50 commercially available colorec-
tal samples for immunoreactivity to T-ag. Thirty four percent of those samples 
were positive for T-ag, and of those 88% were also positive for Agnoprotein, 
while none expressed VP1 [29]. These results are significant because they are the 
first to indicate that JCV T-ag can be found in commercially available tissue ar-
rays Del Valle and Khalili [29], suggesting that JCV may be responsible for their 
transformation. Also, like many previous studies, the absence of VP1 indicates 
that JCV is incapable of productively infecting tumor cells, but that those cells 
retain the ability to express T-ag and Angoprotein, promoting cell proliferation 
and tumor formation [29]. 
That same year Niv et al. [95] determined JCV titers (using anti-bodies to VP1) 
in patients undergoing colonoscopy, some of whom had colorectal cancer and 
others who were healthy. This is an important study because it was the first 
study to directly compare JCV titers in colorectal cancer patients versus healthy 
patients (other studies compared tumor tissue to adjacent normal tissue). While 
the sample size was fairly small (7 adenomas and 11 tumors), the authors ob-
served statistically significant higher titers of JCV in patients with advanced ade-
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nomas and tumors, compared to healthy individuals [115]. While the authors 
found no correlation between T-ag expression and JCV seroreactivity, it was dis-
covered that JCV antibody levels are higher in individuals with more advanced 
disease, suggesting that immunosuppression and/ or JCV reactivation is involved 
in disease progression [115]. 
While the above nine studies suggest that JCV is at least present in colorectal 
tumors, and may drive tumorigenesis, there are a handful of studies that were 
unable to corroborate those results. A study by Losa et a1. [80] was only able to 
detect JCV DNA in one out of 100 colorectal tumors. Similarly, in 2004, Newcomb 
et a1. [94] screened 45 healthy donors and 233 colorectal cancer patients for JCV 
DNA. The authors were unable to detect JCV in any of colorectal tumor samples 
[94]. However, Rollison [115] has noted that these conflicting results are likely to 
due to differences in assay sensitivity, possible contamin~tion, and differences in 
JCV prevalence in the populations examined. Indeed, Newcomb et a1. [94] have 
been criticized for using novel primers (i.e. those not used in the positive studies), 
as well as for not using any positive controls to verify that the primers worked in 
their formalin-fixed paraffin-embedded samples, which are notoriously difficult 
to work with as formalin fixation breaks DNA [10]. 
In addition to being associated with colorectal tumors, JCV has also been 
found to induce chromosomal instability CIN , something many believe initi-
ates colorectal tumorigenesis. Ricciardiello et a1. [111] have demonstrated that 
T-ag alone is able to induce CIN. To do this, they used RKO cells, which are 
a line of diploid colon cancer cells that express wild-type PS3, f3-catenin, and 
APC. They transfected the RKO cells with Mad-l and the t198bp strain. Within 
seven days the authors observed CIN, which was characterized by chromosomal 
breakages, dicentric chromosomes, and aneuploidy [111]. The controls used in 
the study showed no such CIN [111]. The authors concluded that T-ag's binding 
of PS3 and f3-catenin are sufficient to induce CIN [111]. It also seems likely that 
T-ag's interaction with NbSl, Bubl, IRS-I, and Agnoprotein's interaction with 
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KU70, would also contribute to genomic instability. The observations made by 
Ricciardiello et al. [111] are also consistent with the study by Nosho et al. [96], 
who also found that T-ag expression is significantly associated with LOH , and 
is defined as LOH in chromosomes 2P, 5q, 17q, and 18q. Ricciardiello et al. [111] 
also observed that cells started to lose viral DNA soon after transfection, and was 
only detectable by PCR 14-21 days after initiation of the experiment [111]. Given 
these results, the authors proposed the following "hit and run" scenario for ICV-
associated colorectal carcinogenesis: 1) after integration of viral DNA into the 
host genome (a phenomenon common in polyomavirus transformed cells), ex-
pression of the early genes (particularly T-ag ) induces CIN, forcing most cells 
might enter crisis, while fortunate few increase their fitness by removing key 
tumor suppressors genes via CIN ; 2) those cells retain their transformed pheno-
type, but continue to lose ICV DNA, reducing the amount of CIN due to the loss 
of T-ag; eventually the transformed cells that completely lose expression of T-ag 
have the highest fitness, as they re-acquire genomic stability while retaining their 
ability to divide without limit, leading to tumor formation [111]. 
Taken together, the above studies paint the following picture of how ICV might 
induce tumorigenesis: 1) ICV is ingested by consuming contaminated water, and 
establishes a persistent infection in the kidneys; 2) ICV infects lymphocytes, and 
if the Mad-l strain has evolved (either in the kidney, lymphocytes, or colon cells) 
ICV is acquires the ability to infect colon cells; 3) once the Mad-l strain infects 
the colon, it integrates into the genome, preventing productive infection and thus 
expression of VPl; 4) if the ~98 Mad-l strain evolves, possibly due to genomic 
instability, T-ag is expressed at high levels, dysregulating the cell cycle and in-
hibiting apoptosis, driving the cell to divide uncontrollably and inducing CIN; 5) 
eventually the cell loses key tumor suppressor genes, along with expression of 
T-ag, resulting in a T-ag independent transformed cell. An alternative model is 
that ICV Mad-l is able to infect colon cells, and reactivation, due to some sort of 
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immunosuppresion caused by mutations in the Cellular Interfering Factor (CIF) 
barriers, gives ICV the ability to deregulate the cell cycle and inhibit apoptosis. 
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CHAPTER 4 A NEED FOR MODELING 
The reviews in Chapters 2 and 3 reveal that there are two models of colorectal 
tumorigenesis, the Mutation model and the Infection modeL At its core, the Mu-
tation model proposes that key genes are preferentially removed in the following 
order: Adenomatous Polyposis Coli (APC), Kristen Rat Sarcoma Virus (KRAS), 
I8q, P53, and perhaps PI3K. One might conclude that the Mutation model hy-
pothesizes that the cancer barriers are removed the the following order: anti-
growth (APC mutations prevent differentiation), pro-growth (KRAS and SMAD 
mutations allow the cell to divide in the absence of growth factors), apopto-
sis (inactivation of P53 inhibits apoptosis), metastasis (PI3K mutations activate 
Rho/Rac/Cdq2). 
The Infection model hypothesizes that IC Virus aCV) plays a role in tumori-
genesis by interacting with many of the same or similar proteins involved in 
the Mutation model: Large T Antigen (T-ag) transports (3-catenin to the nucleus, 
which has similar effect as mutating APC; Small T Antigen (t-ag)' s interaction 
with PP2A activates PI3K,much like mutations in KRAS; ICV's inhibition of P53 
prevents transcription of P2I, allowing division to occur in the presence of anti-
growth signals, thus having the same effect of mutating SMAD; inhibition of 
P53 also prevents apoptosis, just like in the Mutation model. Thus, the Infection 
model hypothesizes that ICV is able to simultaneously remove the several can-
cer barriers: T-ag's interaction with (3-catenin and pRb inhibits differentiation 
and promotes proliferation, allowing the cell to divide in the presence of anti-
growth signals; the pro-growth barrier is removed by T-ag 's interaction with 
IRS-I, P300/CBP, and t-ag's interaction with PP2A, allowing the cell to divide 
in the absence of pro-growth signals; the apoptosis barrier is removed by T-ag's 
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interaction with P53, IRS-I, and t-ag's interaction with PP2A; the metastasis bar-
rier might be removed by t-ag's interaction with PP2A, which activates PI3K, 
resulting cytoskeletal changes and increased mobility. 
There are two hypotheses of JCV's role in colorectal tumorigenesis. The Hit and 
Run model posits that the ~98 Mad-I strain integrates into the host genome and 
removes key tumor suppressor genes via T-ag Chromosomal Instability (CIN). 
T-ag expression is eventually lost, leading the re-acquisition of genomic stability 
and maintenance of the transformed phenotype. 
The Reactivation model hypothesizes that JCV becomes latent after infection, 
but is reactivated if some sort of immunosuppression occurs when mutation 
compromises the Cellular Interfering Factor (CIF) barriers. Once reactivated, JCV 
expresses its oncoproteins, removing the pro-growth, anti-growth, and apoptosis 
barriers. 
Despite the evidence presented Chapter 3, the Infection model is contentious 
because it is difficult to determine role of JCV in colorectal caner. A primary 
reason for this is that JCV is so prevalent that it is not entirely surprising that 
JCV can be found in tumors [82]. It could simply be that JCV latently infects 
healthy cells and but remains detectable in the tissue after tumor formation. Fur-
thermore, just because JCV can cause tumors in non-human hosts does not nec-
essarily mean it will cause tumors in humans, as JCV may only cause tumors in 
non-permissive hosts. Even so, the criteria frequently used to establish a cause-
effect relationship between infection and cancer includes the detection of the vi-
ral genome and/or its products in tumor tissue but its absence in healthy tissue, 
and a molecular basis for virally induced oncogenesis, and a consistency of the 
association [99]. JCV meets these requirements: ~98 Mad-I is found exclusively 
in tumors but is absent in adjacent healthy tissue; JCV produces several proteins 
that interfere with pathways traditionally associated with colorectal tumorigen-
esis; at least nine studies from five independent laboratories have demonstrated 
an association between JCV and colorectal cancer. 
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While controversial, the consistent association between JCV and colorectal can-
cer, along with JCV's ability to interfere with several tumor suppressors and 
induce CIN, strongly suggests that JCV should increase the risk of colorectal can-
cer. However, is this increase in risk negligible, moderate, or significant? If JCV 
does significantly increase the risk of colorectal cancer, it would be worthwhile 
to develop a vaccine, which could help prevent colorectal cancer, as opposed to 
treating it. 
Lab studies are not be ideal for determining how much JCV increase the risk of 
colorectal cancer, as it takes decades for the disease manifest itself, much longer 
than the lifespan of most lab animals. Animal studies are also not ideal because 
they are non-permissive hosts, which may make them more likely to develop 
tumors. Furthermore, JCV's high prevalence in the human population makes it 
difficult to use population based studies to determine how much JCV increases 
risk. Mathematical and computer modeling, on the other hand, can help deter-
mine if JCV has the potential to increase the risk of colorectal cancer. The use of 
such models allows one to simulate how JCV interacts with cells over a human 
lifetime. One can also remove infection from the model to estimate the preva-
lence of colorectal cancer in the absence of JCV, thereby simulating a population 
in which the prevalence of JCV is zero. Such a simulation helps determine if 
the prevalence of JCV and colorectal cancer are related. Again, neither of these 
conclusions can come from population and lab based studies. 
Three models have developed to estimate whether or not JCV is involved in 
colorectal tumorigenesis. The first is a probability model that determines the 
age-specific probability of developing colorectal cancer by mutation or infection. 
Although this is a simple model, it sheds light on whether the mutation or infec-
tion is the primary driver of colorectal cancer. 
The second model is a separate probability model that estimates the age at 
which colorectal cancer develops under the infection and mutation models. This 
too is a simple model, but it provides an independent estimate of which force, 
infection or mutation, plays the most important role in colorectal tumorigenesis. 
The third model is a more complex agent based model (ABM) that simulates 
the behavior of cells and their interaction with one another. In this model, tumors 
"emerge" from changes in cellular behavior induced by mutation and/or JCV. 
Due to the nature of ABMs, this model is able to capture more of the complexities 
of tumorigenesis. 
The results from these models will shed light on the drivers of colorectal tu-
morigenesis. Is mutation or infection the primary driver of tumorigenesis? Is 
mutation alone sufficient to drive tumorigenesis, and if so, which barriers pro-
vide the most protection? If infection is involved, what is its role and how does 
it increase the risk of colorectal cancer? The answer to these questions and oth-
ers may be useful in understanding the drivers of colorectal tumorigenesis, and 
how those drivers might be blocked so as to reduce the prevalence of colorectal 
cancer. 
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CHAPTERS PROBABILITY MODELS 
5.1 OVERVIEW 
Two different hypothesis of colorectal tumorigenesis have been put 
forth: the first argues that mutation drives tumorigenesis, while the sec-
ond hypothesizes that IC Virus aCV) infection plays an important role 
in tumorigenesis. While much evidence suggests that ICV at least has 
the potential to be oncogenic, there is relatively little evidence about 
how oncogenic the virus actually is in humans. Much of the difficulty 
in assessing the impact of ICV is that fact that it is so common, and so 
it is not surprising that it is associated with various cancers. However, 
while lab and epidemiological studies may not be able to asses the risk 
of ICV infection has on colorectal cancer, mathematical models may be 
able to. A probability model developed by Calabrese and Shibata [17] 
can be modified to determine the probabilities of developing colorec-
tal cancer, with and without infection. These models can be further 
modified to account for genomic instability 1 • 
5.2 ORIGINAL CALABRESE MODEL [? I 
In 2010, Calabrese and Shibata [17] developed a simple heuristic probability 
model that calculates the age-specific cumulative probability that mutation will 
remove all cancer barriers, leading to colorectal tumorigenesis. In this model, 
1 Please see A or a complete description of the R code used to run this model 
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PARAMETERS 
fl = 3 x 1000bp x 10-9 = 3 x 10-6 mutation rate, 3 genes, lOoobp per gene 
d = number of divisions in d days number of divisions for a given age 
k = 6 number of barriers to cancer 
No = 15 (106 ) number of intestinal crypts 
m = 8 number of stem cells per crypt 
Table 5.1: Original Calabrese Model Parameters [171 
Algorithm 5.:1 Probability of Colorectal Cancer Developing by Mutation, per 100,000 
individuals [17] 
( k)Nm PM=l- l-(l-(l-fl)d) x 100,000 
there are six cancer barriers, which are derived from the paper by Hanahan 
and Weinberg [50]: pro-growth, anti-growth, apoptosis, angiogenesis, replication 
limit, and metastasis barriers. In this model, there are five parameters: d, the 
number of stem cell divisions; m x N, where m = the number of stem cells in 
each crypt, and N =the number of colon crypts, yielding the total number of 
stem cells in the colon; k, the number of critical rate-limiting pathway driver mu-
tations (i.e. the number of mutations required to remove all barriers to cancer); 
and J.l, the mutation rate [171. The values used in the model are found in Table 5.l. 
The logic behind the probability model of Calabrese and Shibata [17] is as fol-
lows: 1 - J.l is the probability that there is not a mutation in a gene, so (1 - J.l)d 
is the probability that there is not a mutation in the gene after d stem cell divi-
sions. Similarly, (1 - (1 - J.l) d) k is the probability that k barriers are not knocked 
by mutation after d divisions. Finally, (1 - (1 - (1 - J.l)d) k) Nm is the probability 
that k barriers are not knocked out in N stem cells, in each of m colon crypts, 
divide d times. Therefore, the cumulative probability of oncogenesis by mutation 
can be defined as the probability that k barriers are knocked out after Nm stem 
cells divided d times, which is summed up in Algorithm 5.l. 
Inserting the parameter values in Table 5.1 allows one to calculate the cumula-
tive probability (i.e. prevalence) of colorectal cancer for each age group by using 
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different values of d. For example, the predicted prevalence of colorectal cancer 
in individuals 70 years or less is 
( 
6)8X1.5X107 
PM70 = 1 - 1- (1 - (1 -3 x 10-6)6387.5) = 0.00559, while the preva-
lence of colon cancer in individuals 65 or less is calculated to be PM65 = 0.0036. 
Incidence is the number of new cases between age groups, and so one can con-
vert prevalence to incidence by determining the difference in prevalence between 
any two age groups. For example, the incidence of colorectal cancer in 70-75 year 
old individuals would be IM70 = 0.00559 - 0.0036 = 0.00199. Using these inci-
dence value, one can then predict the incidence of colorectal cancer per 100,000 
individuals. For example, the incidence of colorectal cancer in individuals 70-75 
years old, per 100,00 individuals, would be 0.00199 x 100000 = 199 individuals 
[17]. Incidence values can be calculated for each age group and compared to ob-
served incidence values of colorectal cancer [2], providing a sense of how well 
the model predicts colorectal cancer incidence. The results of such a comparison, 
using the probability model and parameter values of Calabrese and Shibata [17], 
is found in Figure 5.1. 
5.3 INFECTION MODEL DERIVED FROM THE CALABRESE MODEL 
Calabrese and Shibata's original Mutation model can be modified to determine 
what the incidence of colorectal cancer would be if JCV is involved in tumorigen-
esis. By assuming that JCV removes three protective cancer barriers (pro-growth, 
anti-growth, and apoptosis), one can change the number of barriers mutations 
must remove from k = 6 to k = 3. The prevalence of JCV must also be accounted 
for, as not everyone in the population is infected. By finding the slope of regres-
sion line for observed JCV seroprevalence [68], R, one has an estimate of, on 
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5.2 illustrates this calculation, which finds that R = 0.04205513. By multiplying 
R by the prevalence of colorectal cancer, one can thus estimate what fraction of 
the age group is infected with JCV and has colorectal cancer. A third modifica-
tion has to do with the observation that not all stem cells are infected by JCv. 
Del Valle et al. found JCV T-Ag in 95% of CD133+/CD44+ rat mesnchymal stem 
celis (rMSC), suggesting that JCV has the potential to infect most, but not ali, 
stem cells. Asswning that JCV is also able to infect a similar number of colorectal 
stem celis, the total number of cells wlder consideration in the Infection model 
becomes Nm = 8 x 15000000 x 0.95. 
To estimate the probability of infection driven colorectal tumorigenesis it is 
necessary to sum across ali combinations of current age and age of infection. The 
reason for this is that the probability of cancer in each age group depends up 
how long the individual has been infected. For example, an individual who is 70 
could have been infected at ag~ 15 or age 65, but the former individual would 
have a greater probability of developing cancer than the latter individual. Thus, 
to determine the prevalence of cancer for all 70 year old individuals, one must 
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Algorithm 5.2 Prevalence of Colorectal Cancer Developing by Infection for each age 
group, per 100,000 individuals. 
[ 
( 
0 k-3) NmXOo95] 
P1d=.L:f 1- 1-(1-(1-I1-)d-J) Rx100,000 
sum across all differences in current age, d, and the age of infection, j. Summing 
across all ages of infection thus provides the prevalence of colorectal cancer in 
that age group. Making these changes to Calabrese and Shibata [17]'S mutation 
model yields the infection model found in Algorithm 5.2. 
Iterating Algorithm 5.2 across all age groups generates modeled prevalence, 
which can be converted to incidence and compared to both Calabrese and Shi-
bata's model and the observed incidence. The modeled incidence values can be 
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Figure 5+ Euclidian Distance Between Modeled Incidence and Observed Incidence, Using Orig-
inal Parameter Values 
Every individual in the Infection model develops colorectal cancer by the time 
they are 10 years old, which is far from reality. Euclidian distances between the 
modeled incidence and observed incidence provide a way to determine which 
model's results are closest to the real thing. As expected, given the results in 
Figure5.), the Euclidian distances found in Figure 5-4 illustrate that Calabrese 
and Shibata's original Mutation model is much better fit, while the Infection 
model is nowhere close to the observed incidence. Given these results, one can 
conclude that, as modeled, infection cannot be involved in tumorigenesis, and 
that mutation is the primary cause of colorectal cancer. 
PARAMETERS 
~ = 10-10 or Ii = 10-11 stem cell point mutation rate 
d = number of divisions in d days number of divisions for a given age 
k= 3,6,9, 12,16 number of barriers to cancer 
number of intestinal crypts 
m=5 number of stem cells per crypt 
Table 5.2: New Parameter Values 
In future discussions, these two models will be referred to as the Calabrese 
model with Original Parameters (COP) models. 
5.4 CALABRESE MODELS WITH NEW PARAMETERS (CNP) 
While the mutation model developed by Calabrese and Shibata [17] provides 
an exceptional fit to the observed incidence, it makes several assumptions that 
may not be valid. The first assumption is that the stem cell mutation rate is 
the same as the transit cell mutation rate. However, several authors suggest that 
stem cells have mutation rates that are 10-100 times lower than normal cells 
[19,43,16], precisely to avoid accumulating oncogenic mutations over a lifetime. 
In fact, Frank et a1. estimate that the mutation rate of stem cells may be several 
orders of magnitude lower than that of somatic cells, somewhere between 10-10 
and 10-11 mutations per base pair, assuming the average gene is 1000bp long. 
Second, Calabrese and Shibata [17] use eight stem cells per crypt, while Bjerknes 
and Cheng [8] estimate that there are only 4-6 stem cells per crypt. Third, it has been 
estimated that there could be up to 100 genes involved in tumorigenesis[67]. If 
there are six barriers there could be up to 16 genes per barrier. The following 
probability models thus set the stem cell point mutation rate at either lO- lOor 
10-11 , with number of stem cells per crypt at five, and have 3,6,9,12, or 16 genes 
per barrier. A summary of these new parameter values can be found in Table 
Table 5.2. 
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The incidence values generated from using Algorithms 5.1 and 5.2 with new 
parameter values are found in Figure 5.5, while the Euclidian distances are found 
in Figure 5.6. 
Incidence of Colorectal Cancer 
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The results in Figures 5.5 and 5.6 yield several conclusions. The first is that, 
given the modeled incidence values, mutation is not able to drive tumorigenesis, 
which is in contrast the COP models. This is true across all models, indicating 
that the difference between the Original parameter and New parameter models 
is due to the lower stern cell mutation rate, whether it be J..L = 10- 10 or J..L = 10- 11 . 
This in turn reveals that a lower stern cell mutation rate does protect the cell 
from accumulating too many oncogenic mutations. Third, the Euclidian distances 
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Figure 5.6: Euclidian Distances between Models With New Parameter Values 
suggest that infection is only able to produce realistic incidence values if the stem 
cell point mutation rate is ~ = 10- 11 , as at ~ = 10- 10 colorectal cancer occurs 
far too early and frequently. Finally, the Euclidian distances suggest that the 
model with 16 genes and a stem cell mutation rate of ~ = 10- 11 best replicates 
the observed incidence. All together, the results from this model suggest that 
infection is the primary cause of colorectal cancer, as mutation alone is unable 
to generate any cases of cancer. Finally, mutation is required to remove the last 
three barriers, and so may be considered a secondary cause. 
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5.5 GENOMIC INSTABILITY MODELS 
The Calabrese model with New Parameters (CNP) models suggest that JCV in-
fection is absolutely required for colorectal tumorigenesis, indicating that it is 
the primary cause of cancer. However, one can easily argue that the models are 
far too simple, and that they lack one of the driving forces of tumorigenesis, 
genomic instability. A second assumption that CNP make is that all stem cells 
have an equal chance of removing all of the barriers. However, it is more likely 
that the population of cells that removes the first barrier is the most likely to 
remove the second. And that second, smaller, population is the most likely to 
remove the third. Thus, the population of cells that are most likely to remove all 
of the barriers decrease over time. The following family of models incorporates 
this decreasing population size and genomic instability by making a few more 
modifications to the Calabrese models. 
The decreases population size is accounted for by leaving behind the cells that 
do not remove that first barrier, so that N 1 < No. Similarly, the population of 
N1 of cells that remove the second barrier, Nz, is even closer to metastasis, and 
all other cells in N1 are ignored, meaning that Nz < N1 < No. Over time the 
population of pre-metastatic cells gradually decreases in a step-wise fashion until 
the final population of cells that need to remove the last barrier is determined. 
The second modification is based on the assumption that genomic instability 
doubles the mutation rate every time a barrier is removed. This value is based on 
the observation that Hepatitis C Virus induces a mutator phenotype, increasing 
the mutation rate 5-10 fold [81]. Spreading this increase across six barriers means 
that the mutation rate can double every time a barrier is removed. Over six bar-
riers, this means that !lO = 1O-10'~1 = 2 x lO-lO,~z := 4 x 1O-1O,~3 = 8 x 10-10, 
Il4 = 16 X 10-10, and ~5= 32 x 10-10 (assuming a stem cell point mutation rate 
of ~ = 10-10 
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Algorithm 5.3 Probability Stems Cell Removes One Barrier, Mutation Model 
Algorithm 5.4 Probability Stem Cell Removes One Barrier, Infection Model 
These modifications are incorporated into the Genomic Instability Mutation 
Model (GIM) in the following manner. The probability that one stem cell knocks 
down the first barrier, PM (1,110), is found in Algorithm 5.). The expected to-
tal number of cells knock down the first barrier can be calculated as N 1 = 
PM (1, 110) No , where No = 5 x 15 (106), the total number of stem cells in the 
colon. Similarly, N 2 = PM (1, !-l,) N 1. Over time, the population of cells deceases 
as fewer and fewer cells have removed each barrier. This process is repeated for 
each barrier until the population size of cells that have removed the first five bar-
riers is determined. Using this population size, Ns, and the the highest mutation 
rate !-ls, P Mdc = PM (Ns, f..ls) x 100,000 is the prevalence of colorectal cancer in 
age group d, per 100,000 individuals. 
The Genomic Instability Infection Model (GIl) is modified in a similar fashion, 
yielding Algorithm 5-4, which finds the probability one infected cell will remove 
one barrier. Note that in the GIl model mutation only has to remove three bar-
riers, as JCV has already removed other three. JCV has also induced genomic 
instability, and so the initial mutation rate is !-l3. As in the GIM model, the popu-
lation size of cells that removed the first barrier is Nl = PI (1, !-l3) No. In the GIl 
model, N2 = PI (Nl, !-l4) is the population size of cells that have removed five 
barriers. Thus, the probability that an individual has developed cancer at age d 
is PId (N2, !-ls). As in the COP and CNP infection models, the prevalence of each 
age group is determined by summing all ages of infection for each age group; 















Incidence of Colorectal Cancer 
I I I I I I I I I I I I I I I I I I I 
" ~ Rl -.b' "Q) ~ !\-Q) ~ ':')Q) ~ ~ q f.:lQ) ~ 1j:,Q) ~ ... ~Q) ~ • ~~~ ~$~~44~~~#~~¥¥#~ 
Age Group 







* 3 Genes 
6 Genes 
• 9 Genes 
• 12 Genes 










age of infection by JCv. Also like the COP and CNP models, the initial popula-
tion size of cells used in the infection model is 95% of the cells in the mutation 
model. Once prevalence is calculated it is converted to incidence as described 
above. 
There are two sub-models for each model, and 5 different genes barrier in each 
sub-model, creating a total of ten sub-models. The first set of sub-models uses 
a stem cell point mutation rate of I-l = 10- 1°, and uses 3,6,9,12,or 16 genes. The 
second set of sub-models uses the same collection of genes, but has a stem cell 
point mutation rate of I-l = 10- 11 . The results of each model are found in Figure 

































The results of the Genomic Instability Models largely agree with those of the 
CNP models. Both sets of models find that mutation is unable to drive tumorige-
nesis, while infection is only able to generate realistic incidence values if the stem 
cell point mutation rate is IJ. = 10- 11 . Again, these results suggest that infection is 
the primary cause, as mutation cannot generate realistic prevalence values. How-
ever, colorectal cancer cannot occur without mutation removing the last three 
barriers, and so mutation may be considered a secondary cause. The results of 
these models only differ in that the CNP models find that sixteen genes provide 
the best fit, while the ell models indicates that three genes per barrier fits best. 
5.6 CONCLUSIONS 
The above results strongly suggest that infection plays a significant role in the 
development of colorectal cancer. JCV should thus be considered a major risk 
factor. These results are consistent across all incarnations of the model (except 
for the original), suggesting that they are robust. The results also show that in-
fection always results in a higher incidence of colorectal cancer than mutation, 
again indicating that it increases the risk of cancer. However, this result is not 
surprising given that the probability of removing three barriers will always be 
higher than the probability of removing six. What is surprising is that mutation 
is unable to generate any incidence values, no matter the mutation rate. This is 
in contrast to the COP models, where IJ. = 10- 9, which suggests that lowering the 
stem cell mutation rate by one order of magnitude is sufficient to protect against 
cancer. However, at IJ. = 10- 10 infection causes colorectal cancer far to early and 
frequently. JCV is a very common infection, yet colorectal cancer is relatively rare, 
so this result may indicate that the stem cell mutation rate is IJ. = 10- 11 so as to 
protect against infection induced cancers. This value is consistent with the esti-
mation that the stem cell mutation rate could be 10-100 times lower than other 
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All in all, these models require infection for tumorigenesis, and so JCV can 
be interpreted as being the primary cause of colorectal cancer. Mutation plays 
an important secondary role by removing those barriers that infection does not. 
Thus, these results suggest that colorectal cancer is a multi-factorial disease. 
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CHAPTER 6 GEOMETRIC MODEL 
6.1 OVERVIEW 
A fourth probability model is developed to better understand the drivers of col-
orectal cancer. This model is not built around the work of Calabrese and Shibata 
[17], but is based upon the Geometric distribution, which calculates the proba-
bility of a certain number of failed trials before the first success. This algorithm 
simulates the minimal number of divisions that need to occur for cancer to de-
velop. This model uses the same assumptions of the probability models, and 
is applied to both Mutation and Infection modeL Unlike the other probability 
models, the Geometric model finds that the Mutation model best replicates the 
prevalence of colorectal cancerl . 
6.2 THE GEOMETRIC MODEL 
The Geometric distribution is defined as Pr (X = k) = (1 _ V )k- l V. Given that V is 
the probability of success, and k is the number of Bernoulli trials, the Geometric 
distribution can be interpreted as follows: 1 - P is the probability of failure, so 
(1 - V) k- l is the probability of failure before the final k th trial, and so (1 - V) k - l V 
is the probability that there are k - 1 failures and success on the final k th trial. 
In the case of this model, each stem cell division is considered a Bernoulli trial, 
where 'the probability of removing a barrier (i.e. a successful event) is ~. The 
1 Please see B or a complete description of the R code used to run this model 
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Geometric distribution can therefore be used to determine how many stem cell 
divisions are required for each barrier to be removed by mutation. 
6.3 IMPLEMENTATION 
The program R (v 2 .11.1; [107]) has the function rgeom(n,prob), which randomly 
generates n independent observations of how many trials occur before a success-
ful event, given that the probability of success is p. Each of the n observations can 
be thought of as a cell lineage, and the deviates produced by R are interpreted 
as the number of divisions required for a barrier to be removed by mutation. 
In the Mutation model, b1 = rgeom(n=5 x 15000000, prob=3 x 1000 x 10- 1°) cre-
ates a vector containing 7.5 x 107 elements. Each element represents the number 
of years it takes for a barrier to be removed by mutation in each of the 7.5 x 107 
stem cells, given that the probability of removing a barrier in one of three 1000bp 
genes is 10- 7. After the creating of b1, a new vector; b 2, is created in a similar 
fashion, except that the mutation rate is doubled, thus taking into account ge-
nomic instability. The process is repeated for vectors b3, b4, b5, and b6, doubling 
the mutation rate each time a vector is created, so that the mutation rate used to 
create b6 is I.l. = 25 x 3 x 1000 x 10- 1°. After their creation, all vectors are added 
together into the vector T, each element of which now represents the total num-
ber of years it takes for all six barriers to be removed in each of the 7.5 x 107 stem 
cells. The minimum number of years it takes a lineage to remove all six barri-
ers is recorded, as it represents the first lineage to initiate tumorigenesis within 
the individual. This process is repeated 1,000 times, so as to simulate colorectal 
tumorigenesis in 1,000 individuals. Unlike the probability models, every individ-
ual will develop colorectal cancer at some point, and so the Geometric model 
only produces colorectal cancer patients. 
The Infection model assumes that JCV is able to remove three barriers and 
generate genomic instability. Thus, the only difference between the Infection and 
Mutation model is that the mutation rate used to create b1 is in the Infection 
Model is f..L3 = 23 x 3 x 1000 x 10- 10 (assuming there are 3 genes per barrier, and 
the stem cell point mutation rate is f..L = 10- 10) . Similarly, the mutation rate used 
to generate b z is twice that used to create b1, and b3 is twice that used to create 
bz. Finally, as in the other probability models, it is assumed that JCV infects 95% 
of cells, Otherwise, the two models and their implementation are identical. 
Each model is run using either a mutation rate of 10- 10 or 10- 11 , and either 
3,6,9,12, or 16 genes per barrier. All results for each combination of genes and 
mutation rates are collected and binned into age groups. 
6.4 RESULTS 
The Geometric models produce the number of new patients in each age group, 
and so may be considered incidence values. Since this model is stochastic it is 
unlikely it will produce cancer patients in all age groups. For example, it may 
produce one or two patients that are 72 and 74, but none that are 76, leaving the 
75 - 79 year old age bin empty. This is in contrast to the probability models in 
Chapter 5, which produce the cumulative distribution function calculating the 
probability of cancer in each age group. Therefore, as the results in Figure 6.1 
suggest, modeled incidence values for the Geometric models are slightly decep-
tive, as the incidence goes up and down, simply because some age groups do 
not have any patients in them. Prevalence may provide a better picture of the 
results, as it is the total number of individuals that have colorectal cancer at that 
age, regardless of when they developed colorectal cancer. For example, the preva-
lence of colorectal cancer in individuals 70-74 includes everyone that developed 
cancer at 30,40,50, etc .... If the stochastic model does not generate an individ-
ual for a given age group the prevalence remains the same as the prevalence in 
the previous age group, and so does not dip up and down like incidence does. 
Finally, prevalence provides more accurate distance measurements, as modeled 
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AGE MORTALITY 
< 20 0% 
20 - 34 0.6% 
35 - 44 2.5% 
45 - 54 8.6% 
55 - 64 16.5% 
65 - 74 22% 
75 - 84 29% 
85+ 20.8% 
Table 6.1: Mortality From Colorectal Cancer, 2005 - 2009 [2] 
incidence values can skyrocket and then crash to zero. If the observed incidence 
is also close to zero for the age group the model will have a low distance score, 
despite its poor reproduction of the observed prevalence. Prevalence avoids this 
because when the modeled data maxes out, it stays there, and so no calculations 
are biased by having the modeled data return to zero. 
Incidence is converted to prevalence for a given age group by summing how 
many individuals have cancer in all previous age groups. However, some patients 
die from cancer before they reach that age group, and so cancer mortality should 
be to be taken into account. This can be accomplished by multiplying the preva-
lence in each age group by l-age specific mortality. This is done before adding 
that age group to the next age group, and thus removes the individuals that died 
from cancer in that age group. Mortality rates of colorectal cancer can be found 
in Table 6.1. After taking mortality into account, prevalence can be calculated. 
These Geometric models's prevalence values are found in Figure 6.2, while the 
Euclidian distances for each model are found in Figure 6.3. 
6.S CONCLUSIONS 
Consistent with findings of the probability models, the results of the Geometric 
model strongly indicate that infection increases the risk of cancer. As modeled, 
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the Infection model does not fit well with the observed data, no matter if the 
mutation rate is Il- = 10-10 or 10-11 • However, closeness of fit is highly depen-
dent on the parameters of the model that have been altered and presumably on 
parameters that haven't been altered. Therefore, lack of fit should not indicate 
that infection is not playing a role. If nothing else, these results illustrate that the 
presence of infection dramatically increases the risk of cancer. 
Unlike the Calabrese probability models, the results from the Geometric model 
indicate that mutation can drive of tumorigenesis, as the modeled and observed 
prevalence values are close. However, this is only the case when Il- = 10-10, and 
when there are 16 genes per barrier. At Il- = 10- 11 the mutation model fails to 
produce any colorectal cancer patients, which is in agreement with the Calabrese 
model with New Parameters (CNP) and Genomic Instability models from Chap-
ter 5. This indicates that a lower stem cell mutation rate does protect against 
cancer, but only if it is 100 times lower than normal. It thus seems that either 
mutation or infection can be the driver of tumorigenesis, but that which one 
fits best depends on the mutation rate. These mixed results indicate that further 
investigation is required. 
CHAPTER 7 AGENT BASED MODEL 
7.1 OVERVIEW 
The family of models described in the previous chapters suggest that both mu-
tation and JCV are capable of initiating colorectal tumorigenesis. However, those 
models also make many simplifying assumptions that do not capture the com-
plex process of tumorigenesis. An agent based model is developed to address 
these complexities, with the aim of attaining a more accurate picture of mutation 
and infection's role in colorectal tumorigenesis. In this model, each mutation 
and/ or viral oncoprotein generates a behavioral change in the cell, and the accu-
mulation of these phenotypic changes can result in the emergence of a metastatic 
tumor. Agent based models also record a great deal of data which can be used to 
determine not only which factors increase the risk of colorectal cancer, but also 
how each does so. 
7.2 NEED FOR AN AGENT BASED MODEL 
The models described in Chapter 5 and Chapter 6 demonstrate both infection 
and mutation are able to drive tumorigenesis. However, the argument could be 
made that these models are too simple, and ignore many important observations 
on colon tissue dynamics, colorectal tumorigenesis, and JCV's lifecycle. For ex-
ample, symmetric division is not modeled, which is a significant omission as it 
is proposed to be a mechanism involved in spreading a mutation throughout the 
crypt (i.e. monoclonal conversion). Second, the models assume that a single mu-
tation completely removes each barrier, and yet it is known that a single mutation 
in one tumor suppressor allele (i.e. P53, pRb, APC, etc ... ) does provide a selective 
advantage, but that removal of the other allele is required to gain the full selec-
tive advantage[9, 67]. Third, the probability model treats all barriers as equal in 
the sense they simply bring the cell one step closer to metastasis. However, the 
removal of each barrier provides the cell with a particular selective advantage 
that allow the genotype to increase in frequency within the population. Fourth, 
the previous models assume a constant population size, which is very unrealis-
tic, as the definition of cancer is uncontrolled growth. This is a particularly poor 
assumption, as the more cells there are, the greater the probability that one of 
them will acquire all of the mutations required for tumorigenesis. Finally, the ear-
lier models assume JCV is active immediately after infection, and remains active 
throughout the host's life. However, in appears that JCV instead becomes latent 
upon infecting colon cells, and some sort of reactivation is required for the virus 
to express its oncoproteins. Such reactivation may occur either due to immuno-
suppression, due to mutations Cellular Interfering Factor (CIF)-II genes, or by a 
"hit and run" mechanism. 
It is not possible to model these complex processes with a simple probability 
model, and so an Agent Based Model (ABM) is developed. ABMs are ideal for 
such complex processes, as they allow each cell's behavior to change over time, 
either in response to internal and/or external changes, in this case mutation 
and infection. All of the cells then interact with each other, and combinations of 
different behaviors can lead to the emergence of different patterns, in this case 
tumor formation. Thus, this ABM seeks to address the simplifying assumptions 
of the probability models by modeling how mutation and infection affect the 
behavior of cells, and how the combination of these behaviors can result in the 
formation of a metastatic tumor. 
7.3 OVERVIEW OF MODELS 
There are three families of ABMs, each of which is programmed using NetLogo 
version 5.0.31 [147]. Each of following models are run using 3,6,9,12,16 genes per 
barrier, with the average gene length being 1, OOObp. Thus, there is a total of 25 
models, each of which is run 1,000 times. 
7.3.1 Mutation Model 
The first model is the Mutation Model. In this model, mutation is the only way 
that the protective cancer barriers can be removed, even if the individual is in-
fected. As such, the Mutation model assumes that JCV has no role in tumorigen-
esis. If a single mutation lands in a cancer barrier gene, the mutant phenotype is 
expressed 50% of the time. The beneficial phenotype will always be expressed if 
a second mutation lands in that same gene. 
7.3.2 Infection Models 
In the Infection models JCV randomly infects one cell every year. Once that cell is 
infected, there is a 2% chance that the infection will spread to its neighbor cell. If 
the infection fails to spread to all cells, JCV does not establish a chronic infection 
and will attempt to infect the individual the following year. The infection is con-
sidered chronic if JCV successfully spreads to all cells. The parameters used in 
the Infection models are calibrated so as to represent the observed seroprevalence 
of JCV (see Figure 7.1). 
1 Please see the ODD in Appendix C for a complete description of the code used in this ABM 
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Figure 7.1: Modeled Prevalence of JCV 
Each of the following infection models have two sub-models. In each case, the 
first model, referred to as the Full Model, has active JCV completely remove 
each barrier, while in the second model, termed the Partial Model, JCV partially 
removes each barrier. In the case of the Partial models, if there is one pre-existing 
mutation, and JCV partially removes that barrier, the entire barrier is be removed. 
The situation is the same if JCV partially removes a barrier and then mutation 
finishes the task. 
7.3.2.1 Reactivation Model 
The first infection model is the Reactivation model. This model hypothesizes that 
JCV has no effect until the individual becomes immunocompromised. For an in-
dividual to become immunocompromised they must acquire two mutations in 
the CIF-II genes. Recall from Chapter 1 that the CIF-II barrier is involved in in-
hibiting the function of viral oncoproteins[153]. If the CIF-II. barrier is removed, 
simulating immunosuppression, JCV is reactivated and removes the pro-growth, 
anti-growth, and apoptosis barriers (see Chapter 4 for a review of how JCV inter-
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feres with these barriers). If there is only one mutation in a CIF-II gene, JCV only 
has an effect 50% of the time. This is meant to simulate that the individual is not 
completely immunocompromised, and so retains defenses against JCY. However, 
if there are two mutations in the CIF-II genes, JCV is always active. 
7.3.2.2 Hit and Run Model 
The Hit and Run model is the second infection model, and is based upon the 
research conducted by Ricciardiello et al. [112, 113] (see Chapter 3 for a review 
of their findings). The Hit and Run model hypothesizes that genomic rearrange-
ments in JCV's Non-Coding Regulatory Region (NCRR) lead to the development 
of the Mad-I strain, which may use lymphocytes to infect the colon. Alterna-
tively, these genomic rearrangements may occur in JCV that is already in the 
colon. Either way, the Mad-I strain develops into the Mad-I .198 strain when 
there is a second deletion in the NCRR. This event changes the cell's phenotype 
in two ways: 1) the apoptosis, pro-growth and anti-growth barriers are removed; 
2) the virus induces genomic instability, increasing the mutation rate 7.5 fold. 
The increase in virally induced genomic instability comes from the observation 
that Hepatitis C Virus induces a mutator phenotype which increases the muta-
tion rate 5-10 fold [81], and so 7.5 is somewhere between the two. Unlike the 
Reactivation model, JCV Mad-I .198 is only active for 14 - 21 days, after which 
JCV's oncoproteins cease to be expressed, and the cell returns to its previous 
phenotype. 
7-4 MODELING THE STRUCTURE OF A COLON CRYPT 
Figure 7.2 is the world of the ABM. The box on the bottom left is the colon 
crypt, which is divided into the inner crypt (pink) and outer crypt (yellow). The 
tissues are laid out in squares so as to represent a columnar crypt that has been 
laid flat, so that the crypt base is in the center of the square. The black area 
Figure 7.2: Modeled Colon Crypt 
outside of the crypt represents the lumen. The green square is the metastatic 
tissue, which could hypothetically be anywhere in the body. At the center of the 
crypt are five stem cells (blue). Each patch in each tissue represents one cell from 
the underlying tissue. 
Everyday (i.e each tick) each patch, which assumed to contain underlying 
blood vessels, supplies 0.25 units of oxygen to the colon crypt. Each patch then 
diffuses 100% of its oxygen to its neighboring patches, 20 times a day, simulat-
ing constant oxygen diffusion [21]. The oxygen is thus dispersed throughout the 
crypt where it is consumed by cells. Since oxygen dynamics determine cell di-
vision and movement, all oxygen related parameters are calibrated so that each 
crypt contains an average of 250-300 cells, and so that each stem cell divides 
every four to five days [127, 12, 104, 103]. 
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7.5 WILD-TYPE BEHAVIOR 
7.5.1 Stem Cells 
At the center of the crypt (Le. the base of the crypt) are five stem cells laid 
out in a circle [12, 103, 105]. Each of these stem cells is able to divide either 
asymmetrically or symmetrically. Which type of division occurs is determined 
using a Bernoulli distribution, where the probability of successful asymmetric 
division is p = 0.95 [79]. If symmetric division occurs, the most fit stem cell 
(Le. the stem cell with the fewest deleterious mutations) produces two daughter 
stem cells, one of which replaces the least fit stem cell (Le. that stem cell with 
the most deleterious mutations). This is modeled because it is assumed that the 
number of stem cells is tightly regulated, and that the most fit stem cell has the 
greatest probability of surviving while the least fit stem cell is most likely to die. 
After this selection has occurred, the remaining stem cells divide asymmetrically. 
When asymmetric division occurs, each stem cell produces one daughter transit 
cell. This model assumes that stem cell division is prevented by contact inhibition. 
Thus, a stem cell will only divide if there is an empty patch within its cone of 
vision, which has an angle of 1800 and radius of 1.5 patch units. 
During division each stem cell acquires various mutations that are inherited 
by their daughter cells (see section 7.6 for details on how mutation is modeled). 
Finally the ABM assumes that the crypt can determine if it has too few stem cells, 
and will respond by having the most-fit stem cell hatch one daughter stem cell. 
The only time this will occur is if one stem cell acquires a metastatic mutation, 
giving it the ability to roam throughout the crypt. Again, this is modeled based 
on the assumption that the number of stem cells in a crypt is tightly regulated. 
7.5.2 Transit Cells 
Wild-type transit cells produced by stem cells will only divide if there is an empty 
patch within their cone of vision, again simulating contact inhibition. However, 
transit cells must also meet further requirements to divide. They must be in the 
inner crypt, where they are not fully differentiated; they have enough oxygen 
to divide; and they have telomeres remaining. If a transit cell meets these re-
quirements, divides, undergoes mutation, produces one daughter cell, divides 
its oxygen equally between itself and the daughter cell, looses one unit of its 
telomere, metabolizes oxygen, and randomly moves to one of the empty patches 
in its cone of vision, where it consumes oxygen. If the transit cell meets all of the 
criteria except for having enough oxygen to divide, the cell will simply move to 
one of the empty patches, metabolizing oxygen in the process, and then consume 
more oxygen on the patch it now occupies. If there is not enough oxygen in the 
. patch the cell moves to, it will consume half of what oxygen is available. When a 
cell reaches the outer crypt it will follow the same rules of movement and oxygen 
consumption, but will not be able to divide because the cell has differentiated. 
Finally, transit cells are shed once they reach the lumen. Transit cells can also die 
if they lose all of their telomeres or have a low relative fitness when resources 
become scarce during population growth (see subsection 7.8.2 for details). 
7-6 MODELING MUTATION 
7.6.1 Genome Regions 
It is estimated that the human genome contains -7 x 109bp and 70,000 genes, 
each of which has an average length of 1000bp (reviewed in [92]). Assuming 
there are six barriers to cancer, and three genes per barrier, one can estimate 
that there are 6 x 3 x 1000 = 18,000 bp that if mutated or targeted by JCV will 
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damage a cancer barrier. Interfering with these barriers is beneficial to the cell, as 
it either increases the rate of replication or probability of survival (see section 7.7 
for details). Therefore, any mutation that lands in these 18,000bp is considered a 
beneficial mutation. 
Assuming that mutations in the remaining genes are deleterious, one can es-
timate that mutations in any of the (70,000 - 3 x 6) x 1000 = 69982000bp will 
result in a mutation that will decrease a cell's fitness. The ABM also assumes 
there are seven different different genomic instability genes that are involved in 
Chromosomal Instability (CIN) [102]. Thus, there are 7 x 1000 = 7,000bp that, if 
mutated, will increase the mutation rate. Finally, assuming all other mutations 
are neutral, one can estimate that any mutation in the 7 x 109 - (70000 x 1000) = 
6.93 x 109bp will have no effect on the cell's fitness. 
7.6.2 Generating Mutations 
7.6.2.1 Host Mutations 
The stem cell mutation rate used in these models was originally!! = 10-10, and 
the transit cell mutation !! = 10-9, but only lout of 25,000 runs developed a 
metastatic tumor. This hardly provides any information, so the stem cell muta-
tion rate is set to !! = 10-9, while the transit cell mutation rate is !! = 10-8. While 
these mutation rates are higher than observed values, they generate plenty of re-
sults and maintain the hypothesis that the stem cell mutation rate is lower than 
the transit cell mutation rate. 
Using these mutation rates, one can calculate the expected number of muta-
tions in each genome region during each division: 18,000 x 10-8 = 1.8 x 10-4 
and 18,000 x 10-9 = 1.8 x 10-5 beneficial mutations in transit cells and stem cells, 
respectively; 69982000 x 10-8 = 0.69982 and 69982000 x 10-9 = 0.069982 deleteri-
ous mutations in transit cells and stem cells, respectively; 7000 x 10-8 = 7 x 10-5 
and 7000 x 10-9 = 7 x 10-6 genomic instability mutations in transit and stem 
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cells, respectively; and 6.93 x 109 x 10-8 = 69.3 and 6.93 x 109 x 10-9 6.93 
neutral mutations in transit cells and stem cells, respectively. 
Randomly drawing numbers from a Poisson distribution, which predicts the 
number of successes in a fixed interval, allows one to randomly assign how many 
of each type of mutation occurs in each genome region during each cell divi-
sion. For example, drawing a random number from a Poisson distribution with 
A = 69.3 will determine how many neutral mutations land in a transit cell dur-
ing division; a random number from a Poisson distribution with A = 0.069 will 
determine how many deleterious mutations occur in a stem cell division. 
If a mutation lands in a beneficial region, a random number is drawn from 
the Uniform distribution with a range of 1 to 6, one number for each cancer bar-
rier (pro-growth, anti-growth, apoptosis, replication limit, metastasis, and elF-II). 
There is an equal probability that each number will be chosen from the Uniform 
distribution, so using this method allows one to randomly select which barrier is 
mutated. 
Each model is run using different numbers of genes per barrier, using either 
3,6,9,12,or 16 genes per barrier. Therefore, as the number of genes per barrier 
increases, so does the probability of a beneficial mutation. For example, if there 
are 16 genes per barrier, there are 6 x 16 x 1000 = 96000bp that can be mutated 
to increase the cells fitness. The length of the other gene regions will change 
accordingly as well. 
Finally, it is likely the case that more than one mutation is required to com-
pletely remove a barrier. In this model, and like Knudson's two hit hypothesis, 
it is assumed that two events are required to completely remove a barrier, either 
by mutation or infection. However, one mutation still has an affect on the phe-
notype, and the barrier can be considered partially removed. If a cell has one 
mutation, the probability that the mutant phenotype will be expressed is 50%, 
which is modeled using a Bernoulli distribution where the probability of success 
is 0.5. Thus, everyday there is a 50% change that the mutant phenotype will be 
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expressed. If a cell has two mutations in a barrier, it is completely removed and 
the mutant phenotype is expressed 100% of the time. 
7.6.2.2 JCV Mutations 
Activation of JCV in the Hit and Run model requires mutations in the NCRR 
region, and these mutations are modeled in a similar fashion to host mutations. 
The NCRR region is 430bp in length and the mutation rate of JCV is estimated 
to between 7.8 x 10-4 and 4 x 10-6 per site per year [31,47, 121]. This suggests 
that the average mutation rate of JCV is 1.074 x 1 0-6bp / site/ day. Thus, the prob-
ability that the JCV strain within single infected cell will acquire one NCRR on 
mutation on any given day is 1.074 x 10-6 x 430 = 4.6182 x 10-4. Therefore, using 
the Poisson distribution with A = 4.618 x 10-4 will generate how many NCRR 
mutations occur. Finally, NCRR mutations can only occur if the host cell is divid-
ing. 
7.6.3 Genomic Instability 
Since genomic instability, particularly CIN, is believed to playa role in tumori-
genesis, it is modeled as well. Every time a mutation lands in one of the seven 
genomic instability genes, the mutation rate increases linearly by a factor of two. 
For example, if there is one genomic instability mutation, the new mutation rate 
is double the original; if there are four genomic instability mutations the new 
mutation rate is eight times the original mutation rate; and so on until the new 
mutation rate is fourteen times the original mutation rate. 
The JCV Mad-1 .198 strain is able to induce genomic instability in the Hit and 
Run model. This virally induced genomic instability is combined with existing 
genomic instability, so if the cell has 3 genomic i~tability mutations and the 
JCV Mad-1 .198 phenotype, the mutation rate will be increased 6 x 7.5 = 45 fold. 
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However, once JCV is lost, the mutation rate returns to six times the original 
mutation rate. 
7.7 MUTANT BEHAVIOR 
7.7.1 Stem Cells 
Mutations that land in beneficial genes provide that cell with a selective advan-
tage. However, the particular advantage depends on what type of cell mutates. 
If a stem cell acquires one mutation in its metastasis barrier it gains the ability 
to move around the crypt, moving to the neighbor with the most oxygen. Move-
ment to the patch with the most oxygen is modeled because it has been proposed 
as the mechanism that selects for mobile metastatic cells [21]. If the mobile stem 
cell accumulates a second mutation in a metastasis gene, and is next to a blood 
vessel, it will try to invade the metastatic tissue (these blood vessels are produced 
during angiogenesis, see Section 7.8.1 ). However, the probability that the stem 
cell will survive the bloodstream and successfully invade the metastatic tissue is 
only 1/1000 [67]. If the stem cell does successfully invade the metastatic tissue 
it will go through four rounds of symmetric division to produce five metastatic 
stem cells, each of which continues to produce transit cells. 
If the pro-growth barrier of a stem cell is disrupted, either by mutation or in-
teraction with viral oncoproteins, it gains the ability to divide even if there is not 
an empty patch within its cone of vision, thus simulating the loss of contact in-
hibition. If both the metastasis and pro-growth barriers are removed, the mobile 
stem cell is able to move around the crypt and always divide in the inner crypt, 
but never in the outer crypt. 
If a mobile stem cell has the anti-growth barrier removed, it is able to divide in 
the outer crypt, but only if there is an empty patch within its cone of vision. If this 
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mobile stem cell has both the anti-growth and pro-growth barriers removed, that 
stem cell will be able to move around the crypt and divide anywhere, everyday. 
Stem cells that have removed the apoptosis barrier are exempt from the fitness 
search conducted during symmetric division, even if they have the most delete-
rious mutations. This behavior means that a stem cell with the most deleterious 
mutations, and possibly the most beneficial mutations too, will survive, spread-
ing their mutations throughout the population. As stem cells are considered im-
mortal, they do not have a replication limit barrier. Finally, any infected stem cell 
will reactivate JCV if the CIF barrier is removed by mutation, thus simulating 
reactivation by immunosuppression. 
7.7.2 Transit Cells 
Transit cells that acquire one metastasis mutation change their behavior from 
randomly moving to a patch in their cone of vision to moving to the neighbor 
patch that has the most oxygen. However, they follow all other wild-type division 
rules, and thus will only divide if they are in the inner crypt and there is an empty 
patch in their cone of vision. If the transit cell accumulates a second metastatic 
mutation, and is next to a blood vessel, it will attempt to invade the metastatic 
tissue, again with the probability of success being 1/1000. If the metastatic transit 
cell is able to invade the metastatic tissue it will follow the same rules of division 
that it followed in the crypt, except that there are not regions in which the transit 
cell cannot divide. 
If a transit cell removes the pro-growth barrier, it will always divide in the 
inner crypt, regardless of whether or not their is an empty patch within its cone 
of vision. However, it will remain unable to divide in the outer crypt. If the 
cell has both the metastasis and pro-growth barriers removed it will still divide 
anywhere in the inner crypt, but will chose to move to the neighboring patch 
with the most oxygen. 
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Transit cells having the anti-growth barrier removed gain the ability to divide 
in the outer crypt, so long as there is an empty patch in its cone of vision. How-
ever, if the cell also has pro-growth mutations they will acquire the ability to 
divide even when there are no empty patches, meaning that they can divide ev-
ery day, anywhere in the crypt. If these cells have the anti-growth, pro-growth, 
and metastasis barriers removed they will be able to divide anywhere, everyday, 
and will move to the neighboring patch with the most oxygen. 
If a transit cell has the replication limit barrier removed, it will stop losing its 
telomeres during each division. If this mutation occurs in concert with the pro-
growth and anti-growth mutations, the cell will divide anywhere, everyday, and 
without limit. This cell will only stop dividing is if it is shed into the lumen, or 
has low fitness and cannot survive when resources become scarce during popu-
lation growth (see 7.8.2). However, if the cell has the apoptosis barrier removed 
it will always survive when resources are scarce, even it has the lowest fitness. 
7.8 TUMOR EMERGENCE 
7.8.1 Angiogenesis 
Unlike the probability models, this ABM does not assume that angiogenesis is 
the result of mutation and barrier removal. Instead, this model assumes that 
angiogenesis naturally emerges when the tissue becomes hypoxic. This tends to 
occur when there are too many cells for the amount of oxygen being produced 
by a normal crypt. The body thus responds by producing new blood vessels to 
supply the growing tissue with the oxygen it needs. 
Angiogenesis is modeled by asking hypoxic patches that do not have any ves-
sels with five patches to create a new blood vessels. Any other hypoxic patches 
within a radius of five patches secrete VEGF molecules, which migrate towards 
the closest vessel. Once the VEGF molecule is within 0.5 patch units of the blood 
vessel, it stimulates the expansion of the existing blood vessel. The result is the 
gradual growth of new blood vessels, winding their way to the most hypoxic 
areas of the tissue. 
Each of the new vessels is assigned a random lifespan that can be as high 
as 250 days. Each vessel adds oxygen to each patch, and there can be up to 
three vessels on a single patch. The increased amount of oxygen supplied by 
angiogenesis increases the number of cells that the tissue can support, allowing 
the population to increase in size. 
The increase in population size is an important component of the model be-
cause, the more cells there are, the greater the chance that at least one will remove 
all of the barriers to cancer. Also, because angiogenesis tends to create areas with 
higher concentrations of oxygen, metastatic cells migrate towards the blood ves-
sels, where they may attempt to invade the metastatic tissue. This behavior thus 
replicates the close relationship between angiogenesis and metastasis. 
7.8.2 Population Cap 
There are two population size limits in this model. The first is a limit of 300 
cells in the colon crypt. The model assumes that the crypt only produces enough 
resources to support it's normal number of cells, ~250-300 cells. If the population 
rises above 300 cells, resources become scarce and only the most fit cells survive 
while the least fit cells die off. Least fit cells are defined as the cells that have 
the lowest amount of oxygen and the most deleterious mutations. However, any 
cells that inhibit apoptosis are not included in this fitness search, and so there is 
selection for apoptosis mutations. If enough cells accumulate the mutation, the 
population will grow beyond 300 cells. 
Due to limitations in computing power, a second population limit has to be 
set. If this limit were not in place the large population sizes would slow the 
simulation to a crawl, making it difficult to complete 1000 runs of each model. 
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This second population cap is set at 5000 cells, which is more than a sixteen fold 
increase in population size. If this population cap is reached, cells are randomly 
selected for death until the population returns to 5000 cells. No cells are excluded 
from this search, so the probability of being killed is the same for all cells. 
7.8.3 Tumor Formation 
Due to the population cap and limits in computing power, it is not possible to 
diagnose tumor formation by tissue size. For example, a polyp forms when the 
population reaches a size equivalent to a sphere with a diameter of 2cm, but this 
is hundreds of thousands of cells and exceeds the amount of available computing 
power. Due to this limitation, tumors are diagnosed by the presence of cells that 
have removed most barriers. A colon tumor is considered to have formed when 
at least one cell in the population has completely removed the pro-growth, anti-
growth, apoptosis, replication limit barriers. 
A metastatic tumor forms when at least one cell successfully invades the metastatic 
tissue (which is only possible if the metastasis barrier is removed), and has all of 
the other barriers removed. In the case of stem cells, all barrier except the replica-
tion limit barrier must be removed. If such a metastatic tumor forms, the age of 
metastatic tumor formation is recorded and the run is stopped. The run is only 
stopped when metastatic tumors form because the statistics for colorectal tumor 
prevalence are for metastatic tumors [2], thus facilitating comparisons between 
modeled and observed data. The only other way a run is ended is if an individual 
reaches 100 years of age and has not developed a metastatic tumor. 
7-9 RESULTS 




























FR=Full Reactivation, PHR=Partial Hit and Run, PR=Partial Reactivation, FHR=Full Hit and 
Run, M=Mutation 
o =mean, I =median, left bound=lower quartile, right bound=upper quartile 
Figure 7.3: Age Distribution of Colorectal Cancer by Model 
Figure 7.3 illustrates that all models tend to cause cancer primarily between the 
ages of 50-85. While spread of observed and modeled data are quite different, 
this finding is consistent with the observation that the average age of colorectal 































































FR=Full Reactivation, PHR=Partial Hit and Run, PR=Partial Reactivation, FHR=Full Hit and 
Run, M=Mutation 
o = mean, I =median, left bound=lower quartile, right bound=upper quartile 
Figure 7+ Age Distribution of Colorectal Cancer by Model 
The age distribution of colorectal cancer in Figure 7-4 illustrates that the data 
are not normally distributed, and thus ANOVA cannot be used to compare the 
models. However, the Kruskal-Wallis one-way analysis of variance is able to com-
pare multiple datasets that are not normally distributed. This test finds that 
the probability of the models being from the same underlying distribution is 
p «< 0.5. This in turn suggests that the process underlying each model do signif-
icantly affect the age distribution of colorectal cancer. 
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The primary goal of this paper is determine the role of mutation and infection 
in colorectal cancer. Thus, it is useful to know if the infection models are differ-
ent than the mutation model. Using the non-parametric two-sided Kolmogorov-
Smirnov test on each infection model versus the mutation model reveals all in-
fection models are significantly different than the Mutation model. 
7.9.2 Initiators a/Tumorigenesis 
Genomic instability is often argued to be the driver of tumorigenesis, and active 
JCV would seem to be a key driver if infection plays a role in tumorigenesis. The 
ABM records all events and when they take place, providing the opportunity to 
examine which events most frequently initiate tumorigenesis. As Figure 7.5 illus-
trates, the first event is not necessarily the initiating event, as there is frequently 
a long time lag between it and the next event. Infection also cannot be considered 
an initiating event because latent JCV does not change the behavior of the cell. 
Therefore, the initiating event is here defined as the event that has the shortest 
time period between it and the next event. This definition is adopted because 
this is the event that accelerates, or at least jumpstarts, tumorigenesis, as the fol-
lowing events occur within a shorter time span than before. While this definition 
is not perfect, it at least provides some insight into which events accelerate the 
accumulation of beneficial mutations. Finally, the mutations of the parental stem 
cell could not be recorded, so it is not possible to determine exactly which bar-
riers were removed in stem cells and which were removed in daughter transit 
cells. 
Figure 7.6 illustrates how many times each barrier removal event initiated tu-
morigenesis. Inhibition of apoptosis and up-regulation of telomerase are the most 
frequent initiators, a result that is consistent with observation that P53 is removed 
in 80% of colorectal cancers, while telomerase is up-regulated in 85-95% of cancer 
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Figure 7S Example of Initiating Event 
Inhibition of apoptosis may frequently be an initiating event in stem cells be-
cause it allows the stem cell to avoid being replaced during symmetric division, 
even if it has the most deleterious mutations. This increases the longevity of the 
stem cell, which may provide it with more time to accumulate additional muta-
tions. However, up-regulation of telomerase does not affect the stem cell since it 
already has the ability to divide indefinitely. 
Unlike stem cells, transit cells would benefit from up-regulating telomerase. 
However, even if a transit cell has the potential to divide indefinitely it will still 
be shed or die from accumulating too many deleterious mutations. Therefore, 
it is not immediately clear why up-regulation of telomerase is so frequently an 











































Models: FR=Full Reactivation, FHR=Full Hit and Run, PR=Partial Reactivation, PHR=Partial 
Hit and Run, M= Mutation. Events:A=Apoptosis, N=Hit and Run, S=Genomic 
Instability,T = Telomerase,G=Anti-growth,M=Metastasis,P=Pro-growth,R=Reactiva tion 
Figure 7.6: Initiating Events 
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regulation of telomerase sheds light on why this event may initiate tumorigenesis. 
Figure 7.7 shows that the complete removal of apoptosis and up-regulation of 
telomerase is preceded by a single metastasis mutation. This mutation gives the 
cell the ability to move to the patch with the most oxygen, even if those areas are 
lower in the crypt. The transit cell then moves throughout the crypt, looking for 
resources, and thus avoids being shed. Subsequent up-regulation of telomerase 
and inhibition of apoptosis provide the cell with the ability to divide indefinitely 
and avoid apoptosis no matter how many deleterious mutations that cell has. All 
three mutations together allow the cell to replicate without limit, but never die 
(apoptosis and metastasis). Such an immortal transit cell would have plenty of 
time to remove the remaining barriers, and given their higher mutation rate they 
may be able to do so at an accelerated pace. This hypothesis is supported by the 
research of Lamprecht and Lipkin [70], who presented evidence that transit cells 
can acquire mutations that allow them to remain in the crypt. 
It may also be that up-regulation of telomerase is frequently an initiator in the 
infection models because, while the cells are immune to apoptosis, and can di-
vide anywhere and everyday, they still have limited replicative potential. Without 
up-regulating telomerase, the ability to divide so frequently may backfire on the 
cells, as they can soon lose their telomeres. However, up-regulating telomerase 
via mutation gives that cell the ability to survive, and divide anywhere, every-
day, and without limit. This hypothesis is consistent with the observation that 
cells expressing Large T Antigen (T-ag)often become immortalized, can escape 
contact inhibition, and exhibit anchorage-independent growth, but only if they 
also up-regulate hTERT (reviewed in [47]). FInally, this phenotype may provide 
the cell with the more opportunities to accumulate additional mutations, as it is 
constantly dividing. 
Reactivation of JCV by the removal of the CIF-II barrier is also common. Such 
reactivation is accompanied by inhibition of apoptosis, and removal of the pro-
and anti-growth barriers. Even if no other barriers are removed, this combination 
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of events allows the cell evade apoptosis and replicate more frequently. Since mu-
tation occurs during every division, reactivation gives the cell the opportunity to 
accumulate more beneficial mutations at a faster rate. A similar situation occurs 
when JCV hits and runs, except that removal of the barriers and increase in mu-
tation rate only lasts for 14 - 21 days. Even though this is a short period of time, 
this event (N) can either mutate other tumor suppressor or oncogenes, or initiate 
genomic instability by mutation genes involved in CIN. This latter event would 
be particularly important, as it allow a mutator phenotype to last after L\98 Mad-l 
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7·9· 3 Role of Genomic Instability 
While CIN! ( CIN!) is found in 65-70% of sporadic cancers, there is debate over 
whether or not it induces or exacerbate tumorigenesis [4, 102]. As before, ge-
nomic instability is considered to initiate tumorigenesis if the following events 
occur rapidly. However, it is considered an exacerbating event if it occurs within 
an individual but does not initiate tumorigenesis. Finally, if genomic instability 
never occurs it does not playa role in colorectal cancer. Defining the role of 


























These results suggest that when present, genomic instability generally exac-
erbates tumorigenesis. Figure 7.8 also illustrates that, as modeled, genomic in-
stability does not often occur in colorectal cancer. This is in contrast to labora-
tory studies, which find CIN occurs in 65-70% of sporadic cancers, including 
colorectal cancer [102]. This indicates that the ABM does not accurately genomic 
instability. This could for several reasons: there need to be more genomic instabil-
ity genes; genomic instability needs to occur when certain barriers are removed, 
such as apoptosis; genomic instability needs to increase the mutation rate more 
than modeled. However, these modifications may not change the most of the 
conclusions because each model takes advantage of genomic instability. Both 
Mutation and Reactivation models can mutate genomic instability genes, increas-
ing the chances another barrier is removed. JCV-induced genomic instability can 
increase the cell's mutation rate by mutating the hosts own genomic instability 
genes. Thus, the overall conclusions may remain similar, but there would like 
be more tumors in each model. Even so, any future in carnations of this model 
could make the above modifications. 
7.9·4 The Role of Infection 
If infection plays a role in colorectal tumorigenesis it would be useful to un-
derstand how JCV increases the risk of cancer. Does JCV frequently initiate the 
process, or does it exacerbate it? If either are true, this knowledge could be used 
to prevent or treat colorectal cancer. Here, an initiating role for JCV is when the 
virus' reactivation, either by hit and run or removal of CIF-II, is also the initiat-
ing event. JCV is considered to be an exacerbator when activation occurs but is 
not the initiating event. JCV has no role if it never becomes active, and mutation 
removes all barriers. Non infected individuals are those who were generated dur-



































the distribution of roles ICV plays in colorectal tumorigenesis can be found in 
7·9· 
These results indicate that, on average, ICY exacerbates colorectal cancer. This 
is likely because immunosuppression, via removal of CIF-IT, occurs at 59.2 years 
(SD=20.2 years) in the Full Hit and Run model, while in the Partial Reactivation 
model activation occurs at 62.9 years(SD=19.8years). Similarly, the average age 
of the first hit and run event is 57 years and 59 years in the Full and Partial Hit 
and Run models, respectively. Thus, ICV may primarily act as an exacerbator 
because the individual has already accumulated several mutations, and active 
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JCV is able to remove the rest, either by forcing the cell to divide (Reactivation 
models) and/ or inducing genomic instability (Hit and Run models). 
JCV is also frequently an initiator of colorectal cancer. If reactivation of JCV oc-
curs early enough, it would be able to keep the cell alive and dividing constantly, 
increasing the chances of future mutations. However, this seems to occur far less 
often than when JCV exacerbates colorectal cancer. This likely because the prob-
ability of completely removing the CIF-II barrier, inducing immunosuppression, 
is only (16000 x 10-8)2 = 2.56 x 10-8, at most. This event is so unlikely that it 
wouldn't occur in most individuals, and if it did they would most likely be older, 
and thus more likely to already have accumulated initiating mutations. 
The probability of JCV evolving into the ~98 Mad-l phenotype and hitting and 
running is (1.074 * 10-6 * 430bp)2 = 2.132777 x 10-7. Again, this is a fairly rare 
event, and tends to occur in older individuals. However, if JCV did hit and run 
earlier, it would likely initiate cancer by inducing genomic instability. 
7.9.5 Number of Tumors Formed 
Another question one might ask is which model generates the most tumors. This 
question can be answered by summing how many of the 25,000 individuals de-
veloped cancer, and binning by model. One can further determine whether mu-
tation or infection are responsible for tumorigenesis. Mutation is considered the 
cause if a tumor formed when JCV is not present or played no role. Infection is 
considered the cause when it either exacerbates or initiates tumorigenesis. The 
results can be found in Figure 7.10. 
An important conclusion that can be drawn from Figure 7.10 is that mutation is 
able to cause colorectal cancer in the absence of JCv. This is true across all models. 
Since mutation is required for tumorigenesis, and infection is not, mutation can 

























FR=Full Reactivation, PHR=Partial Hit and Run, PR=Partial Reactivation, FHR=Full Hit and 
Run, M=Mutation 
Figure 7 .10: Number of Tumors by Model 
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A second conclusion one can draw from Figure 7.10 is that, in the worlds where 
infection can cause cancer it does so as much or more often than mutation. This 
finding indicates that even though infection is not required for tumorigenesis, 
JCV does play in important role in colorectal cancer. 
7.10 also illustrates how much exacerbation by JCV increases the risk of cancer. 
Three of the four infection models generate more tumors than mutation, indi-
cating that active JCV increases the risk of colorectal cancer. In all cases JCV's 
primary role is that of an exacerbator. This adds weight to the hypothesis that 
activation of JCV occurs after an individual accumulates several mutations, and 
that JCV is able increase the chances all barriers are removed by its ability inhibit 
apoptosis and the pro- and anti-growth barriers. In other words, JCV is able to 
complete the process of tumorigenesis in individuals that would otherwise not 
have developed colorectal cancer. Combined with the finding that JCV activates 
at -60 years of age, this suggests that JCV should cause more tumors in older 
individuals than the mutation model does. As Figure 7-4 illustrates, this is the 
case. 
Figure 7.10 also illustrates that the Reactivation models generate the most tu-
mors, suggesting that JCV is most tumorigenic when the host is immunocompro-
mised. This is likely because the formation of a cancer stem cell only requires 
that the cell already removed three barriers, and so JCV only needs to remove 
the other three. This is particularly true for the Full Reactivation model because 
JCV completely removes those three barriers. This is in contrast to the Partial 
Reactivation model, as the cell must acquire additional mutations to completely 
remove the apoptosis, anti-growth, and pro-growth barriers. This hypothesis is 
consistent with the finding that the Full Reactivation model generates many more 
tumors than the Partial Reactivation modeL 
A surprising finding is that the Full Hit and Run model generates the fewest 
tumors. A possible explanation has to do with that fact activation of .198 Mad-1 
JCV generates genomic instability and completely removes the apoptosis, pro-
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growth, and ant-growth barriers. Genomic instability will make the cell generate 
more mutations than normal, with more being deleterious than beneficial. Re-
moval of the apoptosis, pro-growth, and ant-growth barriers allows the cells to 
divide anywhere and everywhere without being killed. Thus, this cell will pro-
duce a large volume of daughter cells with the same phenotype. Together this 
means that the population will grow rapidly, and that the cells driving the growth 
will have an increased number of deleterious mutations. Angiogenesis is a fairly 
slow process, as it takes time for the vessels to spread throughout the crypt, and 
so it may not be able to provide the rapidly growing population with the oxygen 
it needs. This not a problem when ,198 Mad-1 is active, but as soon as it deacti-
vates all of the cells that did not already have apoptosis removed will likely die 
because they have too many deleterious mutations. Therefore, the only cells that 
will survive are those that either already inhibited apoptosis, or had JCV-induced 
genomic instability remove the barrier. This would remove most of the cells that 
were hit and run by JCV, almost making the impact of hit and run minimal. This 
hypothesis seems to match up with the finding that the Full Hit and Run and 
Mutation models generate a similar number of tumors. 
This scenario does is not necessarily true for the Partial Hit and Run model. 
In this model, while there is JCV-induced genomic instability, the pro-growth, 
anti-growth, and apoptosis barriers are only removed half of the time. This will 
results in a smaller rate of population growth for two reasons: 1), the population 
does not grow as rapidly because the pro- and anti-growth barriers are only re-
moved half of the time, and so the cell cannot divide every time and everywhere; 
2) cells that accumulate large numbers deleterious mutations can be die when 
apoptosis is not being inhibited by ,198 Mad-1 JCv. The decreased rate of popu-
lation growth means that, compared to the Full Hit and Run model, there will 
be more resources available to cells that survive. Some of these cells would have 
acquired beneficial mutations and would have more resources than cells in the 
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Full Hit and Run model, so they would be more likely to survive and accumulate 
more mutations that result in the formation of a metastatic tumor. 
Finally, the above scenario also does not apply to the Reactivation models be-
cause after ICV becomes active apoptosis is inhibited for the remainder of that 
cell's life, and thus will not be killed when resources become scarce. This is par-
ticularly true for the Full Reactivation model, which may also help explain why 
it causes the most tumors. 
7.9.6 Metastatic Cell Type 
It is generally believed that stem cells are the cells which metastasize. The rea-
soning behind this is that stem cells have a long lifespan, giving them plenty of 
time to accumulate all of the necessary mutations. This is in contrast to transit 
cells, whose existence is fleeting, theoretically preventing them from acquiring all 
mutations needed for metastasis. To test this hypothesis, the ABM records which 
cell type, transit or stem, metastasizes. The results can be found in Figure 7.11 
It seems reasonable to assume that because transit cells inherit their parental 
stem cell's mutations, they may only have to acquire one more mutation to have 
the opportunity to metastasize. Furthermore, there is only one of these parental 
stem cells, while over the course of several years that stem cell will produce hun-
dreds or thousands of daughter cells, any of which can acquire that last mutation. 
That transit cells have a higher mutation rate makes this even more likely. It is 
also quite possible that the transit cell inherits the stem cell mutations that con-
fer immortality. This long lifespan, combined with a higher mutation rate, gives 
these transit cells many opportunities to accumulate beneficial mutations, more 
so than stem cells, which have a lower mutation rate. This hypothesis is consis-
tent with the evidence that transit cells may undergo mutation and selection that 
enables them to linger in the crypt, giving them time to accumulate the extra 






















The world of the ABM can be interpreted in one of two ways.The first interpre-
tation is that the world represents one crypt in a single individual, and each run 
represents lout of 1,000 individuals. The second interpretation is that all runs 
represent 1,000 crypts in a single individual. Either situation is far from realistic, 
as it has been estimated that there are 1.5 x 107 colon crypts in an individual. That 
prevalence can only be calculated by assuming that each run simulates the events 
in a single crypt means that modeled prevalence values must be interpreted with 
caution. Even so, modeled prevalence values may reveal the age distribution one 
might expect given each model's hypothesis, and thus which model is most likely 
to be realistic. Each of these models were tested using 3, 6,9,12, or 16 genes, which 
will also shed some light on the number of genes per barrier. The modeled preva-
lence values are found in Figure 7.12, while the Euclidian distance between the 
observed prevalence and modeled prevalence is found in Figure 7.13. 
The modeled prevalence values suggest that the Full Reactivation model with 
six genes per barrier best replicates the observed prevalence, supporting the hy-
pothesis that infection plays an important role in tumorigenesis. Both the Muta-
tion and Full Hit and Run models with nine genes per barrier are not too far 
behind. These results are consistent with the finding that all models are able to 
generate tumors. 
7.10 CONCLUSIONS 
The findings presented above reveal that mutation is the primary cause of col-
orectal cancer, as it is able to generate a large number of tumors without ICV. 
Mutation is also critical in tumorigenesis, not only because it must remove the 
barriers infection cannot, but because mutations that up-regulate telomerase and 
inhibit apoptosis frequently initiate tumorigenesis. 
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While mutation is the primary cause of colorectal cancer, infection plays an 
important secondary role, usually exacerbating cancer. The Reactivation models, 
which posit that JCV is activated by mild immunosuppression, is most frequently 
an exacerbator, but is highly tumorigenic. This is likely because immunosuppres-
sion occurs later in life, after tumorigenesis is already initiated. Once activated, 
JCV removes three important barriers that keep itself and the cell replicating 
and immune to apoptosis. Together, these processes will keep the cell alive long 
enough to accumulate additional mutations, thus increasing the chances that a 
cancer stem cell will evolve. 
The Hit and Run models are also most frequently exacerbators, but they are 
less tumorigenic. The transient nature of hit and run means that the cell will 
only have genomic instability and the transformed phenotype for a short period 
of time, after which it returns to its previous state. The cell will only become 
more carcinogenic if it removes other barriers while the L\98 Mad-1 phenotype 
is present. JCV-induced genomic instability may mutate the host's genomic in-
stability genes, maintaing a mutator phenotype after L\98 Mad-1 is lost, thereby 
increasing the chances additional mutations accumulate [109]. This won't hap-
pen with every cell, which may explain why the hit and run mechanism is less 
tumorigenic. 
While JCV most often exacerbates tumorigenesis, it also frequently initiates the 
process. Activation of JCV by immunosuppression may be able to induce cancer 
by forcing the cell to divide, increasing the chance of mutation and possible bar-
rier removal. Since the cell is constantly dividing, the likelihood of a beneficial 
mutation occurring after reactivation is higher than if JCV is not present, which 
may be how JCV initiates tumorigenesis in the Reactivation model. If a hit and 
run event occurs early, JCV-induced genomic instability could initiate tumorige-
nesis by increasing the chances that a mutation in a beneficial gene soon occurs, 
thus initiating tumorigenesis. 
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Another important finding is that in the infection models mutation is respon-
sible for fewer tumors than in the model where mutation is the only cause of 
colorectal cancer. This may be because individuals have already acquired mu-
tations in the cancer barriers prior to activation of JCV, which usually occurs 
around 60 years of age. JCV can remove the rest of the barrier either by keeping 
the cell alive long enough for it to acquire additional mutations and/or by gener-
ating genomic instability. The finding that, more often than not, JCV exacerbates 
tumorigenesis is consistent with this hypothesis. 
It is difficult to say which infection model is most accurate, as the Hit and 
Run models have the most experimental support, while the Full Reactivation 
model best replicates the observed data. However, in all cases mutation is the 
primary cause of colorectal cancer, but JCV plays an important role by exacer-
bating, and less frequently initiating, colorectal cancer. Given that mutation and 




Taken together, the models presented herein indicate that both mutation and 
infection play important roles in colorectal tumorigenesis. Each of the probability 
models find that mutation is insufficient to drive colorectal cancer, no matter if 
the stem cell point mutation rate is f.1 = 10-10 or f.1 = 10-11 • Conversely, the 
infection model is able to generate realistic incidence values when f.1 = 10-11 • 
These results suggest that infection is the primary cause of colorectal cancer, 
as tumorigenesis will not occur in the absence of ICV. However, the Geometric 
model comes to the opposite conclusion, as it finds that mutation alone is able to 
drive colorectal cancer. Where both models agree is in finding that the presence 
of infection dramatically increases the risk of colorectal cancer. 
The ABM appears to resolve the conflicting results of the probability and Geo-
metric models. This collection of models finds that both mutation and infection 
are able to drive tumorigenesis, and that all models can generate realistic preva-
lence values. Since colorectal cancer does not absolutely require infection, ICV 
cannot be considered the primary cause. Despite its secondary role, the presence 
of active ICV increases the risk of cancer, as it increases the number of tumors 
and initiates or exacerbates tumorigenesis more often that it plays no role. The 
finding that both mutation and infection play important roles in colorectal tu-
morigenesis is also consistent with the estimate that -25% of colorectal cancers 
result from multifactorial contributions of different risk factors [9]. While the 
authors argue that these 25% of cases occur as the result of inheriting many 
rare dominant alleles that have low penetrance, but together increase the risk of 
colorectal cancer, the results presented here suggest the alternative hypothesis 
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that infection is one of those critical environmental factors that accounts for an 
increased risk of cancer. 
Colorectal cancers are usually divided into two categories, but these results 
suggest that it should be divided into three. This first is all colorectal cancers 
caused by germline mutations, primarily Family Adenomatous Polyposis (FAP) 
and Hereditary Nonpolyposis Colorectal Cancer (HNPCC). This category con-
tains the fewest individuals, likely because the high-risk alleles reduce the indi-
vidual's fitness, and have decreased in frequency due to negative selection. The 
second category is colorectal cancer caused soley by somatic mutations. As mod-
eled, this is the second largest category. The individuals in this category likely 
develop colorectal cancer through the accumulation of the mutations described 
in Chapter 2, namely Adenomatous Polyposis Coli (APC), Kristen Rat Sarcoma 
Virus (KRAS), SMAD, and P53. 
The third and new category is JCV associated colorectal cancers. As modeled, 
this is the largest category of colorectal cancer cases. Individuals in this category 
may frequently have somatic mutations in APC , KRAS, SMAD, and/ or P53, pre-
disposing them to colorectal cancer. In the absence of JCV, these individuals may 
simply develop benign colorectal tumors, which are present in 50% of the pop-
ulation [64]. Activation of JCV, either by immuosuppression or the evolution of 
,198 Mad-I, typically occurs at age 60, after the somatic mutations have occurred. 
This event may transform the tumor from benign to malignant, causing tumors in 
individuals that would not have developed malignant colorectal cancer without 
JCV. 
In addition to shedding light on the drivers of tumorigenesis, these models 
add weight to the hypothesis that natural selection has favored a lower stem 
cell mutation rate. While evolution has the power to select against the germline 
mutations that increase the risk of FAP and HNPCC, it cannot directly select 
against somatic mutations. However, by selecting for a lower mutation rate in 
stem cells, evolution can decrease the frequency of colorectal cancer. Both the 
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probability and Geometric models confirm this hypothesis, as mutation is unable 
to generate cancer patients when the stem cell mutation rate is 100 times lower 
than the transit cell rate. This finding is in agreement with the work of Frank 
et al. [43], who also concluded that a stem cell mutation rate that is 100 times 
lower provides sufficient protection against cancer. 
Unfortunately, not much can be said about the number of genes per barrier, 
as the number that fits best is different across each set of models. The primary 
conclusion that can be made is that the more genes that are involved in a pathway, 
the more likely that pathway is to be disturbed. 
The results from these models suggest colorectal cancer is a multifactorial dis-
ease. Mutation is required for tumorigenesis, but infection by JCV increases the 
risk of colorectal cancer, either by initiating or exacerbating colorectal cancer. In 
combination with the findings of numerous studies that demonstrate JCV's onco-
genic potential and frequent presence in colorectal tumors, the results presented 
here suggest that JCV's role in colorectal cancer deserves more attention. A good 
place for future studies to start might be to determine titers of Mad-l JCV in 
colon tumors of cancer patients throughout their treatment. If it is found that in-
dividuals with higher titers of JCV Mad-l are at higher risk of colorectal cancer, 
it would reinforce the hypothesis that JCV is an important risk factor for colorec-
tal cancer. If further studies confirm these findings there would be good reason 
to develop a vaccine against JCV. While vaccination would not eradicate colorec-
tal cancer, as mutation can still drive tumorigenesis in the absence of infection, 
it would reduce the number of colorectal cancer cases. These results, therefore, 
are encouraging, as they present the possibility of decreasing the prevalence of 
colorectal by reducing the rate of infection by JCv. 
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APPENDIX A R CODE FOR PROBABILITY MODELS 
A.1 ESTIMATING PREVALENCE OF COLON CANCER: CONSTANT MUTATION, 
CONSTANT STEM CELL POPULATION 
The following code creates two different models of colon cancer development, 
but in each case the mutation rate and stem cell numbers remain constant. The 
first model argues that mutation drives the development of colon cancer, while 
the second hypothesizes that infection initiates the oncogenic process. Each model 
is also executed using the parameters from Calabrese and Shibata [17] as well as 
more recent parameter estimates1 • 
A.I.1 Creating the Initial Dataframe 
A.I.I.1 Import Observational Data 
The first step of the program is to import actual data of colorectal cancer (CRC), 
using the SEER database SEE [2]. This was accomplished by downloading the 
data and creating new vectors (CRC_2003_2007 and CRC_2ooo_2006) containing 
the incidence data. The data used in Calabrese and Shibata [17] was found in 
the appendix of their paper. The ICV prevalence data was taken from Table 1 
of Knowles et a!. [68]. Note that from ages 0-19, prevalence was recorded every 
5 years, but from ages 20-69 prevalence was recorded only every 10 years. As 
the CRC data are recorded every 5 years, the first five years in each age group 
1 The parameters values used in this example are different than the ones used to generate the results in 
Chapter 5. Here, genomic instability is 1.5, while in the actual models it is 2. Gene length here is 1500bp, 
while in the models it is lOoobp. 
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over 20 years old was assigned an NA value. For example, prevalence of JCV at 
30-34 is considered "NA", while at the ages of 35-39 JCV prevalence is 0.39 (i.e. 
prevalence is not divided across the ten years). 
Plots found on the SEER website and Calabrese and Shibata [17] plot incidence 
data for the median age of an age group. For example, the incidence of CRC in the 
age group of 30-35 is plotted at age 32.5. As such, the vector AverageAgeCancer 
was created to contain these median ages. The code used to accomplish these 
tasks can be found below: 
See r€l3€l7< - read. c s v ( " /Users/ chandlergatenbee/Docurnents/UofL/CancerProbPaper /Observed 
Data/CRCQJ-07.csv") #Co lon cance r data f rom SEER 2€l€l3 -2€l€l7 
CRC_2€l€l3_2€l€l7<-Seer€l3€l7[,2) #Slice CRC incidence values from table 
See r€l€l€l6< - read. c s v ( " /Users/ chandlergatenbee/Docurnents/UofL/CancerProbPaper/Observed 
Data/CRCoo-o6.csv") #Co lon cance r data f rom SEER 2€l€l€l -2€l€l6 
CRC_2€l€l€l_2€l€l6<-Seer€l€l€l6[,2) #Slice CRC incidence values from table 
CalabreseData<-c(€l, €l, €l, €l.€l7, €l.18, €l.47, 1.46, 2.82, 5.59, 11.14, 21.59, 42.72, 
77.94, 125.98, 184.€l4, 25€l.96, 319.14, 387.22, NA) #Actual data used in 
Calabrese 2€l1€l; from SEER 1992-1999 
CalabreseAgeRange<-seq(€l,9€l,5) #Age Values used by Calabrese to calculate 
probability of cancer 
SeerAges<-Seer€l3€l7[,1) #Age categories used by SEER 
JCVPrevalence<-c(NA,€l.11,€l.14, €l.24, €l.22, NA, €l.34, NA, €l.39, NA, €l.34, NA, €l.45, 
NA, €l.5, NA, NA, NA, NA) #JCV Prevalence by age From Knowles 2€l€l3 
AverageAgeCancer<-rep(€l,length(CalabreseAgeRange)) 
forti in 2:1ength(CalabreseAgeRange)){ 
AverageAgeCancer[i)<-mean(CalabreseAgeRange[(i-1):i))} 
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A.1.1.2 Create Empty Dataframes that will be filled in with results 
Two sets of vectors were created to capture the results from the analysis, the 
first set using old parameter values, the second set using new paramter values: 
"ProbInfection", "Incidence_Infection", "ProbMutation", and "Incidence_Mutation" 
were used to collect the results created using the parameters found in Calabrese 
and Shibata [17]; "ProbInfectionNew", "Incidence_InfectionNew", "ProbMuta-
tionNew", and "Incidence_MutationNew" were used to collect the results cre-
ated using new parameter values. The code used to create these vectors can be 
found below: 










A.1.1. 3 Estimating Incidence of ICV Infection 
JCV prevalence data from Knowles et al. [68] only contains estimates for ages 1-4, 
5-9, 10-14, 15-19, 20-29, 30-39, 40-49, 50-59, 60-69, while the CRC prevalence data 
is available for ages 0-85+, in increments of five years. Thus, linear interpolation 
of the regression line was performed on the Knowles et al. [68] data set, so as 
to fill in all missing values as well as to estimate JCV prevalence in individuals 
over 70 years old. The estimated prevalence values were then stored in the vector 
"JCVEstimatedPrev". The code used was as follows: 
RegPrev<-lm(JCVPrevalence-AverageAgeCancer) 
JCVEstimatedPrev<-coef(RegPrev) [2]*AverageAgeCancer+co ef(RegPrev) [1] 
These estimated values were then plotted against the actual values from Knowles 
et a1. [68] to ensure that the prevalence pattern remained consistent. The follow-
ing code generated the plot which can be compared to the plot from Knowles 
et a1. [68] (Figure A.I): 
xrangelm<-AverageAgeCancer 
yrangelm<-seq(0,0.5,0.5/(length(xrangelm)-1)) 
plot (xrangelm, yrangelm, xlab="Age of Infection", ylab="Prevelance of JCY", main=" 
Estimated Prevalence of JCY Infection", type="n") 
points(AverageAgeCancer,JCVPrevalence,pch=l,col=l) #Observed Prevalence 
points(AverageAgeCancer,JCVEstimatedPrev,pch=2,col=2) #Estimated Prevalence 
abline(RegPrev) 
legend(0,0. 5, c( "Actual Prevalence of JCY", "Estimated Prevelance of JCY", "Estimated 
Prevelance for Each Age") , lty=c(NA, 1,NA) ,pch=c( 1,NA, 2) ,col=c( 1,1,2)) 






o Actual Prevalence of JCV 
- Estimated Prevelance of JCV 
Estimated Prevelance for Each Age 
o 
o 20 40 
Age of Infection 
60 80 
(a) Estimated and Observed Prevalence of JCV 
1:J() , 
90i "f- '-.-/ ..... '-_ ...... -- -_"'" 
eo I" 
I .... -_._- -.-. 
/0 I 
Ago grOlJP I ve8rs I 
... - .• BKV 
,-". • SV"0 1'.- .. ........,-----
,0,9 60·69 
(b) Observed Prevalence of JCV from Knowles et aL [68J 
Figure A.I 
Finally, the model developed herein requires JCV incidence, however Knowles 
et a1. [68] only provides JCV prevalence. Thus, JCV incidence was estimated by 
finding the average change in JCV prevalence, the results being stored in the 
vector "JCVIncidence". These values were then averaged, yielding an average 
incidence of 0.02716503 every five years (Note: the first incidence value was not 
included as it is NA): 
JCVlncidence<-rep(NA,length(AverageAgeCancer» 
for(i in 2:length(JCVEstimatedPrev»{ 
JCVIncidence[i]< -JCVEstimatedPrev[i] -JCVEstimatedPrev[(i-Il] } 
AvgJCVIncidence< -mean(JCVIncidence[-I]l 
A.1.1.4 Creatil1g the Dataframe 
All vectors were compiled into a dataframe labeled "CRC" using the code below. 
The resulting dataframe can be found in Figure A.2. 
CRC<-data.frame(SeerAges, CalabreseAgeRange, AverageAgeCancer, JCVPrevalence, 
JCVEstimatedPrev, JCVIncidence, CRC_2000_2006, CRC_2003_2007, CalabreseData, 
ProbMutation, ProbMutationNew, Incidence_Mutation, Incidenc~MutationNew, 
ProbInfection, ProbInfectionNew, Incidence_Infection, Incidence_InfectionNewl 
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Figure A.z: Initial CRC Dataframe 
A.1.2 Setting Initial Parameters 
The following code contains the parameter values used in all models. Parameters 
ending with a /1 1 /1 (or no number) refer to values obtained from Calabrese and 
Shibata [17] I while those ending in /12" refer to those obtained elsewhere. k refers 
to the number of barriers to cancer; u refers to the mutation rate; Nm refers to the 
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number of colon stem cells; N s refers to the number of colon stem cells infected 
by JCv. 
#Constant Parameters 
k1<-6 #number of barriers to cancer (from Hanahan) 
k2<-kl-3 #estimated number of barriers left after JCV infection. 
u1<-3*(10A-9)*(1000) # "If three genes are at risk in a pathway, then the 
probability of mutation (u) of anyone of the three genes in a single division 
is 3 * 10-6 instead of 1* 10-6 with a single gene target[of 1000bp] " Calabrese 
2010 
u2<-3*(10A-8) 
Nm<-8*lS000000 # Number of stem cells in the colon. 8 stem cells per crypt, 
15,000,000 crypts in the colon (From Calabrese) 
Nm2<-S*lS000000 
Ns=Nm*0.9S #Estimated number of actively infected colon crypt cells 
Ns2<-Nm2*0.9S 
A.I. 3 Functions Used to Calculate Probability of Cancer 
The following code was used to create functions that calculate the probability 
of colon cancer for any given age. For the mutation model, the inputs are the 
current age, number of stem cells in the colon (N), and the mutation rate (Il-). 
The infection model includes all of the above, but with the addition of age of 
infection, so that the total amount of time an individual has been infected by JCV 










d2=(agenow-ageinfection)*365*0.25 #Number of infected cell divisions=Number 




A.1.4 Mutation Model 
As the mutation model argues that the oncogenic process begins at birth, cal-
culating the cumulative probability of cancer in the mutation model is simply 
a matter of using the above function (pagel.) on each age group. The vector 
CRC["ProbMutation"] collects the results when using the parameter values found 
in Calabrese and Shibata [17], while CRC["ProbMutationNew"] collects the prob-
abilities when the new parameters are used. 
CRC ["ProbMutation" J<-pagel (CalabreseAgeRange, Nm, ul) 
CRC [ "ProbMutationNew" J < -page I (Ca lab reseAgeRange, Nm2 , u2) 
A.1.5 Infection Model 
Calculating the cumulative probability of cancer with infection is a bit more dif-
ficult than when dealing with mutation alone. The reason is because one must 
take into account how long an individual has been infected, which is the differ-
ence in current age and age of infection. Thus, one must create a matrix that has 
each possible current age as one row, and each possible age of infection as one 
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The empty matrix that is created can be found in Figure A.3 . 
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Figure A.3 
A.1.5 .1 Parameters from Calabrese and Shibata [I7] 
The empty matrix from above can be filled in with the probability of cancer for a 
given period of infection by using the page2 function, using current age and age 
of infection as parameters. Note that Ns is used in these calculations (as opposed 
to N), as it reflects the number of infected colon stem cells (95% of colon stem 
cells). Only half of the matrix was filled in, since an individual cannot be infected 
before they were born (i.e. agenow>ageinfect). The code used to fill in the matrix 
is as follows: 
for(i in l:length(agenow)){ 
for(k in l :length(ageinfect)){ 
ifelse(agenow[ij>=ageinfect[kj, 
agenowVageinfect[i,kj< -page2(agenow[ij,ageinfect[kj,Ns2,u2), 
agenowVageinfect[i , kj< -0 ) } } 
The filled in matrix can be found in Figure A.4 
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Each element of the matrix above gives the probability of cancer given a partic-
ular length of infection (i.e. current age i-age of infection k), and thus provides 
the probability of colon cancer given each combination of current age and age 
of infection. However, one must also take into account the probability that the 
individual was actually infected by JCV at age k, which can be accomplished 
by multiplying each element by the average incidence of JCv. Afterwards, one 
can sum across each row to determine the cumulative probability of colon cancer 
given infection by JCV for each current age, yielding the predicted prevalence of 
colon cancer for each age. The logic behind this is that prevalence is equal to the 
total number of cases, which is the sum of all new cases (incidence), past and 
present, for each current age. For example, the prevalence of CRC at age 60 in-
cludes all individuals that developed CRC at age 30,35,40 ... 60, which is equiv-
alent to summing across each row of the above matrix. These values were then 
157 
stored in CRC["Problnfection"]. The code used to accomplish this is as follows 
(Note: if the cumulative probability of colon cancer exceeded 1, it was replaced 
with a value of I): 
agenowVageinfect[which(is.na(agenowVageinfect==TRUE))]=0 #replace NA values with 0 
for(i in l:length(CalabreseAgeRange)){ 
ifelse(sum(agenowVageinfect[i,l:length(ageinfect)])<l, 
CRC[ "ProbInfection"] [i, l]<-sum(agenowVageinfect [i, 1: length (ageinfect)]) * 
AvgJCVlncidence, 
CRC["Problnfection"] [i,l]<-l) } 
A.1.5.2 New Parameters 
The same method as described in A.1.5.1 was used to calculate the expected 
prevalence of colon cancer with infection, but using the new parameter values. 
The" AgeNowVsAgelnfect" matrix can be found in Figure A.5.After all calcula-
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AgeNowju" , "AgeNOwzs" , "~ow8o" , "~0w8s" , "AgENOwgl" ) , c ( "AgeInfecto" , " 
Agelnfect5" , "AgeInfectIo" , " AgeInfectI5" , "AgeInfect2o" , "Agelnfect25" , "AgeInfect30 
", "Agelnfect35" , "Agelnfect4o", "AgeInfect45" , "Agelnfect50", "AgeInfect55" ," 
Agelnfect6o", "AgeInfect65" , "AgeInfect7o", "AgeInfect75" , "AgeInfectBo"," 
AgelnfectB5" , "Agelnfect90" ) ) ) 
for(i in l:length(agenow)){ 
for(k in l:length(ageinfect)){ 
ifelse(agenow[i]>=ageinfect[k], 
agenowVageinfect[i,k]<-page2(agenow[i],ageinfect[k],Ns2,u2), 
agenowVageinfect[i,k]<-0 ) } } 
agenowVageinfect[which(is . na(agenowVageinfect==TRUE))]=0 #replace NA values with 0 
for(i in l:length(CalabreseAgeRange)){ 
ifelse(sum(agenowVageinfect[i,l:length(ageinfect)])<l, 
CRC ["ProblnfectionNew"] [i, l]<-sum(agenowVageinfect [i, 1: length (ageinfect)] ) * 
AvgJCVlncidence, 
CRC [ "ProblnfectionNew" ] [i, 1] < -1) } 
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Figure A.5 
A.1.6 Converting Data from Prevalence to Incidence 
The probability values generated reflect the cumulative probability (i.e. preva-
lence) of colon cancer for each age group. However, the data from SEE [2] are in 
the form of incidence per age group, per 100,000 individuals. As such, the preva-
lence data were converted to incidence by taking the difference in probability 
of colon cancer between each age group. Afterwards, the incidence values were 
multiplied by 100,000 so as to provide the expected incidence of CRC per 100,000 
individuals. This was accomplished by using the following code: 
#Calculate Incidence of Colon Cancer, per 100,000 
#Mutation 
159 
for(i in 2:length(CRC["ProbMutation")[,I])){ 
CRC ["Incidence_Mutation"] [i, ]<- (CRC[ "ProbMutation"] [i, ]-CRC ["ProbMutation" 
][(i-l),])*leeeee 
} 
for( i in 2: length(CRC[ "ProbMutationNew"] [,1]) ) { 
#Infection 
CRC[ "Incidence_MutationNew"] [i, ]<- (CRC[ "ProbMutationNew"] [i, ]-CRC[" 
ProbMutationNew"] [ ( i-I) , ] ) * leeeee 
} 
for( i in 2: length (CRC [" ProbInfection"] [, 1]) ){ 
CRC [ "Incidence_ Infection" ] [i, ] < - (CRC [" ProbInfection"] [i, ] -CRC [ " 
Problnfection"] [( i-I) , ] ) *leeeee 
} 
for(i in 2 :length(CRC[ "ProbInfectionNew"] [, 1])){ 
A.!. 7 Results 
CRC[ "Incidence_InfectionNew"] [i, ]<- (CRC[ "ProblnfectionNew"] [i, ]-CRC[ 
"ProblnfectionNew" ] [ (i - 1) , ] ) * leeeee 
} 
A.I.7.l Dataframe 
After being filled in by the above code, the CRC dataframe looks as follows: 
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Figure A.6: 
Plots 
For the purposes of plotting, the incidence data were converted to log-scale, so 
as to emphasize the different predictions between the mutation models and the 
infection models. If the incidence was 0, then log (0) yields - 00, which obviously 
cannot fit onto the plot. Therefore, values that did yield - 00 were replaced with 
- 25.22388, which reflects the smallest predicted probability. The code used to 
accomplish this is as follows: 
#Adjust data so the log can be taken: if prob=0, then 10g(0)=-Inf, which won 
't fit on a graph . Set min to -25.22388, the smallest probability 
produced in Stepwise Model that was not -Inf 
logIMOld<- log (eRe [, "Incidence_Mutation"] ) 
10gIMNew<- log (eRe [, "Incidence-MutationNew"] ) 
10gIIOld<- log (eRe [, "Incidence_Infection "] ) 
logIINew<-log (eRe [, "Incidence_InfectionNew "] ) 
#Replace -Inf with -25 
#Mutation, Old Parameters 





#Mutation, New Parameters 




#Infection, Old Parameters 




#Infection, New Parameters 




After transforming the data, the following code was used to generate plots 
comparing the observed data to each model's predictions, given the parameters 
used in Calabrese and Shibata [17] (the resulting plot can be found in FigureA.7a 
#Log Plot of Predicted Cancer Incidence Probability,As a Function of Age, With Real 
Data.lnfection and Mutation Models, Old Parameters xrange<-CalabreseAgeRange 
ymax<-max( CRC [, "Incidence_Infection" jl lymax<-log(ymaxl 
lymin<--25.22388 #8ased off results from stepwise model. Otherwise, log(CRC[," 
Incidence_MutationNew"ll yields -Inf for all values because (CRC[,"Incidence_ 
MutationNew"jl is 0 
yrange<-seq(lymin,lymax,(lymax-lyminl/(length(xrangel-III 
162 
plot(xrange, yrange, type="n", xlab="Current Age",Ylab="ln(Incidence of Cancer, per 
100,00)" ,main="Incidence of Colon Cancer", sub="k=6N=8,u=3*10"---6") points ( 
AverageAgeCancer,10g(CalabreseData),pch=19,lty=1) 
points (Ave rageAgeCancer, log (CRL2f>f>(L2(:Hl6) ,pch=l, lty=l) 
points(AverageAgeCancer,10g(CRC_2f>f>3_2f>f>7),pch=2,lty=1) 
lines (CalabreseAgeRange, 10gIMOld, col="red") 
lines(CalabreseAgeRange,10gIIOld,col="blue",lty=2) 
legend(2f>, -If>,c(''Observed Data 1992-1999", "Observed Data 2000-2006", "Observed Data 
2003-2007" , "Mutation Model", "Infection Model"), col=c (1,1,1, "red" , "blue") , lty=c( 
NA,NA,NA,1,2),pch=c(19,l,2,rep(NA,2))) 
A similar set of code was used to plot the results of each model's predictions, 
given the new parameters (the resulting plot can be found in Figure A.7b): 
#Log Plot of Predicted Cancer Incidence Probability,As a Function of Age, With Real 
Data. Both Models, New Parameters 
xrange<-CalabreseAgeRange 
ymax< -max (CRC [ , "CRC.2ooo_2006" ) ) 
lymax<-log(ymax) 
lymin<--2S.22388 #Based off results from stepwise model. Otherwise,log(CRC[," 
Incidence_MutationNew")) yields -Inf for all values because (CRC [," Incidence_ 
MutationNew")) is f> 
yrange<-seq(lymin,lymax, (lymax-lymin)/(length(xrange)- 1)) 
plot(xrange, yrange, type="n", xlab="Current Age",ylab="ln(Incidence of Cancer, per 




lines(CalabreseAgeRange, 10gIMNew, col="red") 
lines(CalabreseAgeRange, 10gIINew, col="blue", lty=2) 
legend(2f>, -If> ,c( "Observed Data 1992-1999", "Observed Data 2000-2006", "Observed Data 
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A.2 ESTIMATING INCIDENCE OF COLON CANCER: GENOMIC INSTABILITY 
MODEL 
A problem of the static model described above is that it assumes all cells have 
an equal probability of acquiring enough mutations to knock out each barrier. 
However, it seems more realistic that a subset of cells will acquire the first muta-
tion, and that this subset will have a head start in the race towards cancer. Thus, 
the following model tracks how many cells have acquired x mutations. This task 
is accomplished by determining the probability that anyone cell has acquired 
a mutation. That probability is then multiplied by the current number of colon 
stem cells, yielding the expected number of stem cells that have acquired x mu-
tations. This process is repeated until all barriers to cancer have been removed, 
and as such the number of cells carrying x mutations decreases over time. Fur-
thermore, it has been observed that the mutation rate increases throughout the 
development of cancer cells, a process known as genomic instability. This model 
tries to capture the impact of genomic instability by increasing the mutation rate 
by 150% every time a barrier is removed. Finally, this model uses the "new pa-
rameters" described above (i.e. !lo = 3 x 10-8 and m = 5 stem cells per crypt). 
A.2.1 Importing the Observed data 
Just as in the static model, the first step of this code is to import the observed 
data on CRC incidence and JCV prevalence: 
See re3e7< - read. c sv ( "I Usersl chandlergatenbee/Docurnents/UofL/CancerProbPaper IObserved 
Data/CRO:lJ-07.Csv") #Colon cancer data from SEER 2ee3-2ee7 
See reeS6< - read. c s v ( "/Usersl chandlergatenbee/Docurnents/UofL/CancerProbPaper IObserved 
Data/CRCoo-06.csv") #Co lon cance r data f rom SEER 2eeS -2ee6 
CalabreseAgeRange<-seq(e,9S,5) #Age Values used by Calabrese to calculate 
probability of cancer SeerAges<-Seere3e7[,l] #Age categories used by SEER 
CRC_2eee_2eS6<-Seereee6[,2] #Getting actual values 
CRC_2003_2007<-Seer0307[,2) #Geetting actual values 
JCVPrevalence<-c(NA,0.11,0.14, 0.24, 0.22, NA, 0.34, NA, 0.39, NA, 0.34, NA, 0.45, 
NA, 0.5, NA, NA, NA, NA) #JCV Prevalence by age From Knowles 2003 
AverageAgeCancer<-rep(0,length(CalabreseAgeRange)) 




for(i in 2:length(JCVPrevalence)){ 
JCVAvgPrevalence[i)<-mean(JCVPrevalence[(i-1):i]) 
} 
CalabreseData<-c(0, 0, 0, 0.07, 0.18, 0.47, 1.46, 2.82, 5.59, 11.14, 21.59, 42.72, 
77.94, 125.98, 184.04, 250.96, 319.14, 387.22, NA) #Actual data used in 
Calabrese; from SEER 1992-1999 
A.2.2 Creating Empty Vectors 
Two vectors were created to collect the results of this model: "PrevInfectInit" col-
lects the prevalence data generated by the Infection Initiation Model (i.e. Infection 
Model); "PrevMutation" collects the prevalence data generated by the Mutation 
model: 





A.2.3 Estimating leV Incidence 
As in the static model, ICV incidence was estimated by linearly interpolating 
missing values of the ICV prevalence regression line, and then taking the dif-
ference between the prevalence values for each age group. The same code used 
above was used here as well: 
#Force Regression Line to go through origin: no evidence that JCV is vertically 
transmitted 
RegPrev<-lm(JCVPrevalence-AverageAgeCancer) 
JCVEstimatedPrev<-coef(RegPrev) [2]*AverageAgeCancer+co ef(RegPrev) [1] 
#Plot to Verify Predicted Values fit Regression Line 
xrangelm<-AverageAgeCancer 
yrangelm<-seq(0,0.5,0.5/(length(xrangelm)-I)) 
plot (xrangelm,yrangelm,xlab="Age of Infection", ylab="Prevelance of ICY" ,main=" 
Estimated Prevalence of ICY Infection", type="n") 
points(AverageAgeCancer,JCVPrevalence,pch=I,col=l) #Observed Prevalence 
points(AverageAgeCancer,JCVEstimatedPrev,pch=2,col=2) #Estimated Prevalence 
abline(RegPrev) 
legend(0, 0.5, c("Actual Prevalence of ICY", "Estimated Prevelance of ICY", " 
Estimated Prevelance for Each Age"), lty=c(NA,I,NA), pch=c(I,NA,2), col=c(1.1,2) 
#Calculate JCV incidence 
JCVlncidence<-rep(NA,length(AverageAgeCancer)) 




A.2.4 Setting Initial Parameters 
As noted above, the "new" parameter values were used in this simulation, as 
their description is more recent and consistent with stem cell theory. The only 
addition to these parameters was "mutincrease", which describes the degree of 
genomic instability, here estimated as a 1.5X increase in the mutation rate every 
time a barrier is removed. 
#Constant Parameters 
u<-3 #Total number of genes that can knock possibly out each barrier.-4 per barrier. 
Note, on COSMIC (Catolog of Somatic Mutations In Cancer) there are only 7 genes 
known to have mutations related to cancer of the GI tract (http://www.sanger.ac 
.uk/ perl/ genetics/ CGP/ cosmic?action=byhist&ss=NS&ss=lymph_node&sn= 
gastrointestinal_tract_%28site_indeterminate%29&s=3&hn=carcinoid-endocrine_ 
tumour&hn=other&hn=carcinoma). 
kl<-6 #number of barriers to cancer (from Hanahan) 
k2<~3 #estimated number of barriers remaining after JCV infection 
ul<-u*(10A -8) #Muations for stem cell lineages. Mutation rate from Frank 2003, and 
is per gene per divsion (they suggest the division rate for stem cells is 
actually between l0A -7 and l0A -10, so l0A -8 is between, although it is still on 
the higher side). ul=#genes that can knockout pathway * stem cell mutation rate 
* Number of genes active in a cell (Frank 2004) 
Nm<-5*(15000000) # Number of stem cells in the colon. 5 stem cells per crypt, 
15,000,000 crypts in the colon (From Calabrese). Assuming these cells are C0133+ 
Ns=Nm*0.95 #Estimated number of stem cells infected by JCV 
mutincrease<-l.S #Amount mutation rate is increased by after each barrier is 
knocked down: Genomic Instability 
A.2.5 Creating the Dataframe 
After all vectors were created, they were collected in a dataframe called "CRC" 
(the resulting dataframe can be found in Figure A.8): 
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#Main Data frame 
CRC< -data.frame(SeerAges, CalabreseAgeRange, AverageAgeCancer, JCVPrevalence, 
JCVEstimatedPrev, JCVIncidence, CRC_2000_2006, CRC_2003_2007, CalabreseData, 
PrevMutation, Incidence_Mutation, PrevInfectInit, Incidenc~InfectInit) 
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A.2.6 Creating Genomic Instability 
A vector containing the increase in mutation rate was created using the code 
below. A vector was created so that it's elements could be accessed later during 
the modeling process. The resulting vector can be found in Figure A.9. 
#Genomic Instability 
GI< -c(l,rep(NA,kl-l)) 
for(i in 2:length(GI)){ 
GI[i]< -GI[i - l] *mutincrease } 
> GI 
[lJ 1 .00000 1 . 50000 2.25000 3 . 37500 5 .06250 7.59375 
Figure A 9 
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A.2.7 Functions Used to Calculate Probability of Cancer 
Functions similar to those used in the static model were used here to calculate 
each model's probability of cancer. The primary difference is that an individual's 
total number of divisions is divided equally among each barrier (i.e. "(age/h)". 
For example, in the mutation model an individual that is 30 years old has 5 years 
worth of divisions to knock out the first barrier, 5 years worth of divisions to 
knock out the second barrier, and so on. In the infection model the number of 
divisions is divided among the years an individual has been infected: If now 60 
and infected at 30, then the individual has 5 years worth of divisions to knock 
out the fourth barrier OCV knocked out the first 3) ,5 years worth of divisions to 





dl=(age/kl)*365*8.25 #Estimated From Calabrese. Number of stem cell 
divisions. Number of divisions divided equally between barriers 
pl<-(I·((I-(I-(I-u)Adl)AI)AN)) #Probability of I cell knocking out I barrier 




d2=((agenow-ageinfection)/k2)*365*8.25 #Number of infected cell divisions= 
Number of years infected with JCV * Number of days in a year * I 
division every 4 days. Number of divisions divided equally between 
barriers 
p2=(I-(I-(I-(I-u)Ad2)AI)A(N)) #Probability of I cell knocking out I barrier 
after d2/k2 divisions 
p2 } 
A.2.8 Genomic Instability Mutation Model 
A.2.8.1 Calculating Probability of Oncogenesis with Decreasing Cell Population and Increas-
ing Mutation Rate 
The vector "mprev" was created to store the predicted prevalence of colon cancer 
for each age group, per 100,000 individuals. A for-loop was created to calculate 
the probability of oncogenesis for each age group. The first step of this loop was 
to reset all parameters back to their original values every time the probability of 
cancer was being calculated for a new age group: "mutrate" is a vector of the 
mutation rate at each step; "Nm" is the initial number of stem cells; "mN" is a 
vector that stores the number of stem cells that have knocked down k barriers 
(the first value is Nm); and "mprob" is a vector of the probability that a cell has 
knocked down the kth barrier. A sample of these vectors and values can be found 
in Figure A.lO(they are from the last age group, 90 years old). 
The first step of calculating the probability of cancer was to calculate the prob-
ability that 1 cell would knock down the first barrier, given the individual's age 
and the initial mutation rate. This value was stored as "mprob[l]". After this 
initial probability was determined, another loop was initiated. This loop first 
calculates how many cells are expected to have knocked down the first barrier. 
This is accomplished by multiplying "mprob[l]" by the initial number of stem 
cells ("mN[(i-l)]"; i starts at 2). After the number of stem cells that have removed 
the first barrier has been calculated, the probability of one cell knocking down 
the second barrier is calculated, using the next mutation rate ("mutrate[i],,). This 
loop thus tracks how many cells are expected to have removed a barrier, as well 
as the probability of 1 cell knocking down the next barrier given the increased 
mutation rate. 
The above loop is repeated until the 5th barrier has been removed. At this 
point, "mprob" has 5 probabilities, each reflecting the probability that 1 cell has 
knocked out a barrier, up to and including the 5th barrier. "mN" also contains 
5 values, each reflecting the number of cells that are expected to have been able 
to knock out each barrier, up to, but not including, the 5th barrier. Using these 
values, "mN[kI]" (i.e. mN[6]) calculates the number of cells expected to have 
knocked out out the 5th barrier. This is the sub-population of cells that can 
knockout the final barrier. The probability of this is calculated using page1, that 
sub-population of cells ("mN[k1]"; k=6), and the final (highest) mutation rate 
("mutrate[k1]"). This final value, "mprob[k1]", thus reflects the probability that 
the sub-population of cells that already knocked down 5 barriers knocked down 
the final, 6th, barrier. After this final probability had been calculated, it is multi-
plied by 100,000 and stored in "mprev", which keeps track of the prevalence of 
colon cancer per 100,000 individuals, for each age group. 
The above loop is then repeated for each age group (j). After the final preva-
lence value was collected, all prevalence values for each age group were moved 
to CRC[,"PrevMutation"]. 
mprev<-rep(NA,length(CalabreseAgeRange)) #Predicted prevalence of colon cancer for 
each age group, assuming the mutation model 
for(j in l:length(CalabreseAgeRange)){ 
#Reset Values for each Age Group 
mutrate<-GI*ul #Vector of increase in mutation rate 
Nm<-5*(15eeeeee) #Initial number of colon stem cells 
mN<-c(Nm,rep(NA,kl-l)) #Vector storing number of cells remaining after each 
barrier is knocked down, up to 5th barrier 
mprob<-rep(NA,kl) #Vector storing probabilities of knocking down each 
barrier 
#Calculate Probablity 
mprob[l]<-page1(CalabreseAgeRange[j],l,mutrate[l]) #Probability of 1 cell 
knocking down barrier 1 
for(i in 2:(k1-1)){ 
mN[i]<-mprob[(i-1)]*mN[(i-1)] #Number of cells that would have 
knocked out barrier 
mprob[i]<-page1(CalabreseAgeRange[j],l,mutrate[i]) #Having knocked 
down previous barriers, Probability of 1 cell knocking down 
barrier 
} 
mN[k1]<-mprob[k1-1]*mN[k1-1] #Number of cells that would have knocked out 
barrier 5 
mprob[k1]<-page1(CalabreseAgeRange[j],mN[k1],mutrate[k1]) #Probability of 
knocking down all 6 barriers 
mprev[j]<-mprob[k1]*100000 #Predicted prevalence of CRC, per 100,000 
individuals 
} 
CRC[, "PrevMutation" ]<-mprev 
~ mulrale 
[lJ 3.000000e-08 4.500000e-08 6. 750000e-08 1.012S00e-07 1.518750e-07 2.278125e-07 
~ Nm 
[lJ 7. 5e+07 
;> mN 
[lJ 7.500000e+07 3.079624e+03 1.896798e-01 1.752382e-05 2.428387e-09 5.047581e-13 
;> mprob 
[lJ 4.106166e-05 6.159185e-05 9.238636e-05 1.385763e-04 2.078573e-04 1.110223e-16 
I 
Figure A.1O 
A.2.8.2 Calculating Incidence of Colon Cancer with Mutation Model 
As the above results are in the form of prevalence data, they must be transformed 
into incidence data so that they are comparable to the observed data. This was ac-
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complished calculating the difference in prevalence between any two age groups, 
and then stored in CRCl"Incidence_Mutation"] and "Mutation": 
#Calculate Incidence 
for(i in 2:length(mprev)){ 
CRC [i. "Incidence_Mutation" ]<-CRC[i. "PrevMutation" ]-CRC [ (i-I). "PrevMutation"] 
} 
Mutation<- CRC [ • "Incidence_Mutation"] 
A.2.9 Genomic Instability Infection Model 
A.2·9.1 Calculating Probability of Cancer Given Length of Infection 
As in the stepwise mutation model, a for loop was used to calculate the prob-
ability of cancer for each age group. After the probability was calculated, the 
parameters were reset to their original values: "mutrate" is a vector of the mu-
tation rates; "Ns" is the initial number of infected stem cells; "iiN" is a vector 
containing the number of infected stem cells that have knocked out a barrier 
(starting at 0 barriers); "iiprob" is a vector containing the probability that the kth 
barrier has been removed. An example set of these values can be found in Figure 
A.ll (these values are for 90 year old individuals that were infected at 90 years 
old, which explains why iiN and iiprob are zero). 
The logic underlying the stepwise infection model is the same as that under-
lying the mutation model. However, in the case of the infection model, JCV has 
already knocked out three barriers, and so only 3 barriers remain. Thus, a com-
plicated for loop seemed unnecessary and the cell population sizes and probabili-
ties were calculated in a series. Of note is that the mutation rate starts at the level 
expected if three barriers have already been removed, while the cell population 
size is remains at the initial size (see Figure ??). Finally, as in the static model, 
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a matrix was created so as to capture the probability of cancer given the length 
of infection (current age - age of infection). This matrix was filled in with the 
probability of cancer for each combination of current age and age of infection, 





II~", "~'I, "~o", "~511, I'~I', "~5", "~" 
~'I, "~'I, "~'I, "~", "~II, I'~"),C(" 
Agelnfecto", "Agelnfect5", "Agelnfecho", "Agelnfech 5", "Agelnfect2o", " 
Agelnfect25", "Agelnfect30", "Agelnfect35", "Agelnfect4o", "Agelnfect45", " 
Agelnfect50", "Agelnfect55" , "Agelnfect6o", "Agelnfect65", "Agelnfect7o", " 
Agelnfect75", "AgelnfectSo", "AgelnfectS 5", " Agelnfect90" ) ) ) 
#Calculate Probability of Cancer for each current age Vs. age of infection 
for(i in l:length(agenow)){ 
for(j in l:length(ageinfect)){ 
#Reset Parameters for each Age Group 
mutrate<-GI*ul #mutation rates 
Ns<-5*(15000000)*0.95 #initial cell population size 
iiN<-c(Ns,rep(NA,k2-1)) #collects number of cells that have knocked 
out each barrier 
iiprob<-rep(NA,k2) #collects probability of 1 cell knocking out a 
barrier 
#Calculate Probability of Knocking out Each Barrier, given N stem cells and 
a u mutation rate. Infection Already knocked out 3 barriers 





of 1 cell knocking down barrier 4 
# Probability of knocking-out Barrier 5 
iiN[2]<-iiprob[1]*Ns #Number of cells that would have knocked out 
barrier 4 
iiprob[2]<-page2(agenow[i],ageinfect[j],1,mutrate[5]) #Having 
knocked down previous barriers, this is the probability of 1 
cell knocking down barrier 5 
# Probability of knocking-out Barrier 6 
iiN[3]<-iiprob[2]*iiN[2] #Having knocked down previous 
barriers,Number of cells that would have knocked out barrier 5 
iiprob[3]<-page2(agenow[i],ageinfect[j],iiN[3],mutrate[6]) # 
Probability of knocking down all 6 barriers, given the number· of 




agenowVageinfect[i,j]<-0) #Makes sure all probabilites are 
positive 





;> i lprob 
[1] 0 0 0 
o o 
Figure A.ll 
A.2.9.2 Calculating Cumulative Probability of Cancer for Each Age Group 
As in the static model, the cumulative probability of colon cancer given ICV 
infection is found by summing the probabilities of developing cancer for each 
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Figure A.12 
age group, given all possible ages of infection (i.e. summing across the "Current 
Age" rows in the above matrix) . This cumulative probability is first multiplied 
by the average incidence of JCV infection and then multiplied by 100,000, yield-
ing the prevalence of JCV induced colon cancer per 100,000 individuals. These 
prevalence values are then stored in CRC[,"PrevlnfectInit"]: 
iiprev<-rep(NA,length(agenow)) 
for(i in I:length(iiprev)){ 
iiprev[i)<-sum(agenowVageinfect[i,)) *IBBBBB*AvgJCVIncidence 
} 
CRCI, "Prevlnfectlnit" )< -iiprev 
A.2·9·3 Calculating Incidence of JCV Induced Colon Cancer for Each Age Group 
Again, the prevalence data need to converted into incidence data, which was 
then stored in CRC[i,"Incidence_lnfectInit"] and the vector IIlnfection_Initation": 
#Calculate Incidence 
for(i in 2:length(iiprev)){ 
CRCli, "Incidence_InfectInit " )<-CRC[i, " Prevlnfectlnit " )-CRCI (i-I), " 
Prevlnfectlnit ") } 
Infection_Ini tation<-CRC [ , "Incidence_ Infec tlni t " I 
A.2.1O Results 
A.2.1O.I Dataframe 
The CRC dataframe created after running the above code can be found in Figure 
A.13 
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A.2.I0.2 Plots 
As in the static model, the incidence values from the stepwise models were trans-
formed to the log scale so as the emphasize the difference between the Mutation 
and Infection models' predictions. Again, any -Inf values were replaced with -25, 
for the reasons stated above. These transformations were accomplished using the 
following code: 
#Adjust data so the log can be taken : if prob=0, then 10g(0)= · Inf, which won't fit 
on a graph. Set min to -25 
logMutation<-log (Models [, "Mutation")) 
loglnfection<-log (Models [ , "Infection_ Ini ta tion") ) 
#Replace -lnf with -25.22388 
#Mutation 











Once log-transformed, the data was plotted against the observed data using 





lymin<-max (log (Models [, "Mutation") )) 
yrange<-seq(lymin,lymax, (lymax-lymin)/(length(xrange)- 1)) 
plot(xrange, yrange, type="n", xlab="Current Age",ylab="ln(Incidence of Cancer, per 







lines(CalabreseAgeRange, 10gInfection,col="blue", lty=2) 
legend (20, -10, c ("Observed Data 1992-1999", "Observed Data 2000-2006", "Observed Data 
2003-2007", "Mutation Model,k=6", "Infection lnitation Model,k=3") ,col=c(l, 1, 1," 
red", "blue"), lty=c(NA, NA, NA, 1,2), pch=c(19, 1, 2, rep(NA,2») 
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Figure A.14 
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Finally, infection's impact on the probability of developing cancer was calcu-
lated by dividing the probability of cancer with infection by the probability of 
cancer by mutation alone, A value of 1 had to be added to each probability as 
many of the mutation probabilities were equal to 0 (see FigureA.13). The result-
ing plot can be found in Figure A.lS. 
#Plot of the Increase in Probabilty 
RatiolncreaseProb<-(iiprev+l)/(mprev+l) 
plot (RatioIncreaseProb-CalabreseAgeRange, main="Impact of Infection 01 Probability 
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APPENDIX B R CODE FOR GEOMETRIC MODEL 
There are ten models total, each which has a different combination of genes 
per barrier and the stem cell mutation rate. The two stem cell mutation rates are 
Il = 10-10 and Il = 10-11 , while there can be 3,6,9,12 or 16 genes per barrier. 
In this example code, there are 3 genes per barrier, and the stem cell mutation 
rate is Il = 10-1°. In order to provide examples, some of the parameters are 
changed, primarily the number of stem cells in the colon and the number of 
repetitions. When conducting runs to generate the data presented in Chapter 6, 
Nm = 5 x 15000000 and reps = 10000. 
B.1 SETUP 
The first few lines setup the parameters used in the model: 
> genes. per. barrier <- 3 
> stem.cell.mutation.rate <- leee * leA-le 
> genomic. instability <- 2 
> u<-genes.per.barrier 
> #Number of barriers in Mutation Model 
> kl<-6 
> #Number of barriers in Infection Model 
> k2<-3 
> #initial stem cell mutation rate 
> ul <- u*stem.cell.mutation.rate 
> #umber of stem cells in the colon. 
> Nm<- 18# Set to 5*(15888888) in model 
> #5 stem cells per crypt, 15,888,888 crypts (Calabrese). 
> #Estimated number of stem cells infected by JCV 
> Ns=Nm*8.95 
> #Redundent, but used in model 
> mutincrease<-genomic.instability 
> # number of times to run model. Set to 18 here for example 
> #purposes, but lis set to 1888 when collecting all results 
> reps<-18 
> # prints when every 18th iteration is completed 
> printscale<-seq(8,reps,18) 
The next chunk of code creates a vector what the mutation rate will be after 
genomic instability increases the mutation rate when a barrier is removed: 
> GI<-c(1,rep(NA,k1-1)) 





[1] 3.0e-07 6.0e-07 1.2e-06 2.4e-06 4.8e-06 9.6e-06 
B.2 MUTATION MODEL 
This part of the code creates 6 different vectors that determine how many trials 
will occur before the first success (days,mutation) in each of Nm cell lines. This 
process is repeated for all six barriers. Note that the mutation increases as each 
barrier is removed, thus simulating genomic instbaility .After each vector is cre-
ated, they can be added together to find the total number of divisions it takes to 
remove all six barriers. 
After the total number division have been calculated, the mean, max, min, 
and standared deviation are calculated. Afterwards, the number of divisions are 
converted to years, assuming that stem cells divide once every four days, i.e. 
N divisions 4days 1 year 
x 1 d' .. x 365d = age in years. The results are exported to IVlSlon ays 
a .csv.Note that in these examples the number of years is high. However, when 
there are the vector is 7.5 x 107 elements long, some values will be lower. 
This procedure is repeated for each value of rep, which in this case is 10 indi-
viduals. As the data are generated they are added to a data frame. 
> # 
> #rgeom(n=Nm, prob=mutrate[i)) 
> # 
> forti in l:reps){ 




+ #number of divisions required before second mutation. 
+ N.div.for.mutaiton.r2<-rgeom(Nm,mutrate[2)) 
+ N.div.for.mutaiton.r2 
+ # number of divisions required before third mutation. 
+ N.div.for.mutaiton.r3<-rgeom(Nm,mutrate[3)) 
+ N.div.for.mutaiton.r3 
+ # number of divisions required before fourth mutation. 
+ N.div.for.mutaiton.r4<-rgeom(Nm,mutrate[4)) 
+ N.div.for.mutaiton.r4 
+ # number of divisions required before fifth mutation. 
+ N.div.for.mutaiton.r5<-rgeom(Nm,mutrate[5)) 
+ N.div.for.mutaiton.rS 
+ #number of divisions required before sixth mutation. 
+ N.div.for.mutaiton.r6<-rgeom(Nm,mutrate[6]) 
+ N.div.for.mutaiton.r6 
+ #Total Number of Divisions 
+ Mutation. Total.Divisions <- N.div.for.mutaiton.rl + 
+ N.div.for.mutaiton.r2 + 
+ N.div.for.mutaiton.r3 + N.div.for.mutaiton.r4 + 
+ N.div.for.mutaiton.rS + N.div.for.mutaiton.r6 
+ #Calculate mean, standard deviaition, min, and max 
+ mean.years<-mean(Mutation.Total.Divisions)*4*(1/36S) 
+ stdev.years <- sd(Mutation.Total.Divisions)*4*(1/36S) 
+ min.years <- min(Mutation.Total.Divisions)*4*(1/36S) 
+ max.years <- max(Mutation.Total.Divisions)*4*(1/36S) 
+ # 
+ Model <- "Mutation" 
+ iteration <- i 
+ # 
+ #Build data frame 
+ if (i==l){ 





Mutation.Data <- data.frame(Model,mean.years, 
stdev. years, min. years, max. years) 
} 
+ #Add to data frame 
+ New.Data <- data.frame(Model,mean.years, 
+ stdev.years,min.years,max.years) 
+ Mutation.Data <- rbind(Mutation. Data, New. Data) 
+ } 
+ } 
> Mutation. Data 
Model mean.years stdev.years min. years max. years 
1 Mutation 58943.96 28289.22 33575.781 120091. 5 
2 Mutation 98563.89 61002.97 23388.011 208677.3 
3 Mutation 54854.77 37885.94 16042.586 154127.4 
4 Mutation 61352.80 34357.45 7745.896 136633.1 
5 Mutation 73895.62 36610.36 12873.534 119736.3 
6 Mutation 86052.36 35054.35 42257.238 145139.3 
7 Mutation 63963.59 28471.03 32581.655 119885.1 
8 Mutation 66089.51 36094.76 25705.140 131563.8 
9 Mutation 67877.19 40096.74 14720.285 126313.1 
10 Mutation 83613.25 39647.85 13310.718 140384.5 
B.3 INFECTION MODEL 
The infection model is implemented in much the same way as the mutation mode. 
One difference is that the population of cells is 95% of the cell population in the 
mutation model. A second difference is the the model starts using the fourth 
mutation rate because the three previous barriers have all ready been removed. 
Finally, the model 
> for{i in l:reps){ 
+ # number of divisions required before first mutation in 4 barrier 
+ Infection.N.div.for.mutaiton.r4<-rgeom{Ns,mutrate[4]) 
+ # number of divisions required before first mutation in 5th barrier 
+ Infection.N.div.for.mutaiton.r5<-rgeom{Ns,mutrate[5]) 
+ # number of divisions required before first mutation in 5th barrier 
186 
+ Infection.N.div.for.mutaiton.r6<-rgeom(Ns,mutrate[6]) 
+ #Total Number of Divisions 
+ Infection. Total. Divisions <- Infection.N.div.for.mutaiton.r4 + 
+ Infection.N.div.for.mutaiton.r5 + Infection.N.div.for.mutaiton.r6 
+ Model <- "Infection" 
+ iteration <- i 
+ mean.years<-mean(Infection.Total.Divisions)*4*(l/365) 
+ stdev.years <- sd(Infection.Total.Divisions)*4*(l/365) 
+ min.years <- min(Infection.Total.Divisions)*4*(l/365) 
+ max.years <- max(Infection.Total.Divisions)*4*(l/365) 





#Initiate Data frame 






#Add to data frame 
New.Data <- data.frame(Model,mean.years, 
stdev.years, min. years, max. years) 
+ Infection.Data <- rbind(Infection. Data, New. Data) 
+ } 
+ } 
> Infection. Data 
Model mean. years stdev.years min.years max. years 
1 Infection 8547.683 3373.122 4925.898 14949.26 
2 Infection 7196.665 4658.234 1649.921 14864.99 
3 Infection °19975.619 7244.343 3424.252 23861.61 
4 Infection 7297.763 4685.493 3631. 321 19927.34 
5 Infection 7867.534 5559.963 2564.679 17529.11 
187 
6 Infection 6748.620 3537.967 1665.644 12705.71 
7 Infection 8132.100 6050.912 1092.427 18647.27 
8 Infection 5970.298 4333.681 1669.677 13285.05 
9 Infection 9644.497 7154.300 1686.542 24798.86 
10 Infection 6233.749 3317.813 2677.786 12019.61 
Like the Mutation model, the mean, standard deviation, min, and max are 
calculated and converted to age in years 
B-4 BINNING DATA 
The observed data are in groups of 5 years, so the results of the Geometric model 
also need to binned in to 5 year age groups. This is done by creating a function 
that bins the data and converts to incidence per 100,000 individuals. 
> bin. data <- function( summary. data, age. of. metastatic. tumors) ( 
+ indv <- length(summary.data[,l]) 
+ ages1<- (length (subset(age.of.metastatic.tumors, 
+ 
+ 
age.of.metastatic.tumors < 1 & 
age.of.metastatic.tumors > e)))/indv*leeeee 
+ ages4<- (length (subset(age.of.metastatic.tumors , 
+ 
+ 
age.of.metastatic.tumors < 5 & 
age.of.metastatic.tumors >= l)))/indv*leeeee 
+ ages9<- (length (subset(age.of.metastatic.tumors , 
+ 
+ 
age.of.metastatic.tumors < 1e & 
age.of.metastatic.tumors >= 5)) )/indv*leeeee 
+ ages14<- (length (subset(age.of.metastatic.tumors , 
+ age.of.metastatic.tumors < 15 
+ & age.of.metastatic.tumors >= 1e)))/indv*leeeee 
+ ages19<- (length (subset(age.of.metastatic.tumors , 
188 
+ age.of.metastatic.tumors < 2e & 
+ age.of.metastatic.tumors >= 15)))/indv*leeeee 
+ ages24<- (length (subset(age.of.metastatic.tumors , 
+ age.of.metastatic.tumors < 25 & 
+ age.of.metastatic.tumors >= 2e)))/indv*leeeee 
+ ages29<- (length (subset(age.of.metastatic.tumors , 
+ age.of.metastatic.tumors < 3e & 
+ age.of.metastatic.tumors >= 25)))/indv*leeeee 
+ ages34<- (length (subset(age.of.metastatic.tumors , 
+ age.of.metastatic.tumors < 35 & 
+ age.of.metastatic.tumors >= 3e)))/indv*leeeee 
+ ages39<- (length (subset(age.of.metastatic.tumors , 
+ age.of.metastatic.tumors < 4e & 
+ age.of.metastatic.tumors >= 35)))/indv*leeeee 
+ ages44<- (length (subset(age.of.metastatic.tumors , 
+ age.of.metastatic.tumors < 45 & 
+ age.of.metastatic.tumors >= 4e)))/indv*leeeee 
+ ages49<- (length (subset(age.of.metastatic.tumors , 
+ age.of.metastatic.tumors < 5e & 
+ age.of.metastatic.tumors >= 45)))/indv*leeeee 
+ ages54<- (length (subset(age.of.metastatic.tumors , 
+ age.of.metastatic.tumors < 55 & 
+ age.of.metastatic.tumors >= 5e)))/indv*leeeee 
+ ages59<- (length (subset(age.of.metastatic.tumors , 
+ age.of.metastatic.tumors < 6e & 
+ age.of.metastatic.tumors >= 55)))/indv*leeeee 
+ ages64<- (length (subset(age.of.metastatic.tumors , 
+ age.of.metastatic.tumors < 65 & 
+ age.of.metastatic.tumors >= 6e)))/indv*leeeee 
1~ 
+ ages69<- (length (subset(age.of.metastatic.tumors , 
+ 
+ 
age.of.metastatic.tumors < 7e & 
age.of.metastatic.tumors >= 65»)/indv*leeeee 
+ ages74<- (length (subset(age.of.metastatic.tumors , 
+ 
+ 
age.of.metastatic.tumors < 75 & 
age.of.metastatic.tumors >= 7e»)/indv*leeeee 
+ ages79<- (length (subset(age.of.metastatic.tumors , 
+ 
+ 
age.of.metastatic.tumors < 8e & 
age.of.metastatic.tumors >= 75»)/indv*leeeee 
+ ages84<- (length (subset(age.of.metastatic.tumors , 
+ 
+ 
age.of.metastatic.tumors < 85 & 
age.of.metastatic.tumors >= 8e»)/indv*leeeee 
+ ages85up<- (length (subset(age.of.metastatic.tumors , 
+ 
+ 
#age.of.metastatic.tumors <=lee & 
age.of.metastatic.tumors >= 85»)/indv*leeeee 
+ # 
+ d. f <- c(ages1, 
+ ages19, ages24, 
+ ages44, ages49, 
+ ages69, ages74, 
+ # 










The bin.data function is applied to both the infection results to put them into 
an age group. 
> options(width=6e) 
> Mutation.Min.Results <- Mutation.Data$min.yea"rs 












Table B.1: Mortality From Colorectal Cancer, 2005 - 2009 [2] 
[1] 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 
[10] 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 
[19] le+05 
> # 
> Infection.Min.Results <- Infection.Data$min.years 
> Infection.Binned<- bin.data(Infection.Data,Infection.Min.Results) 
> Infection.Binned 
[1] 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 
[10] 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 0e+00 
[19] le+05 
B.5 CONVERTING INCIDENCE TO PREVALENCE 
Since each repetition is one individual, the results are incidence of colorectal 
cancer. The prevalence of in each age can be determined by summing up the 
incidence values of earlier ages. However, some people die before they move 
to the next age group, so mortality from colorectal cancer is worked into the 
calculation of prevalence by multiplying the prevalence value by the number 
of people that did survive colorectal cancer. The mortality rates used in this 
procedure are found in Table B.1. 
> Calculate.Prevalence.With.Mortality <- function(binned.data){ 
+ ages1<- binned.data[l] #ages < 1 
+ total <- ages1 
+ ages4<- binned.data[2]+total #ages 1-4 
+ total <- ages4 
+ ages9 <- binned.data[3]+total #ages 5-9 
+ total <- ages9 
+ ages14 <- binned.data[4]+total #ages 19-14 
+ total <- ages14 
+ ages19 <- binned.data[5]+total #ages 15-19 
+ total <- ages19 
+ # 
+ #Mortality in 29-34=9.6% 
+ ages24 <- binned.data[6]*(1-9.996)+total #ages 29-24 
+ total <- ages24 
+ ages29 <- binned.data[7]*(1-9.996)+total #ages 25-29 
+ total <- ages29 
+ ages34 <- binned.data[8]*(1-9.996)+total #ages 39-34 
+ total <- ages34 
+ # 
+ #Mortality in 35-44=9 2.5% 
+ ages39 <- binned.data[9]*(1-9.925)+total #ages 35-39 
+ total <- ages39 
+ ages44 <- binned.data[19]*(1-9.925)+total 
+ #ages 49-44 
+ total <- ages44 
+ # 
+ #Mortality in 45-54=9 8.6% 
+ ages49 <- binned.data[11]*(1-9.986)+total #ages 45-49 
+ total <- ages49 
+ ages54 <- binned.data[12}*(1-8.886)+total #ages 58-54 
+ total <- ages54 
+ # 
+ #Mortality in 55-64=16.5% 
+ ages59 <- binned.data[13}*(1-8.165)+total #ages 55-59 
+ total <- ages59 
+ ages64 <- binned.data[14}*(1-8.165)+total #ages 68-64 
+ total <- ages64 
+ # 
+ #Mortality in 65-74=22% 
+ ages69 <- binned.data[15}*(1-8.22)+total #ages 65-69 
+ total <- ages69 
+ ages74 <- binned.data[16}*(1-8.22)+total #ages 78-74 
+ total <- ages74 
+ # 
+ #Mortality in 75-84=29% 
+ ages79 <- binned.data[17}*(1-8.29)+total #ages 75-88 
+ total <- ages79 
+ ages84 <- binned.data[18}*(1-8.29)+total #ages 88-85 
+ total <- ages84 
+ # 
+ #Mortality in 85+ =28.8% 
+ ages85up <- binned.data[19}*(1-8.288)+total #ages 85+ 
+ # 
+ d.t <- c(ages1, ages4, ages9, ages14, ages19, 
+ ages24, ages29, ages34, ages39, ages44, ages49, 




+ returned. f) } 
This prevalence function can then be applied to the results generated by the 
Geometric model 
> options(width=68) 























> Infection.Prevalence <- Calculate.Prevalence.With.Mortality(Infection.Binned) 
> Infection.Prevalence 




















The prevalence values calculated above can be added to a summary data frame 
that includes both observed values and modeled values. 
> Seer.Age.Group <- c("<1", "1-4","5-9", "18-14", "15-19", "28-24","25-29", 
+ "38-34","35-39","48-44","45-49","58-54","55-59","68-64","65-69", 
+ "78-74", "75-79", "88-84", "85+") 
> Age. Group<-seq(8,98,5) 
> # 
> #Observed Data From SEER 1992-1999 
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> #Build Data Frame 
> Observed.Data<-c(9,9,9,9.97,9.18,9.47,1.46,2.82,5.59,11.14,21.59, 
+ 42. 72, 77.94,125.98,184.94,259.96,319.14,387.22,NA) 
> Model <- rep(IObserved", length (Observed. Data)) 
> Prevalence <-Calculate.Prevalence.With.Mortality(Observed.Data) 
> Obs.Data<-data.frame(Model,Seer.Age.Group,Age.Group,Prevalence) 
> Data<- Obs.Data 
> # 
> #Mutation Data 
> Model <- rep(IMutation", length (Observed. Data) ) 
> Prevalence <-Mutation. Prevalence 
> Mutation.Data<- data.frame(Model,Seer.Age.Group,Age.Group,Prevalence) 
> Data<-rbind(Data,Mutation.Data) 
> # 
> #Infection Data 
> Model <- rep(IInfection", length(Observed.Data)) 
> Prevalence <-Infection. Prevalence 
> Infection.Data<- data.frame(Model,Seer.Age.Group,Age.Group,Prevalence) 
> Data<-rbind(Data,Infection.Data) 
> Data 
Model Seer.Age.Group Age.Group Prevalence 
1 Observed <1 0 0.00000 
2 Observed 1-4 5 0.00000 
3 Observed 5-9 10 0.00000 
4 Observed 10-14 15 0.07000 
5 Observed 15-19 20 0.25000 
6 Observed ·20-24 25 0.71718 
7 Observed 25-29 30 2.16842 
8 Observed 30-34 35 4.97150 
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9 Observed 35-39 40 10.42175 
10 Observed 40-44 45 21. 28325 
11 Observed 45-49 50 41. 01651 
12 Observed 50-54 55 80.06259 
13 Observed 55-59 60 145.14249 
14 Observed 60-64 65 250.33579 
15 Observed 65-69 70 393.88699 
16 Observed 70-74 75 589.63579 
17 Observed 75-79 80 816.22519 
18 Observed 80-84 85 1091.15139 
19 Observed 85+ 90 NA 
20 Mutation <1 0 0.00000 
21 Mutation 1-4 5 0.00000 
22 Mutation 5-9 10 0.00000 
23 Mutation 10-14 15 0.00000 
24 Mutation 15-19 20 0.00000 
25 Mutation 20-24 25 0.00000 
26 Mutation 25-29 30 0.00000 
27 Mutation 30-34 35 0.00000 
28 Mutation 35-39 40 0.00000 
29 Mutation 40-44 45 0.00000 
30 Mutation 45-49 50 0.00000 
31 Mutation 50-54 55 0.00000 
32 Mutation 55-59 60 0.00000 
33 Mutation 60-64 65 0.00000 
34 Mutation 65-69 70 0.00000 
35 Mutation 70-74 75 0.00000 
36 Mutation 75-79 80 0.00000 
37 Mutation 80-84 85 0.00000 
38 Mutation 85+ 90 79200.00000 
39 Infection <1 0 0.00000 
40 Infection 1-4 5 0.00000 
41 Infection 5-9 10 0.00000 
42 Infection 10-14 15 0.00000 
43 Infection 15-19 20 0.00000 
44 Infection 20-24 25 0.00000 
45 Infection 25-29 30 0.00000 
46 Infection 30-34 35 0.00000 
47 Infection 35-39 40 0.00000 
48 Infection 40-44 45 0.00000 
49 Infection 45-49 50 0.00000 
50 Infection 50-54 55 0.00000 
51 Infection 55-59 60 0.00000 
52 Infection 60-64 65 0.00000 
53 Infection 65-69 70 0.00000 
54 Infection 70-74 75 0.00000 
55 Infection 75-79 80 0.00000 
56 Infection 80-84 85 0.00000 
57 Infection 85+ 90 79200.00000 
B.7 PREVALENCE PLOT 





> Prevalence. Plot <- ggplot(data=Data,aes(x=Age.Group, 
+ y=Prevalence,group~odel,colour~odel)) + 
+ geom_point() + 
+ geom_line(aes(x=Age.Group,y=Prevalence)) + 
+ coord_cartesian(ylim=c(9, 2999))+ 
+ scale_x_discrete(breaks=Age.Group, 
+ labels= Seer.Age.Group,name="Age Group") + 
+ scale_y_continuous(name="Prevalence (Per 199,999)") + 
+ opts (ti tle="Prevalence of Colorectal Cancer", 
+ axis.text.x = theme_text(angle = 45)) 
> grid.arrange(Prevalence.Plot, sub = textGrob( 
+ expression (paste(frac(genes, barrier), " = 3 , ",mu, "=",19"{-19})), 
+ hjust = 9.87,vjust=9.3, gp = gpar(cex = 9.7)) 
+ ) 
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The distance between each modeled prevalence point and the observed preva-
lence point can be calculated using R dist function. However, to make sure the 




[,1] [,2] [,3] [,4] [,5] [,6] [,7] [, 8] 
[1,] 
[2, ] e e 
[,9] 
e e.ee e.ee e.eeeee e.eeeee e.eeee 
e e.e7 e.25 e.71718 2.16842 4.9715 
[,Ie] [,11] [,12] [,13] [,14] 
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> EDistance <- Mut.Dist[l] 
> EDistance 
[1] 16e8.818 
> Model<- "Mutation" 
> Dist.Data<-data.frame(Model,EDistance) 








1 Mutation 16e8.818 
2 Infection 16e8.818 
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Once the distance has been calculated it can be plotted to get a sense of how 
well each model replicates the observed data. 
> Dist.Plot <- ggplot(Dist.Data, 
+ aes(x=Model,y=EDistance,color~odel,size=188,alpha=8.5) )+ 
+ geom_point()+ 
+ scale_size(range = c(2, 15))+ 
+ guides(size=FALSE,alpha=FALSE)+ 
+ coord_ trans(y=ll og2")+ 
+ opts(title="Euclidian Distance Between Observed and Modeled Prevalence")+ 
+ ylab(IDistance") 
> grid.arrange(Dist.Plot, 
+ sub=textGrob (expression (paste(mu, "=",18"{-18})), 
+ hjust = 8.87,vjust=8.3, gp = gpar(cex = 8.7))) 
> Dist.Plot 
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This model was designed to better understand the roles of mutation and infec-
tion in the development of colon cancer. Is mutation alone sufficient to generate 
the emergence of metastatic tumors, or is infection needed to "kick-start" the 
process of oncogenesis? How does the order of mutations affect the probability 
of developing a metastatic tumor? Does this order change if infection is present? 
If infection does turn out to play an important role, how much does the age of 
infection by ICV affect the probability of developing a metastatic tumor? 
C.l.2 Entities, State Variables, and Scales 
The model has six entities: patches, stem cells, metastatic stem cells, transit cells, 
VEGF molecules, and vessels. 
There are 3721 patches laid out in a grid, creating a non-wrapping square 
world that is 6lX6l patches, centered around patch (0,0). Each patch is meant to 
represent the cells underlying stem and transit cells of the colon crypt. This world 
is subdivided into a colon crypt and metastatic tissue. The colon crypt is centered 
around patch (-17,-17), and is 25x25 patches, creating a total of 625 patches. The 
crypt is further subdivided into the inner and outer crypt. The inner crypt, also 
centered around patch (-17,-17), is l5x15 patches, and is colored yellow. The 
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outer crypt is composed of the remaining crypt patches and is colored pink. The 
metastatic tissue is centered around patch (13,13), and is 30x30 patches, for a 
total of 900 patches. All remaining patches are colored black. The state variables 
of each patch can be found in Table C.l on page 204. 
PATCH STATE VARIABLES 
oxygen 
infected 
Table C.l: Patch State Variables 
Stem cells are located in a circular layout around the center of the colon crypt, 
and face outwards. Stem cells are responsible for producing the initial transit 
cells in the model. Each stem cell has several state variables, which are listed in 
Table C.3 on page 205 
STEM CELL STATE VARIABLES 
count-stem-cell-divisions CIF-II-removed? 
stem-cell-mutation-rate count-barriers-removed 
count-neutral-mutations order-of-barrier-removal (list) 









order-of-mutations (list) most-recent-event 






Table C.3: Stem-Cel1-State-Variables 
Metastatic stern cells have the same state variables as regular stern cells (see 
Table C.3 on page 205); they simply have the ability to survive in the metastatic 
tissue if they successfully invade. 
Transit cells have many of the same state variables as stern cells, except that 
track telomere length, telomerase mutations, oxygen levels, and hypoxic state. 
See Table C.5 on page 206 for a complete list of the transit cell state variables. 
TRANSIT CELL STATE VARIABLES 
count-transit-cell-divisions count-barriers-removed 











order-of-mutations (list) parent 






ClF-I1-removed? JCV-Mad -1-d98-deactivated 
Table C.5: Transit Cell State Variables 
VEGF molecules do not own any state variables, but the vessels they are at-
tracted to do, and can be found in Table C.6 on page 207. 
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VESSEL STATE VARIABLES 
lifespan 
time-alive 
Table C.6: Vessel State Variables 
Finally, there are many global variables, which can be found in Table C8 on 
page 219. 
In this model, one time step is equal to one day. 
C.1.3 Process Overview and Scheduling 
The schedule of this ABM is as follows: 
1. determine-if-simulation-should-end (global procedure) 
2. tick (global procedure) 
3. determine-if-mutant-phenotype-on 
4. determine-location 
5. infection-modeled? = true [infection] (occurs only if infection is being mod-
eled) 
6. hit-and-run? (if true, the "Hit and Run" infection model is run) 








12. transit-cell-division-mutation-and-movement (transit cell procedure) 
13. angiogenesis (turtle procedure) 
14. oxygen-replenish (patch procedure) 
15. oxygen-diffusion (global procedure) 
16. oxygen-recolor-patches (patch procedure) 
17. transit-cell-death (turtle procedure) 
18. maintain-population-cap (turtle procedure) 
19. evaluate-state-and-record-data (global procedure) 
This schedule is repeated until one of two events occur: 1) the crypt reaches 100 
years, or 2) a metastatic tumor forms and at least one cell in that tumor has 
completely removed all of the cancer barriers. 
The details of each sub-model can be found in Section C.3.3 
C.2 DESIGN CONCEPTS 
C.2.1 Basic Principles 
The basic principle of this model is the formation of metastatic tumors, and the 
roles that mutation and infection play in this process. It is commonly accepted 
that stem cell mutations playa critical role in the development of colon cancer Mi-
chor et al. [85], Boman and Huang [11], but there is also experimental evidence 
indicating that infection by Je Virus may also playa role in tumor formation 
[35, 69, 82, 89, 24]. Thus, this model aims to determine the roles that mutation 
and infection play in the development of colon cancer. It is hoped this model 
can answer this question by determining how many crypts develop metastatic 
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tumors by mutation alone, and how many develop metastatic tumors with infec-
tion and mutation. 
It has also been argued that a particular order of mutations is most likely 
to cause colon cancer [85, 39], although this is not universally accepted [132]. 
This model will also look for a relationship between the order of mutations and 
timing of tumor development and tumor size. Furthermore, as infection is being 
considered, it seems worthwhile to determine if there is any relationship between 
the age of infection and the age of tumor formation, and the strength of any such 
relationship. 
C.2.2 Emergence 
The accumulation of mutations and presence of infection can lead to changes in 
cellular behavior that result in the emergence of metastatic tumors. 
C.2.3 Adaptation 
In this model, cellular behavior changes to match patterns observed in can-
cers (i.e. the agents exhibit indirect-objective-seeking behavior). Behaviors change 
whenever there is a mutation in a beneficial gene belonging to one of six cat-
egories: pro-growth genes; anti-growth genes; anti-apoptosis genes; metastasis 
genes; telomerase genes; elF-II pathway genes. 
The effect of disrupting each pathway was hypothesized using the descriptions 
provided in [50, 153, 67]. 
Mutations in pro-growth genes allow cells to divide every time step, so long 
as they are in the inner-crypt and their telomeres have not deteriorated. 
Mutations in anti-growth genes allow transit cells to divide in the outer crypt. 
Mutations in anti-apoptosis genes allow cells to avoid death by accumulation 
of deleterious mutations. For stem cells, this means that these cells are never lost 
during symmetric division. For transit cells, this means that these cells are never 
killed when the population reaches its maximum size (normal-max-pop-size). For 
both cell types, any anti-apoptotic mutations also increases the mutation rate via 
genomic instability. 
A single mutation in a metastasis gene gives stem and transit cells the ability 
to detect the neighbor patch with the most oxygen, and then move to that patch 
. If angiogenesis has occurred, and a cell has two metastatic mutations and is 
close to a blood vessel (produced by angiogenesis) the cell will try to invade the 
metastatic tissue. However, successful invasion is not certain, and is controlled 
by the parameter probability-of-successful-invasion. 
Mutations in the telomerase gene prevent the degradation of telomeres, essen-
tially giving transit cells the ability to divide without limit. 
If a cell is infected by JCV, and has acquired mutations in ClF-II, then JCV will 
remove the pro-growth, anti-growth, and apoptosis barriers. In the "Full Trans-
formation" version of the model, JCV completely removes each of those barriers, 
while in the "Partial Transformation" version JCV only partially removes each of 
those barriers. Thus, mutations in the ClF-II pathway are required for transfor-
mation by JCv. 
C.2-4 Objectives 
As the cells use indirect-objective seeking behavior, there are no specific agent 
objectives. 
C.2.5 Learning 
No agents in this model learn from past experiences.· 
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c.2.6 Prediction 
No agents in this model make predictions. 
C.2.7 Sensing 
Un-mutated cells must decide if they can divide. They do so by determining if 
there is an unoccupied patch within a cone with an angle of 1800 and radius of 
1.5 pathes. If there is such an empty patch, the cell will divide and move to the 
empty patch; if not, the cell will remain where it is and not divide. 
During angiogenesis, VEGF molecules sense the closest vessels and move to-
wards them. 
c.2.8 Interaction 
During asymmetric division, stem cells produce daughter transit cells, who in-
herit their parent's mutations. Likewise, daughter transit cells inherit their parent 
transit cell's mutations. 
During angiogenesis, VEGF molecules are produced by hypoxic patches, and 
those VEGF molecules are attracted to the closest vessel. 
C.2.9 Stochasticity 
The order in which cells are chosen to move/divide is decided randomly. 
The number of mutations per division is modeled by choosing a Poisson ran-
dom number, with an appropriate mean (see C.3.3.6 for a detailed description) 
Determining whether stem cell division will be symmetric or asymmetric is 
decided randomly (see C.3.3.6 for details) 
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The direction that stem cells face each run is chosen randomly, so that there is 
no bias on a particular stem cell orientation (i.e. those that directly face a corner 
could divide more frequently). 
C.2.1O Collectives 
There are three primary collectives in this model: stem cells, metastatic stem 
cells, and transit cells. Stem cells usually produce transit cells (during asym-
metric division), but occasionally produce a stem cell (during symmetric divi-
sion). Metastatic stem cells also arise from stem cells that accumulate sufficient 
metastatic mutations. Finally, transit cells produce other transit cells. 
C.2.11 Observation 
This model tracks the population size of the colon crypt and metastatic tissue so 
as to determine the presence and size of polyps and tumors, and the age at which 
they occur. This model also tracks the order and timing of each mutation in each 
cell, as well as the order and timing of when cancer barriers are removed in each 
cell. From this one can determine if a certain order of mutations leads to more 
rapid tumor development. Finally, the age of infection, whether the infection has 
become chronic, and time to transformation are tracked so as to help determine 
the role of infection. 
The results of experiments will be recorded in .csv files. At the end of each run, 




























• m. tumor.cell.mutations. timing 
• m. tumor.cell.barriers.removed 















In addition to this data, more detailed data on each run will be also be collected, 
in the event that more resolution is needed (see C.3.3.18 for details.) 
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C.3 DETAILS 
C. 3.1 Initialization 
The model is initialized by creating the world that is 61X61 patches, and cen-
tered around patch (0,0). Each patch is meant to represent the cells underlying 
stem and transit cells of body. This world is subdivided into a colon crypt and 
metastatic tissue. The colon crypt is centered around patch (-17, -17), and is 
25x25 patches, creating a total of 625 patches. The crypt is further subdivided 
into the inner and outer crypt. The inner crypt, also centered around patch 
(-17,-17), is 15x15 patches, and is colored yellow. The outer crypt is composed 
of the remaining crypt patches and is colored pink. The metastatic tissue is cen-
tered around patch (13, 13), and is 30x30 patches, for a total of 900 patches. All 
remaining patches are colored black. 
Five stem cells are created around the the center of the colon crypt, and laid 
out in a circle. Each each stem cell faces outward, but their position in the circle 
is chosen randomly during the setup procedure. Below is a table of the initial 
global parameter values 
MONITORS 
























number-of-stem-cells 5 [12] 
number-of-metastatic-stem-cells 0 
number-of-transit-cells 0 
normal-max-pop-size 300 [12] 
max-pop-size 5000 
probability-of-asymmetric-stem-cell-division 0·95 [79] 
metastatic-cell-type 













































PARAMETER VALUE SOURCE 
probability-of-JCV-spreading-to-neighbor 0.02 calibrated 






PARAMETER VALUE SOURCE 
JCV-NCRR-region-Iength 430 [47] 
JCV-mutation-rate-per-day 1.0 74 [31] 
JCV-mutation-in-NCRR 4.6182 x 10-4 
JCV-genomic-instability 7·5 [81] 
OXYGEN 
PARAMETER VALUE SOURCE 
amount-of-oxygen-per-patch 1 
oxygen-in-non-tissue calibrated 
oxygen-replaced -by-patch-each-time-step 0.25 calibrated 
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oxygen-needed-to-move 0.1 calibrated 
oxygen-consumed -by-cell 1 calibrated 
oxygen-metabolized -d uring-division 1 calibrated 
oxygen-diffused-by -cell 1 calibrated 
oxygen-of-hypoxic-cells 6 x 10-4 calibrated 
ANGIOGENESIS 
PARAMETER VALUE SOURCE 
vessel-detection-radius 5 
vessel-forward -movement 1 
oxygen-added -by-vessel calibrated 
Table C.8: Initial Parameters 
C.3.2 Input Data 
There is no input data in this model. 
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C.3.3 Submodels 
C.3.3.1 Determine If Simulation Should End 
This sub-model determines whether or not the simulation should continue. The 
simulation will end if either of the following conditions are true: a metastatic 
tumor has formed; the crypt has reach 100 years of age. 
C.3.3.2 Determine if Mutant Phenotype is On 
The model as a whole assumes that it takes more than one mutation to remove 
each barrier, but that any single mutation would still have some effect on the 
cell's behavoir. Thus, a sub-model is needed to determine if a mutant phenotype 
is expressed, based on the number of mutations in each barrier. This is accom-
plished by using a Bernoulli reporter to determine if the phenotype is expressed, 
where the probability that the mutant phenotype is expressed is equal to number 
of mutations in that barrier divided by how mutations it takes to remove each 
barrier. For example, if a cell has one pro-growth mutation (i.e. count-pro-growth-
mutations = 1) and it takes two mutations to remove each barrier (Le. mutations-
needed-to-remove-each-barrier = 2) , then the probability that the pro-growth phe-
1 
notype is expressed is equal to "2 = 0.5. Thus, that particular cell will exhibit the 
pro-growth phenotype 50% of the time. 
If a stem cell has one metastatic mutation it will find the neighbor with the 
most oxygen, and then move to that neighbor (even if there is already another cell 
there). If the stem cell has two metastatic mutations, and is there is a blood vessel 
the radius of 1 patch, then the stem cell will attempt to invade the metastatic 
tissue. The probability that invasion will be successful is determined using the 
Bernoulli reporter report-successful-invasion?, where the probability of success is 
probability-of-successful-invasion. If invasion is successful, the stein cell moves to 
the center of the metastatic tissue, hatches a metastatic stem cell, and dies. This 
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leaves only the metastatic stem cell, but it inherits all of the parent stem cells 
variables (i.e. mutations, barriers removed, mutation rate, ect...). 
Similarly, if a transit cell has one metastatic mutation it will move to the neigh-
bor with the most oxygen, and if it has two mutations it will try to invade the 
metastatic tissue. See C.3.3.11 for a full description of the metastatic mutations 
interact with the other mutations. 
VERIFICATION 
This sub-model was verified by creating a world with 100 stem cells, with 
the option to manually add a mutation to any barrier in all of the stem 
cells. Next to the "world view" are histograms of how many stem cells 
are expressing the mutant phenotype during that tick. If one adds a single 
mutation, then the histogram hovers around 50 (i.e. -50 of the 100 stem cells 
are expressing the mutant phenotype); if an additional mutation is added 
to that barrier, all of the stem cells will express the mutant phenotype. 
C.3.3.3 Determine Location 
This sub-model simply reports which type of tissue (colon crypt or metastatic 
tissue) each cell is in when a critical event occurs. Such critical events include 
mutations, barrier removal, transformation, etc..See C.3.3.18 for a complete list 
of events recorded during each run. 
C.3.3.4 Infection 
JCV is a common virus, and most individuals tend to be infected by adolescence 
Viscidi et al. [144], Knowles et al. [68]. Thus, if infection? is set to "true", then 
infection is modeled by giving JCV the opportunity to infect each crypt every 
frequency-of-infection-year years. During each infection attempt, a random transit 
cell is chosen to be infected. This infected transit cell can then infect one of its ran-
domly chosen neighbors, with the probability of successful infection being equal 
to probability-of-JCV-spreading-to-neighbor. If all of the cells in the crypt become 
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infected, then the cell is considered to have become chronic, and the global pa-
rameter chronic-infection? is set to true, and the age at which the infection became 
chronic is also recored. 
Initially, an infected cell's phenotype remains the same as other wild-type 
cells of the same breed (i.e. transit cell or stem cell). This is because the cell's 
CIF-II pathway is preventing the expression of viral oncogenes [153]. However, 
if the CIF-II pathway is "removed" by the accumulation of "beneficial" muta-
tions, then viral oncoproteins are expressed. JCV produces several oncoproteins 
that, in animal models, strongly interfere with apoptosis (P53), and cell division 
(pRb,(3-catenin, MAPK (via PP2A», resulting in multi-nucleation, increased dou-
bling time, growth in anchorage dependent conditions, uncontrolled cell growth, 
and chromosomal instability (reviewed in [82]). In the "Full Transformation" 
model, these processes can be modeled by completely removing the apoptosis 
barrier (chromosomal instability and uncontrolled cell growth), the pro-growth 
barrier (growth in increased doubling time and anchorage dependent conditions; 
i.e. no contact inhibition), and the anti-growth barrier (uncontrolled cell growth). 
In the "Partial Transformation" model, each of these barriers are only partially 
removed; however, if there is already a mutation in one of those barriers, then 
JCV will serve to completely remove that barrier. In the "No Infection" model, 
mutations in if the ClF-II pathway do not have any effect. 
Note that transformation is modeled by adding mutations to the pro-growth, 
anti-growth, and anti-apoptosis barriers whenever CIF-II-removed? is true. How-
ever, it is not hypothesized that removing the ClF-II pathway literally adds muta-
tions to each of these pathways; this method was chosen simply because it allows 
one to easily change the phenotype of the cell using the existing code. 
VERIFICATION 
The infection model was visually verified by creating a model in which 
cells do not move, and then randomly selecting a cell to infect, and then 
changing the shape and size of that infected cell. One could then watch the 
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infection spread among neighboring cells, each changing to the infected size 
and shape. 
Varying the probability-of-JCV-spreading-to-neighbor parameter between 0 and 
1 also ensured that the infection sub-model is behaving as expected. Low 
values of probability-of-JCV-spreading-to-neighbor resulted in a large number 
of time steps until the entire crypt is infected, while large values of probability-
of-JCV-spreading-to-neighbor resulted in few time steps until every cell is in-
fected. 
Transformation was verified by manually adding a single pro-growth, anti-
growth, anti-apoptosis, and CIF-II mutation to each stem cell. One could 
then step through the model and inspect the stem-ceIl's pro-growth-removed?, 
anti-growth-removed?, apoptosis-removed?, and CIF-II-removed? parameters. When-
ever CIF-II-removed? was true, each of the other three barriers had a muta-
tion added to it. However, when CIF-II-removed? was false, the mutations 
returned to its previous value. This verifies that the transformation proce-
dure only adds mutations when CIF-II is removed. 
CALIBRATION 
The parameters frequency-of-infection-year years and probability-of-JCV-spreading-
to-neighbor were calibrated so that the modeled incidence of infection had 
a pattern similar to that observed in Viscidi et al. [144], Knowles et al. [68]. 
After several parameter sweeps, frequency-oJ-infection-year was set to 1, and 
probability-of-JCV-spreading-to-neighbor was set to 0.02. In other words, each 
crypt is exposed to infection once a year, and there is only a 2% chance that 
each infected cell would be able to infect its neighbor. 
C.3.3.5 Hit and Run Model of Infection 
An alternative infection model is built upon the research of [113], who argue 
that JCV may increase the risk of colorectal by some sort of "hit and run" mecha-
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nism. Under this hypothesis, JCV first infects the kidneys, mutates into the Mad-1 
strain, giving it the ability to infect colorectal cells. This mutation event is then 
followed by a deletion in the non-coding control region (NCRR), which may al-
low JCV to express its oncoproteins in the colon cells, as well as increasing CIN, 
a process that may result in the formation of a colon cancer stem cell. Such trans-
formation may occur for 14-21 days, which how long LT can be detected after 
transfection [111]. 
The infection component of the "Hit and Run" model is conducted in the same 
manner as described in C.3.3+ However, in this case mutations in the CIF path-
way are not required for transformation. Instead, mutations in the NCRR region 
allow for transformation. In this case, JCV mutations events in JCV's NCRR re-
gion are determined by the reporter report-JCV-NCRR-mutation?, which uses a 
Bernoulli random distribution, where the probability of success is JCV-mutation-
in-NCRR, which is calculated as JCV-NCRR-region-length x JCV-mutation-per-day. 
If a cell is dividing and has infected?=true and report-JCV-NCRR-mutation?=true, 
the cell acquires one NCRR mutation. Ensuring that NCRR mutations only oc-
cur when the host cell divides was accomplished by inserting the JCV-mutation 
within each cell's division procedure. In this Hit and Run model, a single NCRR 
mutation simulates cell's acquired ability to infect the colon, but does not other-
wise affect the cell's phenotype. If a second mutation occurs, and infected?=true, 
the cell is expresses its oncoproteins, removing the pro-growth, anti-growth, and 
apoptosis barriers. Additionally, the expression of these oncoproteins induces 
CIN, increasing the cell's current mutation rate 7.5 fold [81]. 
Once the JCV starts expressing the oncoproteins it is assigned a random lifes-
pan between 14-21 days, which is recorded under the JCV-Mad-l-d98-survival 
parameter of the cell. Similarly, once the cell accumulates two NCRR muta-
. tions it has its JCV-Mad-l-d98-evolved? set to true, and JCV-Mad-l-d98-days-active 
set to o. Every time the cell divides it increases JCV-Mad-l-d98-days-active by I, 
and when JCV-Mad-l-d98-days-active = JCV-Mad-l-d98-survival the cell returns to 
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its previous mutation rate, removes the effects of ICV's oncoproteins on the 
barriers, resets JCV-Mad-l-d98-days-active back to zero, and sets JCV-Mad-l-d98-
evolved? back to false. Returning to the previous mutation rate is accomplished 
by dividing the infected cell's mutation rate by JCV-genomic-instability, thus re-
moving ICV induced genomic instability. Similarly, returning to the previous 
number of barriers removed is accomplished by subtracting mutations-added-by-
transformation from count-anti-growth-mutations, count-pro-growth-mutations, and 
count-anti-apoptosis-mutations. By doing so, any additional mutations accumu-
lated during the genomically unstable transformation period will remain present. 
FInally, JCV-Mad-l-d98-days-active is reset to zero because it is assumed that ICV, 
and not the cell, become inactive. This means that the cell can be re-infected. If 
this occurs, the cell will acquire a new value for ICV-Mad-l-d98-survival, ICV-
Mad-l-d98-evolved? set to true, and the process will repeat. 
VERIFICATION 
The Hit and Run model was verified by creating a world in which all cells 
were infected and NCRR mutations could be added manually, one by one. It 
was verified that when a cell has only one NCRR mutation there is no pheno-
typic change, but when there are two NCRR mutations pro-growth-removed?, 
anti-growth-removed?, and apoptosis-removed? were all set to true. Similarly, 
the mutation rate was increased 7.5 fold. By inspecting each transformed 
cell, one is also able to confirm that JCV-Mad-l-d98-days-active increases by 
one every day, and that the cell does die when JCV-Mad-l-d98-days-active 
= JCV-Mad-l-d98-survival. By creating links between parent and daughter 
cells, one can also verify that daughter cells inherit the parental values of 
JCV-Mad-l-d98-days-active and JCV-Mad-l-d98-survival. By following these 
same cells, one can also verify that the mutation rate returns to its previous 
state, that the effect of ICV's oncoproteins on the barriers is removed, and 
that JCV-Mad-l-d98-days-active returns to zero and JCV-Mad-l-d98-evolved? 
returns to false when JCV-Mad-l-d98-days-active = JCV-Mad-l-d98-survival. 
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Furthermore, by manually adding NCRR mutations to those same cells af-
ter JCV-Mad-l-d98-evolved? is reset to false, one can verify that the cell is 
assigned a new value for JCV-Mad-l-d98-survival. 
That NCRR mutations only occur when the cell divides was verified by 
setting JCV-mutation-in-NCRR to I, and filling the crypt with cells. In this 
scenario the stem cells cannot divide, and so no NCRR mutations occur. 
However, when the crypt is not filled, the cells are able to divide and if they 
are infected they can acquire NCRR mutations. This was further verified by 
having each infected cell print a message that it divided and had a mutation 
in the NCRR. 
C.3.3.6 Stem Cell Determine Division Type 
Stem cells can either divide asymmetrically or symmetrically [12]. During asym-
metric division, each stem cell produces one daughter transit cell and one daugh-
ter stem cell. During symmetric division, the stem cell produces either 2 stem 
cells or 2 transit cells. It has been suggested that symmetric division occurs 5% 
of the time [79]. 
To model this process, one can use the reporter asymmetric-division?, which uses 
a Bernoulli random distribution, where the probability of success is probability-of-
asymmetric-stem-cell division. If "true" is returned, asymmetric division occurs; if 
"false" is returned, symmetric division occurs. 
ASYMMETRIC DIVISION 
If asymmetric division occurs, then any stem cells that have pro-growth-removed? 
and anti-growth-removed? as false will call the stem-cell-normal-division procedure. 
In this procedure, each the stem cell will undergo mutation (see the C.3.3.6 for 
details of the mutation procedure) and hatch a transit cell if there is an empty 
patch within a cone having an angle of 1200 and radius of 1.5 patches. If there is 
no such empty patch, the stem cell will not undergo mutation or division. If this 
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stem cell is mobile (because it has one metastatic mutation), it will only be able 
to divide in the inner crypt. 
Any stem cells with pro-growth-removed? as true but anti-growth-removed? as 
false, call the stem-cell-pro-growth-division procedure. When this procedure is called, 
the stem cell will always undergo mutation and division, producing a transit cell 
that moves to a randomly chosen patch with a cone with an angle of 1200 and 
radius of 1.5 patches. If this stem cell is mobile (because it has one metastatic 
mutation), it will only be able to divide in the inner crypt. 
Any stem cells with anti-growth-removed? as true but pro-growth-removed? as 
false, call the stem-cell-anti-growth-division procedure. When this procedure is 
called, and if the cell is in the inner-crypt, the cell will divide as in the stem-
cell-normal-division procedure. However, if this stem cell is mobile (because it has 
one metastatic mutation), it gains the ability to divide in both the inner crypt and 
the outer crypt. 
Any stem cells with anti-growth-removed? as true and pro-growth-removed? as . 
true, call the stem-cell-anti-and-pro-growth-division procedure. When this proce-
dure is called, the stem cell will always undergo mutation and division, pro-
ducing a transit cell that moves to a randomly chosen patch with a cone with an 
angle of 1200 and radius of 1.5 patches. Furthermore, if this stem cell is mobile 
(because it has one metastatic mutation), it also gains the ability to divide in both 
the inner crypt and the outer crypt. 
SYMMETRIC DIVISION 
If asymmetric-division? returns false, then symmetric division will occur. Dur-
ing symmetric division, the stem cell with the most deleterious mutations 
is killed and replaced by a daughter from the stem cell with the fewest 
deleterious mutations. However, it is important to note that any stem cells 
with anti-growth-removed? as true will be exempt from symmetric division. 
It is thus possible that the true least fit stem cell could survive symmetric 
division (assuming it has anti-growth-removed? as true). All of the other stem 
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cells (i.e. not the least or most fit stem cells) will follow the asymmetric di-
vision procedure rules. Symmetric division is modeled this way to capture 
the idea that the stem cell crypt has evolved to minimize the risk of disease 
by periodically killing off the least fit ( most deleterious) cells [12]. 
STEM CELL MUTATION 
The number of each type of mutation added during each division is deter-
mined by drawing a random number from a Poisson distribution, with an 
appropriate mean (.\). Mutations of each type accumulate over the life of 
the cell. Finally, the mutation rate will increase proportionately with count-
anti-apoptosis-mutations xgenomic-instability. 
NEUTRAL MUTATIONS 
The human genome is ~7 x 109bp, and there are 70,000 genes, each of 
which has an average length of 1000bp (reviewed in [92]). Assuming 
that mutations anywhere in any of these 70,000 genes will either re-
sult in a deleterious of beneficial phenotype, then mutations elsewhere 
must be neutral. Thus, one can assume that 7 x 109 - 70000 (1000) = 
6.93 x 109bp of the genome are neutral. If the stem cell mutation rate 
is 1 x 10-9, then one should expect 10-9 x 6.93 x 109 = 6.93 neutral 
mutations per stem cell division. Thus, to determine how many neu-
tral mutations will occur during each division, one can draw a random 
number from a Poisson distribution with .\ = 6.93 mutations per divi-
sion. 
BENEFICIAL MUTATIONS 
Assuming there are 6 barriers to cancer, 3 candidate genes that can in-
hibit each one of those barriers, each with an average length of 1000bp, 
then there are 6 x 3 x 1000 = 18,OOObp, that if mutated will remove a 
barrier to cancer. As these mutations increase the cell's ability to survive 
and replicate, they can be considered beneficial mutations. Thus, one 
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can expect that there are 1 x 10-9 x 18000 = 1.8 x 10-5 beneficial mu-
tations during each stem cell division. Thus, one can determine how 
many beneficial mutations will occur by drawing a random number 
from a Poisson distribution with ,\ = 1.8 x 10-5 mutations per division. 
If a beneficial mutation does occur, then a random number X is drawn 
from a Uniform distribution that has a range from 1 to 6. This number 
then determines which kind of beneficial mutation will occur. If X = 1 
there is a pro-growth mutation; if X = 2 there is an anti-growth muta-
tion; if X = 3 there is an anti-apoptosis mutation and the mutation rate 
is increased by multiplying it by genomic-instability; if X = 4 there is a 
telomerase mutation; if X = 5 there is a metastatic mutation; if X = 6 
there is a elF-II mutation. A Uniform distribution is used because it is 
assumed that the mutation is equally likely to "land" in anyone of the 
beneficial genes, since they all have equal lengths. 
GENOMIC INSTABILITY MUTATIONS 
Assuming there are 7 genomic instability genes, there are total of 7 x 
1000 = 7000bp, that if mutated will increase the mutation rate. There-
fore, the expected number of genomic instability mutations per division 
is ,\ = 7000 x 10-9 = 7 x 10-6 . Each mutation that lands in a genomic 
instability gene linearly increases the mutation rate by a factor of two. 
For example, one mutation doubles the mutation rate, 3 mutations in-
crease the mutation rate by a factor of 6, and so on until the mutation 
rate is increased 14 fold. 
DELETERIOUS MUTATIONS 
Assuming that there are 70,000 genes, each with an average gene length 
of 1000bp, then there are 70000 (1000) = 7 x 107bp that are not neutral 
when mutated. If there are 6 barriers to cancer, 3 candidate genes that 
can inhibit each one of those barriers, then there are 6 x 3 x 1000 = 
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18,000bp, that if mutated will remove a barrier to cancer. These mu-
tations can be considered beneficial. Finally, there are 7000bp that in-
duced genomic instability when mutated. Thus, the remaining 7 x 107 -
18,000 -7000 = 69975000bp, if mutated, will be deleterious. One should 
then expect 1 x 10-9 x 69982000 = 0.069982 deleterious mutations per 
each stem cell division. Thus, to determine how many deleterious mu-
tations there will be during each stem cell division, one can draw a 
random number from a Poisson distribution with A = 0.069982 muta-
tions per division. 
PARTIAL BARRIER REMOVAL 
Whether or not a mutation will be expressed is determined using the 
reporter express-mutation? This reporter will randomly report a true or 
false value, using a Bernoulli distribution where the probability of suc-
cess is 
count-mutations-in-barrier F l'f . p = . . . or examp e, 1 mutatlOns-
mutatlOns-needed-to-remove-each-barrzer 
needed-to-remove-each-barrier = 2, and count-pro-growth-mutations = 1, then 
p = ~ = 0.5. If "true" is returned, the mutation will have its effect; if 
"false" is returned the mutation will not have its effect. NetLogo does 
not include a built in Bernoulli distribution, but Grimm and Railsback 
do provide the code for how to create such a distribution [108]. 
Partial barrier removal is included in the model to capture the idea 
that it likely takes more than a single mutation to completely remove a 
barrier to cancer, but disruptions in the pathways(s) by single mutations 
still have some affect on the phenotype. 
VERIFICATION 
The rate of symmetric division was verified simply by adding a monitor 
that recorded how frequently symmetric division occurred. Once also had 
the option to change the rate of asymmetric division, which did result in a 
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change in the monitored rate of symmetric division (i.e. increasing the prob-
ability of asymmetric division decreased the rate of symmetric division). 
The code used to identify the least fit and most fit stem cells during symmet-
ric division was verified by outputting each stem-cell's number of deleteri-
ous mutations, and which cells were being identified as the most fit, least fit, 
and other stem cells. The code was verified because the cell with the most 
deleterious mutations was successfully identified, colored green, and then 
killed off in the next round of division. Similarly, the most fit stem cell was 
successfully identified, changing its shape, and producing a daughter cell 
(with the same shape) during the next round of division. 
The code for partial barrier removal was verified by creating a world with 
100 stem cells. Next to the world were histograms of how many cells had the 
pro-growth phenotype, anti-growth phenotype, etc ... One could then manu-
ally add mutations to all of the stem cells. The parameter mutations-needed-
to-remove-each-barrier was set to two, so when one mutation was added to 
all of the stem cells, the histogram showed that -50% of the cells exhibited 
the mutant phenotype, verifying the the mutated cells expressed the mutant 
phenotype -50% of the time. When a second mutation was added, all of the 
stem cells expressed the mutant phenotype. 
Normal stem cell division (i.e. only divide when there is an empty patch 
ahead) was verified by creating a world with only two stem cells, each of 
a different color. One can place a stationary transit cell in front of the stem 
cell, and then ask the stem cell to identify all patches that it could have its 
daughter transit cell move to. This verifies that the code works because the 
stem cell will identify all patches within their cone of vision, except for that 
with a transit cell already on it. 
The pro-growth phenotype was verified by filling the crypt with stationary 
transit cells and then setting pro-growth-removed? to true for one stem cell, 
and then adding a single metstatic mutation. When the simulation is run, 
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the stem cells produce transit cells, even though there are already transit 
cells on every patch. However, it is only able to divide in the outer crypt 
The anti-growth phenotype was verified by giving one of the stem cells 
one metastatic mutation (making it mobile), and then setting anti-growth-
removed? to true. This mobile stem cell will then divide in divide in both the 
inner and outer crypt. 
The CIF-II deficient phenotype was verified by infecting one stem cell, adding 
two ClF-II mutations, and adding one metastatic mutation. Stationary tran-
sit cells were then added to every patch in the crypt. When the simulation 
was run, the mutated and transformed stem cell then had cif-ii-removed?, pro-
growth-removed?, anti-growth-removed?, and anti-apoptosis-removed? as true, ver-
ifying that transformation removed these other barriers. Furthermore, the 
mutated and transformed cell was able to move around the crypt (because 
of the metastatic mutation) and divide everywhere, even when proability-of-
asymmetric-division is set to 0 (verifying the anti-apoptosis phenotype). 
It was also verified that stem cells with apoptosis-removed? as true were ex-
cluded from being identified as the least fit cell. This was accomplished by 
choosing one stem cell and manually adding 100 deleterious mutations, set-
ting apoptosis-removed? to true, and changing its color to black. Throughout 
the simulation, this stem cell was never killed off, even though it had the 
most deleterious mutations. 
See C.3.3.7 for a description of how the behavior of stem cells with metastatic 
mutations was verified. 
C.3.3.7 Stem Cell Replace Metastatic Stem Cell 
This model assumes that the crypt can determine if it has too few stem cells, and 
will respond by having the most-fit stem cell (i.e. that stem cell with the fewest 
deleterious mutations) hatch one daughter stem cell. The only time the crypt will 
have too few stem cells will be if one stem cell acquired a metastatic mutation, 
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giving it the ability to roam around the crypt. Again, if this occurs, the most-fit 
stem cell hatches a daughter stem cell, returning the number of non-metastatic 
stem cells to its normal amount. 
VERIFICATION 
The creation of metastatic stem cells from stem cells was verified by creating 
a world where the probability-of-successful-invasion was set to 1, vessels could 
be added manually, and metastatic mutations could also manually be added. 
After adding vessels and one metastatic mutation, the mutated stem cell 
moves toward the neighbors with the most oxygen, which in this case are 
the neighbors with vessels. The mutated stem cell will keep moving around 
the vessels as long as it only has one metastatic mutation. One can then 
add a second metastatic mutation to this stem cell, after which the stem 
cell moves the metastatic tissue, hatches 1 metastatic stem cell, which then 
hatches four more metastatic stem cells. 
C3.3.8 Metastatic Stem Cell Fill Tissue 
After a stem cell invades the metastatic tissue, it hatches number-of-stem-cells - 1 
metastatic stem cells. After there are number-of-stem-cells metastatic stem cells, the 
metastatic stem cells are laid out in a circle. 
C3.3.9 Metastatic Stem Cell Determine Division Type (symmetric or asymmetric; a global 
procedure) 
This procedure is identical to the stem cell division type procedure, except that 
it applies only to metastatic stem cells in the metastatic tissue. 
C3.3.1O Transit Cell Consume Oxygen 
Each transit cell will consume a certain amount of oxygen every time step. If the 
underlying patch has enough oxygen, then the transit cell will consume oxygen-
consumed-by-cell units of oxygen. If there is less than oxygen-consumed-by-cell units 
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of oxygen in the patch, then the transit cell will only consume half of the available 
oxygen. 
For a description of the calibration process for how much oxygen each cell 
consumes, see C3.3.14. 
C3.3.11 Transit Cell Division, Mutation, and Movement (turtle procedure) 
Every time a transit cell divides it undergoes mutation (see C3.3.11 for details), 
uses up some oxygen (determined by the parameter oxygen-metabolized-during-
division; if there is not enough oxygen the cell will not divide), divides its oxygen 
equally between itself and it's daughter, and decreases it's telomere length by 
one unit (so long as there aren't any telomerase mutations). After hatching the 
daughter cell, the parent then moves to a different patch, using some more oxy-
gen in the process (determined by the parameter oxygen-needed-to-move). Where 
exactly the parent cell can divide and move to is determined by which (if any) 
mutant phenotypes it has. 
If the transit cell has no pro-growth, anti-growth, or metastatic mutations, it 
will call the transit-cell-normal-division procedure. In this procedure, the transit 
cell will only divide if it is in the inner crypt and there is an empty patch with its 
cone of vision, which has an angle of 1800 and radius of 1.5 patch units. If it can 
divide, the parent then randomly choses and moves to one of the empty patches 
in it's cone of vision. If the cell is in the outer crypt, it will use the same rules to 
decide to move (Le. there must be an empty patch) 
If the transit cell has no pro-growth, anti-growth, but one metastatic mutation, 
it will call the transit-cell-normal-metastasis-division procedure. In this procedure, 
the transit cell will only divide if there is an empty patch with its cone of vision, 
which has an angle of 1800 and radius of 1.5 patch units. If the parent can divide, 
it moves to the empty neighbor with the greatest amount of oxygen. 
If the transit cell has pro-growth-removed? as true (see C3.3.2 for details) , but 
not anti-growth, or metastatic mutations, it will call the transit-cell-pro-growth-
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division procedure. In this procedure, the transit cell will only divide if it is in 
the inner crypt, but it does not require that there be an empty patch within it's 
cone of vision. If it can divide, the parent then randomly choses and moves to 
one of the patches in it's cone of vision. If the cell is in the outer crypt, it will use 
the same rules to decide to move (i.e. it can move to any patch within its cone of 
vision). 
If the transit cell has pro-growth-removed? as true, one metastatic mutation, but 
no anti-growth mutations, it will call the transit-cell-pro-growth-metastasis-division 
procedure. This procedure is very similar to the transit-cell-pro-growth-division pro-
cedure, but randomly choosing a patch in the cone of vision, the parent moves 
to the neighboring patch with the most oxygen, regardless of whether or not that 
patch is already occupied. Again, these transit cells can only divide if they are in 
the inner crypt. 
If the transit cell has anti-growth-removed? as true (see C.3.3.2 for details), but no 
pro-growth or metastatic mutations, it will call the transit-cell-anti-growth-division 
procedure. In this procedure, division requires that there be an empty patch 
within the transit cell's cone of vision, but these transit cells can divide in both 
the inner and outer crypt. If it can divide, the parent then randomly choses and 
moves to one of the empty patches in it's cone of vision. 
If the transit cell has anti-growth-removed? as true, one metastatic mutation, but 
no pro-growth mutations, it will call the transit-cell-anti-growth-metastasis-division 
procedure. This procedure is very similar to the transit-cell-anti-growth-division 
procedure, but instead of randomly choosing an empty patch in the cone of 
vision, the parent moves to the empty neighbor patch with the most oxygen. 
If the transit cell has both anti-growth-removed? and pro-growth-removes? as true 
(see C.3.3.2 for details), but metastatic mutations, it will call the transit-cell-anti-
and-pro-growth-division procedure. In this procedure, the transit cell does not re-
quire that there be an empty patch within it's cone of vision, and it can divide 
in both the inner and outer crypt. When these cells divide, they randomly chose 
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and move to one of the patches in it's cone of vision, regardless of whether or 
not it is already occupied. 
If the transit cell has both anti-growth-removed? and pro-growth-removes? as true 
and one metastatic mutation, it will call the transit-cell-anti-and-pro-growth-metastasis-
division procedure. This procedure is very similar to the transit-cell-anti-and-pro-
growth-division procedure, but instead of randomly choosing a patch in the cone 
of vision, the parent moves to the neighbor patch with the most oxygen, even if 
it is already occupied. 
If any transit cell has telomerase-removed? as true, the telomeres do not decrease 
in length after division. 
For a full description of the apoptosis mutations, see C3.3.17. For a description 
of how elF-II mutations affect the transit cell's phenotype, see C3.3-4. 
MUTATION 
The mutation procedure for transit cells is nearly identical to that of the 
stem cells, except that the mutation rate is ten times higher, increasing the 
expected number of mutations per division accordingly. 
Transit cells will also exhibit partial barrier removal, using the same process 
as described in the stem cell mutation section. 
VERIFICATION 
The code used for mutation is exactly the same as that used for stem cells 
(see C3.3.6), except that the transit cells use the transit-cell-mutation-rate in-
stead of stem-cell-mutation-rate, and so was already verified. 
Normal transit cell movement was verified by randomly placing station-
ary transit cells around the crypt, and then following mobile transit cells. 
The mobile transit cells identify all potential target patches by changing 
the patch color, and then moves to one of them. The movement code was 
verified because patches with stationary transit cells on them were not iden-
tified as target patches, and the mobile transit cells did not move to them. 
Furthermore, it was verified that the parent moves to the target patch by 
changing the color of the parent celL 
The pro-growth mutation was verified by removing the pro-growth barrier 
in one stem cell (i.e. setting count-pro-growth-mutations to two), and changing 
the color of all of its daughter cells to green (instead of red). One can then 
step through each tick, verifying that, when in the inner crypt, the mutated 
cells will move to occupied patches, and divide (visualized by creating links 
between the parent and daughter cells). One can also observe that the mu-
tated transit cells cannot divide in the outer crypt, which can be verified by 
inspecting such a cell and making sure that count-transit-cell-divisions does 
not increase. 
The anti-growth code was verified by removing the anti-growth barrier in 
one of the stem cells (i.e. setting count-anti-growth-mutations to two), and 
stepping through the model until some of the mutated cells (colored brown 
instead of red) reached the outer crypt. Once the mutated cell reaches the 
outer crypt, one can inspect it and continue to step through the model, 
allowing the mutated cell to move and divide in the outer crypt. Count-
transit-cell-divisions continues to increase (so long as telomeres remain and 
there are empty patches in the cone of vision), verifying that the anti-growth 
code. 
It was also verified that the pro-growth and anti-growth phenotypes worked 
together; that is, transit cells with both of these barriers removed can divide 
anywhere in the crypt, even if there are not any empty patches within their 
cone of vision. This was verified by removing both barriers in one stem cell 
(i.e. setting count-anti-growth-mutations to two and setting count-pro-growth-
mutations to two), and filling the outer crypt with stationary transit cells. The 
mutated cells have the ability to move to and divide on occupied patches 
in both the inner and outer crypt, verifying that code for the two mutant 
phenotypes work together. 
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The anti-apoptosis phenotype was verified by randomly hatching 300 tran-
sit cells, each with a random number of deleterious mutations, ranging be-
tween 1 and 100. Afterwards, 20 of those transit cells had the apoptosis 
barrier removed, their number of deleterious mutations set to 200, and their 
shape changed to a square (instead of a circle). Next, the population cap pro-
cedure was executed, but all of the cells with apoptosis removed survived 
the cap (see C.3.3.17). This verifies that anti-apoptotic cells a exempt for the 
fitness search conducted during the population cap procedure, giving them 
the ability to survive even though they have the most deleterious mutations. 
The metastasis phenotype was verified in the same manner as described 
in C.3.3.7, except that if the transit cell successfully invades the metastatic 
tissue it still behaves as if it were in the crypt (i.e. it still uses the transit-cell-
division-mutation-and-movement procedure). 
The telomerase mutation was simply verified by removing the telomerase 
barrier in one of the transit cells, and then inspecting it to make sure that 
telomere-length did not decrease even when the cell underwent division. 
C.3.3.12 Angiogenesis (turtle procedure) 
Angiogenesis is the production of new blood vessels during hypoxic stress. Such 
stress can occur if there are too many cells and not enough oxygen; in this situ-
ation, the body responds by producing new blood vessels to supply oxygen to 
the extra cells. This process is modeled by asking any patches that oxygen levels 
below oxygen-of-hypoxic-cells and no other vessels within vessel-detection-radius to 
sprout a new blood vessel. If a patch is hypoxic (i.e. oxygen levels below oxygen-
of-hypoxic-cells), but there is a blood vessel within vessel-detection-radius, it will 
sprout a VEGF molecule. The VEGF molecule then detects the closest vessel and 
moves towards it one patch unit for each tick. Once the VEGF molecule is within 
0.5 patch units of the nearest vessel, it stimulates the vessel to produce one more 
vessel, which moves forward vessel-forward-movement patch units. After such ves-
sel growth, the stimulating VEGF molecule dies. 
Each blood vessel is randomly assigned a lifespan, ranging from 1-250 days 
Chen et al. [21]. 
During each tick, the vessels add oxygen-added-by-vessel units of oxygen to the 
underlying patch, thus increasing the amount of oxygen available to the crypt. 
VERIFICATION 
Angiogenesis should only occur when there is not enough oxygen in the 
crypt for the number of cells present, which would occur if the population 
increased beyond its normal size. Such a population increase would only 
occur if mutations drive the cells to divide more frequently than normal, as 
occurs when many of the cancer barriers are removed. This was verified by 
running the model and manually adding mutations to the stem cells. When 
there are no mutations, angiogenesis does not occur. However, after several 
barriers are removed, angiogenesis begins to occur, increasing the amount 
of oxygen available, and allowing the population to increase from ~250 cells 
to 5000 cells (see C.3.3.17 for a description of why the population is capped 
at 5000 cells). 
C3.3.13 Oxygen Replenish (patch procedure) 
Each tick, oxygen-replaced-by-patch-each-time-step is added to each patch in the 
colon crypt. This process is meant to simulate the process of the underlying 
bed of blood vessels supplying oxygen to support the cells in the crypt. Until a 
cell successfully invades the metastatic tissue, all patches in the metastatic tissue 
have their oxygen kept at amount-of-oxygen-per-patch, so as to simulate homeosta-
sis prior to invasion. 
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C.3.3.14 Oxygen diffusion (global procedure) 
Oxygen diffusion is modeled using NetLogo's built in primitive, diffuse. Thus, 
oxygen-diffused-by-cell percent of the patches oxygen is divided equally among 
the patch's neighbors. Also, all patches that do not represent tissue (Le. the black 
patches) have their oxygen levels set to oxygen-in-non-tissue. These two processes 
are repeated 20 times each tick, so as to stimulate constant oxygen diffusion 
throughout the day Chen et al. [21]. 
CALIBRATION OF OXYGEN AND ANGIOGENESIS PARAMETERS 
It has been observed that colon stem cells divide approximately once ev-
ery four to five days, there are ~250 cells in each colon crypt, and an-
giogenesis does not occur under normal growth conditions Potten et al. 
[103], Booth and Potten [12], Kleinsmith [67]. As oxygen levels determine 
whether or not a transit cell can divide or move (making room for other 
cells), a series of seven parameter sweeps were conducted on all oxygen pa-
rameters to narrow down a final set of values to sweep. The values tested 
in this final sweep were: oxygen-added-by-vessel ranged from 0.1 - 0.5 in 0.1 
increments; oxygen-replaced-by-patch-each-time-step ranged from 0.25 - 1 in 
0.25 increments; oxygen-metabolized-during-division ranged from 0.25,0.5, 1.0; 
oxygen-of-hypoxic-cells ranged from 3 x 1 0-4 - 8 x 10-4 in increments of 1 x 
10-4; oxygen-consumed-by-cell was tested at 0.25,0.5, 1.0; oxygen-diffused-by-
cell was tested at 0.5,0.75, 1.0; oxygen-in-non-tissue was tested at 0.5,0.75, 1.0. 
All values were tested in combination using NetLogo's "Behavior Space", 
resulting in a total of 4860 runs, each of which lasted 500 ticks. The final set 
of parameter values, which can be found in C.S, resulted in a average stem 
cell division rate of 0.2212 divisions per day (or one division every 4.5 days), 
an average of 255.766 transit cells in the crypt, and 0 vessels. 
Of note is that mutations were turned off during the parameter sweeps mu-
tation. This was done because mutations affect the cell's phenotype, chang-
ing the rules about when and where division can occur, and thus the stem 
cell's division rates and total population size (which could induce angio-
genesis). By turning off mutation, one can thus get a better idea of the stem 
cell's division rate and population size under normal conditions. 
C3.3.1S Oxygen Recolor Patches (patch procedure) 
The shade of each patch can be changed to reflect the amount of oxygen that it 
has. This can easily be accomplished using NetLogo's scale-color primitive, using 
oxygen as the number input. 
C3.3.16 Transit Cell Death (turtle procedure) 
In a normal crypt, transit cells die in one of two ways: they move outside the 
crypt and are shed, or they completely lose their telomeres. 
C3.3.17 Maintain Population Cap (turtle procedure) 
In this model there are actually two maximum population sizes, normal-max-pop-
size and max-pop-size. If the population grows larger than normal-max-pop-size, the 
number of excess cells is determined by subtracting the current population size 
from normal-max-pop-size. Next, a sub-population of the least fit cells (Le. most 
deleterious mutations) of size 1.5 x number of excess cells is found. The oxygen 
levels of each of these "least fit" cells is then determined. In the end, excess-
cells least fit cells with the lowest oxygen levels are then killed off, bringing the 
population size back to normal-max-pop-size. The idea behind this is that when 
resources become scarce, the least fit cells with the fewest resources (in this case 
oxygen) would be the most susceptible to death. 
It is important to note that cells with anti-apoptosis-removed? as true are ex-
cluded from the search for the least fit cells. This is because the apoptosis mu-
tations prevent cell death, even in the presence of deleterious mutations and 
limited resources. This means that if enough cells have anti-apoptosis-removed? as 
true, the population grow much larger than narmal-max-pap-size. Due to limited 
computing power, a second population size limit had to be created, so as to 
prevent the computer from freezing while it attempts to track tens to hunderds 
of thousands of cells. This absolute limit is set by max-pap-size, and when it is 
reached the number of excess cells is calculated (as above) and excess-cells are 
randomly chosen from all cells to be killed off, returning the population size 
back to max-pap-size. 
VERIFICATION 
This procedure was verified by filling the crypt with 300 transit cells, each 
with a random number of deleterious mutations, ranging between 1 and 100, 
and a random oxygen level, ranging between 0 and 1. The color of each cell 
was also scaled according to how many deleterious mutations they had; the 
lighter the color, the more deleterious mutations. One could then identify 
the 1.5 x number of excess cells with the most deleterious mutations, and 
change their shape to a small circle. The average number of deleterious mu-
tations in the ID'd cells was higher than the average number of deleterious 
mutations in the cells not identified as being the most deleterious, verifying 
that the search procedure was working correctly. Next, of those least fit cells, 
excess-cells were identified that had the lowest oxygen levels. Again, the av-
erage oxygen levels of these cells was lower than the average oxygen levels 
of the cells not identified as being "least fit" or most hypoxic. Together, this 
verifies that the population cap procedure successfully identifies the least 
fit cells, and then finds the most hypoxic of those cells. Finally, one can kill 
of the least fit and most hypoxic cells, returning the population level back 
to max-pap-size. 
C.3.3.18 Evaluate state and Record Data (global procedure) 
In addition to the summary data (described in C.2.11), major events of each run 
are also recored, in the event that more details are needed about what led to 
tumor formation. Such major events include: 
• Stem cell mutation 
• Metastatic stem cell mutation 
• Stem cell barrier removal 
• Metastatic stem cell barrier removal 
• Stem cell transformation 
• Metastatic stem cell transformation 
• Stem cell symmetric division 
• If a mutation has spread to all stem cells, either by symmetric division or 
mutation 
• Formation of colon tumor (i.e. cell in crypt has pro-growth, anti-growth, 
apoptosis, and telomerase barriers completely removed) 
• Successful invasion into metastatic tissue 
• Formation of metastatic tumor (i.e. cell invaded metastatic tissue and has 
pro-growth, anti-growth, apoptosis, metastasis, and telomerase barriers com-
pletely removed) 
Every time a major event occurs in a run, the following data is recorded by the 
cell experiencing the major event: 
• Date and time 
• Infection.Modeled (true/false) 
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• Beneficial.Mutations (list of mutations) 
• Timing.of.Beneficial.Mutations (list) 
• N.Barriers.Removed 
• Barriers.Removed (list of barriers removed) 
• Timing.of.Barrier.Removal (list) 
• Cell.Infeded (true/false) 
• Cell.Transformed (true/false) 




• Metastasis.Occurred (true/false) 
• Age.of.Metastasis 
• Colon.Tumor.Formed (true/ false) 





CDK Cyclin Dependent Kinase 
EC Endothelial cell 
VEGF Vascular Endothelial Growth Factor 
CAM Cell-Cell Adhesion Molecules 
MSI Microsatellite Instability 
CIN Chromosomal Instability 
LOH Loss of Heterozygosity 
CIF Cellular Interfering Factor 
FAP Family Adenomatous Polyposis 
ACRONYMS 
HNPCC Hereditary Nonpolyposis Colorectal Cancer 
APC Adenomatous Polyposis Coli 
KRAS Kristen Rat Sarcoma Virus 
MMR Mismatch Repair Enzymes 
ACF Aberrant Crypt Foci 
GSK3 Glycogen Synthase Kinase 3 
JCV JC Virus 
PML Progressive Multifocal Leukoencephalopathy 
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NCRR Non-Coding Regulatory Region 
T-ag Large T Antigen 
t-ag Small T Antigen 
COP Calabrese model with Original Parameters 
CNP Calabrese model with New Parameters 
GIl Genomic Instability Infection Model 
GIM Genomic Instability Mutation Model 
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